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Abstract 
Emerging evidence supports that prescription opioid analgesic (POA) drugs 
have become widely misused over the last 20 years in Australia. Prescription drug 
seeking or doctor shopping can allow potentially drug-dependent persons to obtain 
POA drugs for misuse and diversion. However, there is a lack of consensus in regards 
to definitions of doctor shopping. 
 
A first study sought input from a range of experts in the fields of drug 
dependence and pain management to determine whether there was agreement on what 
levels of doctor shopping or POA drug misuse might relate to substance misuse 
disorders. A Delphi study was undertaken over two iterations to see if agreement could 
be reached. Results did not support consistent agreement between experts with only 
general consensus that dependence or abuse could be related to even minimal levels of 
doctor shopping. 
 
In a second study, these elements of doctor shopping were then tested in the 
Queensland POA drug-monitoring database of all 248,389 persons who received POA 
drugs in 2013. The aim of the study was to determine what elements of doctor shopping 
could discriminate between non-problematic and potentially aberrant POA drug use. 
 
A total of 15,545 persons who were potential doctor shoppers were assessed on 
prescription activity variables, volumes of drugs obtained, and known drug 
dependence status. Results found a sub-population of 2,842 persons not previously 
identified as drug dependent that appeared to be aberrant POA drug users based on 
volume of prescriptions obtained and drugs consumed. 
 
A third study examined historical prescription records to determine the length of 
time persons had been exposed to prescription opioids and whether this exposure was 
related to aberrant POA drug use. Results found that the majority of aberrant POA 
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drug users had similar previous years’ levels of consumption, and non-aberrant POA 
drug users had limited previous years POA drug consumption. 
 
Outcomes suggest that doctor shopping is not consistently relate to aberrant POA 
drug use. Chronic long-term prescribing of multiple prescriptions for high doses and 
volumes of drugs with any level of doctor shopping could equally suggest a person at 
risk of having or developing drug misuse disorders on POA drugs. This suggests that 
policy and intervention focus on doctor shopping as a key issue of POA drug misuse 
might require further examination. Results, also suggest that long-term high dosage 
patients are perhaps a more appropriate target of interventions to reduce harms related 
to POA drugs use. 
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Chapter 1: Introduction 
1.1  INTRODUCTION 
In the last two decades there has been a significant increase in the prescription 
of opioid analgesic (POA) drugs across most Western countries, particularly in the 
United States of America (Campbell et al., 2010; Dowell, Haegerich, & Chou, 2016; 
Gilson & Dahl.J., 2004; Manchikanti, 2008; Sehgal, Manchikanti, & Smith, 2012; 
Vowles et al., 2015). Australia has experienced a similar rise in the rates of prescription 
of POA drugs over the same timeframe (Bell, 1997; Berecki-Gisolf, Hassani-
Mahmooei, Clapperton, & McClure, 2016; Blanch, Buckley, Srasuebkul, Litchfield, 
& Pearson, 2015; Dobbin, 2010a; Karanges, Blanch, Buckley, & Pearson, 2016; 
Leong, Murnion, & Haber, 2009; Roxburgh, 2011). 
 
Opioid analgesic drugs are an accepted and essential part of conventional pain 
management treatment. These drugs are similar in chemical structure to illicit heroin, 
and the cause of similar physiological effects. Opioids – licit or illicit – are prone to 
being abused and causing dependence and other harms when used inappropriately, 
however recent evidence suggest particular formulations are more likely to be misused 
than others.  
Australia is signatory to the United Nations Single Convention on Narcotic 
Drugs of 1961 (United Nations, 1988), under which heroin is considered an illicit drug 
and subject to various legal sanctions by signatory governments to prevent its 
production and supply, and reduce the harms caused by its misuse. The broader policy 
response to manage illicit drugs is captured in Australia’s National Drug Strategy 
(Ministerial Council on Drug Strategy, 2004, 2011). 
 
Pharmaceutical opioid analgesic (POA) drugs, on the other hand, are legal in 
most countries’ jurisdictions and are subject to legislation and regulation in regards to 
their import, production, supply and use, as are other medications. In Australia this 
process is administered by the Therapeutic Goods Administration (TGA) 
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(Commonwealth of Australia, 1989). The use of many medications in Australia is 
subsidised by the Commonwealth Government under the Pharmaceutical Benefits 
Scheme (PBS) administered by Medicare Australia (Medicare Australia, 2011). 
 
Reasons for this increase in the use of POA drugs include: an increasing 
prevalence of chronic pain conditions (Access Economics Pty Ltd, 2007; Blyth et al., 
2001; Zacny et al., 2003); improved quality of care by use of these drugs in palliative 
care and pain management (American Academy of Pain Medicine & American Pain 
Society, 1996; Zacny, et al., 2003); safer and improved extended release versions of 
POA drugs (Passik, 2009); more confidence or less reticence by medical practitioners 
in the use of these drugs (Cicero, Inciardi, & Surratt, 2007; Elise Bailey, 2006); and 
successful marketing and promotion of certain POA drugs by pharmaceutical 
companies (Elise Bailey, 2006; Van Zee, 2009). 
 
There is also evidence that the increased volume of prescribed POA drugs might 
not be accounted for by the increases in prevalence of chronic or palliative pain 
management in the community (Hollingsworth, 2013, Manchikanti, 2007; 
Manchikanti, 2008; Manchikanti et al., 2012). This issue remains untested at this point; 
however, it implies that a proportion of these POA drugs are being used for non-
therapeutic purposes. It is now widely held that the increasing availability of these 
drugs has led to greater numbers of people being exposed to the potential risks of 
misuse (Fischer, Gittins, & Rehm, 2008; Joranson, Ryan, Gilson, & Dahl, 2000; 
McCabe, Teter, & Boyd, 2006). 
 
There are a number of negative consequences associated with this increase in 
use of POA drugs. These drugs have been linked to significant increases in drug-
related harms such as dependence and abuse, overdose, and death (Fischer & Rehm, 
2009; Florida Medical Examiners Commission, 2010; Graham, Gold, & Goldberger, 
2009; Hall, 2008; Layne, Pellegrino, & Lerfald, 2009; McLellan & Turner, 2008; 
Rintoul, Dobbin, Ozanne-Smith, & Drummer, 2010). Furthermore, epidemiological 
evidence shows that non-medical use and abuse of these drugs has similarly increased 
in the general population (Amari, Rehm, Goldner, & Fischer, 2011; Becker, Sullivan, 
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Tetrault, Desai, & Fiellin, 2008; Centers for Disease Control, 2010a; Fischer, 
Nakamura, Rush, Rehm, & Urbanoski, 2010; Manchikanti, 2008; Maxwell, 2005). A 
systematic review by Vowles and others of 38 studies of opioid use in chronic pain 
found rates of misuse between 21% and 28%, and rates of addiction between 8 and 12 
per cent (Vowles, et al., 2015). 
 
In Australia, use of POA drugs has increased almost 400% in the period from 
1990 to 2014 (Karanges, et al., 2016). The main factors influencing this increase 
appears to be the 17-fold increase in the use of long-acting opioids, such as morphine 
and methadone between 1990 and 2000; and then marked increase in oxycodone, 
codeine and other POA drugs between 2000 and 2011 (Hollingworth, Gray, Hall, & 
Najman, 2015; Karanges, et al., 2016). Campbell and others (2015) found evidence of 
dependence in a sample of Australian chronic pain patients on long-term POA drugs 
at rates of 8.5% within their lifetime and 4.7% in the past year (Campbell et al., 2015). 
There is limited Australian evidence based on large-scale community surveys and key 
informant research that suggests POA drug are also being used for non-medical 
purposes, and being more frequently used by illicit drug users as substitutes for illicit 
drugs (Cogger & Kinner, 2009; Crime and Misconduct Commission, 2010; 
Degenhardt et al., 2006; Dobbin, 2009; Iversen, Topp, & Maher, 2010). However, 
there is limited information about the extent of the inappropriate use of these drugs in 
the Australian population and the harm caused (Berecki-Gisolf, et al., 2016; Rintoul, 
et al., 2010). 
 
There is evidence that an increasing incidence of people are entering drug 
treatment services reporting POA drugs as their primary drug of dependence (AIHW 
(Australian Institute of Health and Welfare), 2009a, 2009b). It has been suggested that 
this phenomenon could be largely due the established illicit drug-misusing population 
that is using POA drugs as alternative sources to other illicit opioid drugs. Initial 
research in this area shows that these drugs users are not obtaining prescriptions for 
POA drugs themselves, but obtaining the drugs after they are possibly diverted from 
prescription recipients (Crime and Misconduct Commission, 2010; Fischer, Gittins, 
Kendall, & Rehm, 2009; Inciardi, Surratt, Kurtz, & Cicero, 2007; Inciardi et al., 2010). 
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It has been further hypothesised that another population of drug misusers are 
emerging who have only been exposed to POA drugs by being prescribed these by 
medical practitioners (Dart, 2006; Edlund et al., In Press; Fischer, Gittins, et al., 2008; 
Fredheim, Skurtveit, Breivik, & Borchgrevink, 2010). It is suggested that this 
population might be unrelated to known illicit drug-using populations (Nielsen & 
Thompson, 2008). These first-hand POA drug consumers might be at risk of 
developing drug dependence or abuse due to their therapeutic exposure to these drugs. 
Therefore, it is possible there is an emerging population of persons with drug-related 
harms that is different from the known illicit opioid users. 
 
Drug-seeking behaviour is one key indicator that suggests possible drug misuse 
or dependence. The amount of time a person devotes to obtaining drugs of dependence 
is one criteria used in most accepted diagnoses of drug dependence or abuse, such as 
DSM-IV-R (American Psychiatric Association, 2000) or ICD9-CM (Medicode (Firm), 
1996) or ICD-10 (World Health Organisation, 2007). Furthermore, the DSM 5 
(American Psychiatric Association, 2014) released during the course of this study also 
retained a criteria for substance use disorders related to the amount of time a person 
devoted to obtaining their substance of dependence (See Appendix A).  However, there 
are different understandings of problematic prescription drug use that are pertinent. 
The American Academy of Pain Medicine proposed the construct of ‘addiction’ 
(Campbell et al, 2016), that is different again from the construct of dependence derived 
from the DSM. This highlights some of the diverse opinion in expert fields in this area 
and the complexity of assessing substance use disorders with POA drug use. 
 
‘Doctor shopping’ is the common term used to describe the behaviour of 
obtaining multiple prescriptions for POA drugs from multiple prescribing doctors for 
dosages in excess of accepted therapeutic limits (Brettingham-Moore, 2010; Mailloux, 
Cummings, & Mugdh, 2010; Martyres, Clode, & Burns, 2004; Medicare Australia, 
2011; Pradel et al., 2009). It is suggested that ‘doctor shopping’ could be used as one 
diagnostic criterion in attempting to assess opioid drug dependence or abuse in POA 
drug-using populations. 
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Medicare Australia in 1996/97 identified more than 10,000 persons as ‘doctor 
shoppers’ for any class of drug (Medicare Australia, 1998). ‘Doctor shopping’ was 
defined as visiting 15 or more different general practitioners within 12 months and 
obtaining more prescription medication than is clinically necessary (Medicare 
Australia, 1998). It was estimated this cost the community over $31 million in possibly 
unwarranted consultations and subsidised prescriptions (Medicare Australia, 1998). 
The definition does not establish what is meant by ‘more medication than necessary’, 
nor does it provide clarity on how many prescriptions were obtained, how many 
prescribers consulted and only suggests these criteria have a possible relationship to 
substance use disorders. 
 
Each Australian state has different state-based legislation to regulate POA drugs. 
Queensland is one of the few states that maintains a prescription drug-monitoring 
system of POA drugs that records all prescriptions dispensed at community 
pharmacies via its health department, Queensland Health. This information allows for 
the complete capture of the state’s POA drug prescribing in the general community 
and the identification of people engaged in ‘doctor-shopping’ behaviour. This capture 
of an entire population dataset in an area of emerging public health concerns around 
POA drug misuse gives a unique opportunity to examine and analyse aspects of this 
issue. 
 
The aim of this research is to identify and describe the population of persons 
engaged in ‘doctor shopping’ and to determine what characteristics of the POA drug-
misusing population and their drug-seeking behaviour suggest substance misuse 
disorders and what factors might discriminate them against other persons receiving 
POA drug therapy. These results could determine whether central database records of 
dispensed POA drug prescriptions, and what particulars of those records, might help 
identify and monitor problematic POA drug use. To be able to appropriately identify 
and reduce misuse of POA drugs and their diversion into the community where they 
could cause harm when used outside of a therapeutic regime is important for healthcare 
providers and regulators. However, a critical consideration is that any actions to reduce 
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inappropriate use of POA drugs do not inadvertently lead to their use being limited in 
legitimate therapeutic circumstances. This is a particular conundrum in the 
management of POA drugs, because, as opposed to illicit drugs, the initial means of 
supply is within the control of healthcare providers and regulators. 
 
This thesis is presented in five sections: the first section (Chapter Two) is a 
literature review and research overview of the area of POA drug use and the 
phenomenon of doctor shopping, and establishes the underlying concepts and ideas. 
The next sections are three studies to understand the concepts of doctor shopping and 
quantify and describe that behaviour. The first study (Chapter Three) involves seeking 
the views of various experts on their definition of problematic POA drug use and 
doctor-shopping behaviour. The second study (Chapter Four) takes the outcomes of 
the first study and seeks to apply a definition of doctor shopping using the information 
from a single year of dispensing of the prescription drug-monitoring program (PDMP). 
The final study (Chapter 5) then examines those persons identified in Study Two to 
investigate their historical prescription records to investigate patterns over time in the 
establishment of doctor-shopping behaviour. A final summary and conclusion of all 
studies in presented in the last section of this thesis (Chapter Six). 
 
 23 Prescription opioid analgesic drug misuse: What can we learn from doctor-shopping behaviour 
Chapter 2: Literature Review and Research 
Overview 
A review of the literature has been conducted to provide background and context 
to the emerging concern of POA drug misuse. The review will also determine gaps in 
current knowledge, especially as it relates to determination of misuse and dependence 
on pharmaceutical opioid drugs and how this might be determined via prescription 
drug monitoring.  
The preliminary literature review is in eight sections. The following nine areas 
set out the various dimensions around POA drug use: 
1. Opioid analgesic drug defined 
2. Policy context of opioid drugs 
3. Clinical context of opioid drugs use 
4. Evidence of increasing supply and availability 
5. Costs and benefits of increased supply 
6. Concepts and theories in opioid drugs use 
7. Populations of opioid drug users 
8. Relevance of ‘doctor shoppers’ 
The final section examines the current practice of managing pharmaceutical 
opioid dependence in Queensland, Australia, and the opportunities available to address 
the gaps in knowledge in this area, particularly through the use of prescription drug-
monitoring systems. 
 
2.1 OPIOID ANALGESIC DRUGS DEFINED 
‘Opiates’ refer to any drugs derived from the opium poppy, whereas the term 
‘opioid’ refers to any synthetic narcotic that produces the same effects as opiates. 
However, opioid has become a general term to describe both opioids and opiates. 
Opioid drugs are also defined by their action, as any substance that binds to the 
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particular opioid receptors in the human brain (Gutstein & Akil, 2006). Opioid 
analgesic drugs refer to the class of pain-relieving drugs that act on the central nervous 
system (American Academy of Pain Medicine & American Pain Society, 1996; 
American Academy of Pain Medicine & American Society of Addiction Medicine, 
2001). 
 
‘Analgesic’ is the broad medical term that refers to any medication capable of 
reducing or eliminating pain, and can include non-opioids or opiates. For ease of 
reference the more general and widely-accepted term ‘pharmaceutical opioid 
analgesic’ (POA drugs) will be used throughout to describe pharmaceutical 
preparations of opiates and opioids. 
 
POA drugs include preparations such as morphine, methadone, oxycodone, 
pethidine and others.  Opioid analgesic drugs can be used to treat acute and chronic 
pain conditions and are also used as substitution agents to manage persons dependent 
on illicit opioids such as heroin. This is discussed in more detail in later sections.  
 
Table 2.1 sets out the full range of POA drugs available in Australia, the 
opioid/opiate status of each drug, as well as brand names used by particular 
pharmaceutical companies. The list of drugs presented here are only those known as 
controlled or ‘Schedule 8’ drugs in Australia (Commonwealth of Australia, 2010). 
These Schedule 8 drugs are POA drugs that are only available on prescription and have 
extra controls on their use. The form or preparation of each POA drug that is the subject 
of this study is presented in Table 2.1. The table also includes the form of the drugs – 
such as whether it is a tablet, capsule or liquid – and the indicated means of 
administering or route of administration of each drug. Both features potentially have 
been associated with the inappropriate use of particular POA drugs. Figure 2.1 
illustrates the two most commonly prescribed POA Schedule 8 drugs – morphine and 
oxycodone controlled-release tablets – in the various dosage sizes that are available in 
Australia. 
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Table 2.1.  
POA drug preparations available in Australia as Schedule 8 drugs 
Generic name Opioid/ 
Opiate 
 Common 
brand 
name 
 Preparation  Route of 
administration 
Buprenorphine Opioid  Subutex** 
Suboxone*
* 
Temgesic 
 Tablet 
Strip 
Liquid 
 Sublingual 
Sublingual 
Oral 
Codeine Opiate    Tablet  Oral 
Fentanyl Opioid    Patch/Matrix  Topical 
Hydromorphone Opioid  Dilaudid  Tablet  Oral 
Methadone Opioid  Physeptone  Tablet  Oral 
   Methadone
** 
 Liquid  Oral 
   Methadone
** 
 Liquid  Oral 
   Biodone  Syrup  Oral 
Morphine Opiate  MS Contin*  Tablet  Oral 
   MS Mono*  Tablet  Oral 
   Kapanol*  Capsule  Oral 
   Morphine  Ampoule  Intravenous 
Oxycodone  Opioid  Endone  Tablet  Oral 
   OxyContin*  Tablet  Oral 
Oxycodone + 
Naloxone 
  Targin  Tablet  Oral 
Pethidine  Opioid    Ampoule  Intramuscular 
Tapentadol Opioid    Tablet  Oral 
        
*controlled/slow release preparations 
**opioid substitution preparation treatments 
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Figure 2.1. Pictures of morphine and oxycodone controlled-release tablets 
(source Purdue Pharma) 
 
Some POA drugs are in other drug schedules – such as tramadol, which is a 
Schedule 4 drug –  and are not subject to the same levels of controls or monitoring via 
prescription drug-monitoring under Australian law. Some opioid drugs, such as lower 
strengths of codeine, are available as ‘over-the-counter’ medications that can be sold 
by pharmacists to patients without a doctor’s prescription. These preparations are also 
not monitored. This study covers those POA drugs that are in set out in Table 2.1.  
 
Opioid drugs are chemically similar in structure and action to illicitly-used 
heroin. All opioids have similar neurochemical actions and generally cause similar 
effects. Opioids are classed as ‘depressant drugs’ due to their actions on the central 
nervous system that cause sedation and respiratory depression (Gutstein & Akil, 2006). 
Opioids also act in various ways on certain opioid receptors in the human brain to limit 
the reception of pain responses from the body to the brain (Gutstein & Akil, 2006). 
 
Opioids can also stimulate the release to the neurotransmitter dopamine that is 
associated with sensation of pleasure (Gutstein & Akil, 2006). The human brain 
produces its own opioids, known as endogenous opioids (Gutstein & Akil, 2006), by 
which it regulates pain responses. Non-endogenous opioid drugs possess particular 
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structures that allow them to bind to the same receptor sites as endogenous opioids to 
either mimic or increase the endogenous opioid effects. 
 
Synthetic analogues of opiates, known as opioids, were first derived in the early 
19th century and were patented as proprietary drugs by pharmaceutical corporations 
(Brownstein, 1993). Recent innovations over the last two decades have seen the release 
of some sustained release preparations of morphine, known as Kapanol™, MS 
Contin™, MS Mono™, and oxycodone, marketed as OxyContin™ (Elise Bailey, 
2006; Manchikanti, 2007) (see Table 2.1). These preparations for oral administration 
include retardant agents to ensure the opioid is more slowly absorbed into the gastro-
intestinal tract, so the dosage effect can be sustained for a six or twelve hour time 
period (Bruera et al., 1998; Watson, Moulin, Watt-Watson, Gordon, & Eisenhoffer, 
2003). 
 
Different opioid preparations are not all of equivalent, or equal, analgesic dosage 
or strength. To compare the dosages of different opioids equianalgesic tables are used 
that relate dosage to equivalent dosage of morphine, or the dose of a certain preparation 
required to equate to a therapeutic dosage of morphine. Table 2.2 below sets out 
examples of equianalgesic comparisons for the commonly prescribed POA drug 
preparations in Australia. 
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Table 2.2. Total daily oral morphine equivalent table for Australian POA Schedule 8 drugs*7 
Drug  Recommended 
research OME 
Conversion factor 
ORAL PREPARATIONS   
Swallowed   
Morphine mg/day 1 
Oxycodone mg/day 1.5 
Hydromorphone mg/day 5 
Codeine mg/day 0.13 
Dextropropoxyphene mg/day 0.1 
Tapentadol mg/day 0.4 
Methadone mg/day 4.7 
Buccal/Sublingual mg/day  
Buprenorphine mg/day 37.5 
Fentanyl mcg/day 0.1 
TRANSDERMAL PREPARATIONS   
Buprenorphine mcg/hr 25 
Fentanyl  mcg/hr 3 
PARENTERAL PREPARATIONS   
Morphine mg/day 3 
Oxycondone mg/day 3 
Hydromorphone mg/day 15 
Pethidine mg/day 0.4 
Fentanyl mcg/day 0.2 
Methadone mg/day 13.5 
Buprenorphine  75 
RECTAL PREPARATIONS   
Oxycodone mg/day 15 
Note: mg-milligrams, mcg-micrograms 
*Excerpt from (Nielsen, 2014) 
 
 
2.1.1 Evidence for increased opioid supply and availability 
 
From an international perspective, many countries have limited access to 
pharmaceutical opioid analgesic preparations. The ‘Montreal Declaration’ 
(International Association for the Study of Pain, 2011) of the International Association 
for the Study of Pain representing 84 countries declared chronic pain was under-
recognised and under-treated in most countries of the world. The United Nations has 
recognised access to pain treatment as a basic human right (Lohman, Schleifer, & 
Amon, 2010) and opioid analgesic drugs are recognised as essential medicines (World 
Health Organisation, 2013).  
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The United Nations under the provisions of the Single Convention on the use of 
Narcotic Drugs (United Nations Office on Drugs and Crime, 1961) collects data on 
worldwide opioid analgesic consumption by country. Since 1986, it found that a small 
number of developed countries consume most of the world’s POA drugs, whilst the 
remaining countries consume only a small proportion, but contain over 80% of the 
world’s population (International Narcotics Control Board, 2014).  
 
Prescriptions for POA drugs have increased significantly in the last two decades, 
particularly in the United States of America. Medical use of morphine and oxycodone 
increased 59% and 22% respectively from 1991 to 1996 (Joranson, et al., 2000). The 
volumes of sales of opioids per person increased from 74 milligrams per person per 
year in 1977 to 329 milligrams in 2006 (Manchikanti, 2008), which represents a 347% 
increase. 
 
In Australia the prescribing rates of opioid analgesic drugs has steadily increased 
over the past two decades (Bell, 1997; Berecki-Gisolf, et al., 2016; Degenhardt, et al., 
2006; Dobbin, 2010a; Karanges, et al., 2016; Leong, et al., 2009). Data from the 
Commonwealth Government’s Office of Chemical Safety’s (Commonwealth of 
Australia, 2011) monitoring of wholesale supplies of all opioid drugs shows there has 
been an over 900% increase in POA drugs sales since 2001. Figure 2.2 below 
graphically shows this increase by POA drug type. 
 
 30 Prescription opioid analgesic drug misuse: What can we learn from doctor-shopping behaviour 
 
 
Figure 2-2. Australian wholesale sales of POA drugs by drug type (1991-2009) Source: 
(Commonwealth of Australia, 2011) 
 
Figure 2-3. Opioid Analgesics person and prescription count, 1999-2009 for Queensland, 
Australia. Source: (Drugs of Dependence Unit, 2010) 
 
Queensland Health’s annual statistical reports show similar increases in the rates 
of POA drugs being dispensed on prescriptions in the general community, with a 
greater than 300% increase from 2001 to 2009 for total prescriptions issued for, and 
persons receiving, prescriptions of POA drugs (Drugs of Dependence Unit, 2006, 
2010). Figure 2-3 above graphically shows this increase over 10 years. 
 
Suggested reasons for the increased use of POA drugs include: an ageing 
population with increased chronic pain management requirements; increased use in 
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acute pain conditions and palliative care; doctors’ comfort and confidence in using 
new formulations of POA drug preparations; and marketing campaigns by 
pharmaceutical companies (Gilson, 2004; Zacny, et al., 2003). The dramatic rise in use 
of POA drug prescribing has led to suggestions of overprescribing or inappropriate use 
of POA in pain management (Manchikanti, 2007). This over-use has been proposed as 
a cause of increased exposure to persons with these drugs and ease of access which 
has been associated with the rise in the drug-related harms where POA drugs are the 
principal drugs of use. 
 
Controlled release preparations of the morphine (e.g. MS Contin ™, Kapanol 
™) and oxycodone (e.g. OxyContin™) were launched in the Australian market in 1991 
and 2001 respectively. These preparations all obtained subsidy status under the PBS 
at this time, and a rapid escalation in the prescription of both preparations can be shown 
after their release dates (See Figure 2-3 above). 
 
The above factors and introduction of new drug preparations appear to have 
contributed in some combination to the current situation of high volume prescribing 
of POA drugs and associated harms. 
 
2.2 COSTS AND BENEFITS OF INCREASED OPIOID SUPPLY AND 
AVAILABILITY 
POA drugs have legitimate therapeutic applications and are prone to misuse and 
the cause of harm. It is important therefore to consider both the benefits and detriments 
of increased access to these drugs for the community. 
 
2.2.1 Benefits of increased supply and availability 
The legitimate use of pharmaceutical opioid drugs for certain indicated 
conditions provides effective and appropriate treatment for many individuals and helps 
relieve considerable suffering. In particular, greater access to and improved 
formulations of POA drugs has provided benefits to persons suffering pain conditions, 
in palliative or end of life treatment, and for the treatment of those people with opioid 
dependence. 
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Persons suffering from short-term or acute pain conditions due to injury or 
recovery from surgical procedures benefit significantly from the use of POA drugs in 
the short-term. POA drugs also have an established pain management treatment in 
palliative care and cancer pain treatments. A recent Australian review examining the 
clinical and research literature to date found there was reliable evidence for the efficacy 
of POA drugs in the management of acute pain conditions (Australian and New 
Zealand College of Anaesthetists and Faculty of Pain Medicine, 2010). 
 
However, there is more contention about the use of POA drugs in the treatment 
of chronic non-malignant or persistent pain conditions. In an assessment of the 
prevalence of chronic pain in Australia, Access Economics suggested more than one-
third of the population would experience such a condition at some point in their life 
(Access Economics Pty Ltd, 2007; AIHW Australian GP Statistics and Classification 
Centre, 2008). Rosenblum and et al (Rosenblum, Marsch, Joseph, & Portenoy, 2008) 
summarised these concerns. Firstly, there remain questions as to the safety and efficacy 
of POA drugs in treatment of chronic pain; and secondly there are concerns about their 
abuse liability. Shifts in attitudes to these concerns have led to different levels of 
restrictiveness or liberalness with the use of POA drugs for chronic pain conditions. 
Most recent reviews now question the efficacy of POA drugs for treatment of chronic 
pain conditions (Chou et al., 2015; Martell et al., 2007). However, with chronic un-
resolving pain conditions that are not responding to other treatments, POA drugs are 
often front-line treatments. There is some consideration that for those patients who are 
not at risk of abuse or dependence, maintenance on POA drugs might be the optimal 
course of treatment (Noble et al., 2010). 
 
POA drugs also form the basis of medically-based substitution treatments for 
people who are dependent on heroin and illicitly obtained opioids. Methadone and 
buprenorphine are prescribed in controlled doses to assist stabilising drug dependent 
individuals. This reduces the risk of harms such as injecting drug use, the acquisition 
of blood borne viruses, and engagement in criminal activity to support illicit drug use 
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(AIHW (Australian Institute of Health and Welfare), 2009b; Commonwealth of 
Australia, 2007)). 
 
There is increasing evidence that much of the increased use in POA drugs is not 
supported by their use as an appropriate treatment for many persistent pain conditions 
(Dowell, et al., 2016). While the utility of the use of POA drug to treat long term pain 
conditions is not the topic of this study, this overuse is linked to other problems. There 
is also now increasing evidence of individuals developing abuse or dependence on 
POA drugs, and of the ‘leakage’ or diversion of these drugs outside of the doctor-to-
patient supply chain, as well as other evidence of harms derived from inappropriate 
use of these drugs. 
 
2.2.2 Costs of increased supply and availability 
Recently there has been increasing concerns that POA drugs are becoming more 
frequently misused and making greater contributions to drug-related harms in the 
Australian community. Coronial investigations in the United States of America into 
the deaths of celebrities – actor Heath Ledger and entertainer Michael Jackson – found 
that POA drugs were associated with their fatalities. 
 
International evidence 
 
In the USA, reports from the last 15 to 20 years have shown that the increasing 
prescription volume of these drugs is related to greater drug-related harms (Compton 
& Volkow, 2006; Joranson, et al., 2000; Manchikanti, 2008). This includes growing 
numbers of persons being admitted for opioid dependence treatment and for overdose 
at emergency departments where POA are the principal drugs of concern. POA have 
also been more frequently found as significant contributors in cases of drug-related 
deaths (Centers for Disease Control, 2010a, 2010b; Coolen, Lima, Sabel, & Paulozzi, 
2009; Fischer & Rehm, 2009; Graham, et al., 2009; Layne, et al., 2009; Okie, 2010).  
 
General community surveys have also corroborated rises in inappropriate use of 
POA drugs. A US study detailed the prescription drug abuse of nine different POA 
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drugs using four different data sources (Schneider et al., 2009). Furthermore, a 2007 
household survey data in the US estimated that 5.2 million people used POA non-
medically in the last month (Substance Abuse and Mental Health Services 
Administration, 2009). 
 
Australian evidence 
 
POA drug misuse is now recognised as an emerging public health concern in 
Australia (Bruno, 2007; Degenhardt, et al., 2006; Dobbin, 2009, 2010a; Rintoul, et al., 
2010; Royal Australasian College of Physicians, 2009). This issue presents significant 
challenges to treatment providers and regulators. The increasing prevalence of chronic 
pain suggests there will be a growing role for the use of POA drugs in management of 
these conditions (Access Economics Pty Ltd, 2007; AIHW Australian GP Statistics 
and Classification Centre, 2008). However, over-prescribing could inadvertently 
create risks of harm to some sections of the community (Dobbin, 2009, 2010a). 
Furthermore, the licit status of POA drugs means regulators can also play a role in 
influencing community use of these drugs. The challenge is to do so in a manner that 
does not restrict individuals’ access to legitimate and appropriate treatment but, at the 
same time, reduce the harms associated with misuse. 
 
Household survey data from Australia in 2007 estimates 0.2% of the population 
had used a pain-killer/analgesic drug for non-medical purposes in the last month, and 
4.4% had ever used any pain killer/analgesic drug for non-medical purposes in their 
lifetime (AIHW (Australian Institute of Health and Welfare), 2007). However, data 
from both sources has some limitations as these questions are not related to POA drug-
use alone.  
 
There is evidence that the use of POA drugs has increased in illicit drug users 
over the last 10 years (Stafford et al., 2009). Injecting drug users are increasingly 
reporting injection of, and acquisition of, POA drugs (Cogger & Kinner, 2009). 
Furthermore, there is increasing reports of persons entering formal treatment programs 
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for opioid dependence reporting POA drugs as their primary drug of dependence 
(AIHW (Australian Institute of Health and Welfare), 2009b). 
 
There is some converging evidence of the increased availability of, and misuse 
of, POA drugs in the general community. It is reasonable to conjecture that Australia 
might experience similar trends in harms to the USA given similar trajectories of POA 
drug prescribing. Dobbin has suggested that based on current volumes of prescribing 
of POA Australia is at the same point that the USA was in the early 1990s, when harms 
associated with controlled-release oxycodone misuse began rapidly escalating 
(Dobbin, 2010a). Recent studies show the increasing use of POA drugs in Australia 
(Karanges, et al., 2016; National Centre for Education and Training on Addiction, 
2013)and a corresponding increase in associated harms (Berecki-Gisolf, et al., 2016; 
Nicholas, Lee, & Roche, 2011; Roxburgh, 2011) 
 
There is little direct information available about the possible population not in 
formal treatment programs that might be experiencing health related problems 
associated with POA drug misuse.  
 
2.3 THE POLICY CONTEXT OF OPIOID DRUGS 
The policy context around the use of opioids is focussed on the medical 
application of these drugs in therapeutic circumstances, and the illicit use of these 
drugs as either illicit or licit preparations. This section will discuss the policy context 
in Australia around therapeutic use, illicit drugs, and the growing convergence of these 
areas. The application of these policies in regards to the monitoring and surveillance 
of POA drugs in Australia is also discussed. 
 
2.3.1 Illicit opioid drugs policy 
 
In the case of illicit drugs, Australia is signatory to a number of UN conventions 
(United Nations, 1988) that provide internationally agreed legal mechanisms to 
address illicit drug supply, and allows for international cooperation in the interdiction 
of the trafficking of illicit drugs across national boundaries. Heroin is one drug covered 
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in such conventions. Adherence to these treaties also imposes obligations on how 
signatory countries can regulate illicit drugs within their own borders. For the benefit 
of clarity, the illicit opioids referred to here are non-pharmaceutical opioids. POA 
drugs that are diverted or used for non-medical reasons are potentially considered 
illicit; however, this will be addressed in the next section. 
 
All drugs and medicines, POA drugs, and illicit drugs are subject to scheduling 
under the Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) 
or the ‘Poisons Standard’ (Commonwealth of Australia, 2010). Heroin is listed as a 
Schedule 9 – Prohibited Substance. As with licit drugs, each state and territory adopts 
particular legislative and regulatory frameworks in general agreement with the 
Commonwealth. In Queensland, heroin, cocaine and methamphetamine are considered 
illicit drugs under the Drugs Misuse Act 1986 (Queensland Government, 1986) and 
certain criminal penalties apply to individuals possessing or selling these drugs. If not 
obtained via legitimate means – for example, by prescription – POA drugs are 
considered illicit drugs under provisions of the Drugs Misuse Act 1986 (Queensland 
Government, 1986).  
The national policy position on the management of illicit drugs, including heroin 
and the misuse of pharmaceutical drugs is the National Drug Strategy (NDS) 
(Ministerial Council on Drug Strategy, 2004). As with other aspects of policy and 
legislation in Australia, this policy is adopted in full or part by the constituent states 
and Territories. Queensland has its own Queensland Drug Strategy (Queensland 
Government, 2006) that is largely based on the NDS. 
 
The harm minimisation approach set out in the National Drug Strategy 
(Ministerial Council on Drug Strategy, 2011) is based on the underpinning concepts, 
demand reduction, supply reduction and harm reduction.  Demand reduction refers to 
strategies to reduce the uptake of drugs. Supply reduction refers sanctions and 
regulation of licit and illicit drugs, and harm reduction is about reduces harms caused 
by drug use. 
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This study is focussing on strategies of supply reduction, to reduce individuals’ 
exposure to non-therapeutic use of POA drugs, either via directly prescribed drugs or 
by diverted drugs. Similarly, outcomes of this study are focussed on harm reduction 
strategies, that recognise there are legitimate uses of POA drugs and better informed 
treatment decisions should lead to better prescribing. Furthermore, in the National 
Pharmaceutical Drugs Misuse Framework for Action (Australian Government, 
2012)identified that there needed to be improved education of prescribers, better 
monitoring and regulation of pharmaceutical drugs as well as implementation of real-
time reporting of dispensing events in PDMPs. This study also aims to provide 
information for the prescribing clinicians and facilitate how prescribing information 
could be effectively used in any future PDMPs with real-time reporting capabilities.  
Regulatory actions can also act as supply reduction strategies and might be developed 
from outcomes of this investigation. A regulator or professional body might implement 
sanctions against errant prescribers or dispensers to limit their abilities to prescribe or 
dispense, based on information about their management of drug seeking patients. . 
Potentially improved prescribing of opioid and a reduction in iatrogenic opioid 
dependence might be considered a demand reduction strategy. This study is a health 
focussed approach to improve treatment outcomes of patients and improve clinical 
practice particularly focussed on the supply issue related to doctor shopping. 
 
 
2.3.2 Pharmaceutical opioid drugs policy context 
 
Pharmaceutical preparations are regulated according to various international 
treaties in regards to their manufacture, and supply is administered by the International 
Narcotics Board (United Nations, 1988). Australia is signatory to various United 
Nations Conventions in regards to the appropriate use of opioid analgesics and treaties 
about individuals’ rights to receive appropriate medical treatments for their illnesses 
(United Nations, 1961). 
 
Individual countries are signatories to these treaties and conventions and regulate 
the use of these drugs within their jurisdictions. In Australia, pharmaceutical drugs and 
medicines are regulated under the Therapeutic Goods Act 1989 (Commonwealth of 
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Australia, 1989). This Act is administered by the TGA that lists all medicines and 
poisons under The Schedule for the Uniform Scheduling of Medicines and Poisons 
(SUSMP) (Commonwealth of Australia, 2010). 
 
The SUSMP includes nine schedules that broadly equate with the degree of 
access of these substances. Lower scheduled drugs are available for direct purchase in 
supermarkets (Schedule 1 & 2), in pharmacies (Schedule 3) and higher scheduled 
drugs require prescriptions by medical practitioners or special permits for use via the 
TGA. POA drugs are listed as Schedule 8 drugs. 
 
Each Australian state and territory jurisdiction sets its own legislation and 
regulations around these drugs. For the most part, these regulations seek to restrict the 
use of POA drugs to registered health practitioners. The use of POA drugs in 
therapeutic circumstances in Australia is limited to certain health practitioners who are 
registered according to national and state legislations. This is primarily medical 
practitioners, dentists, optometrists, veterinary surgeons, pharmacists and some other 
professions in different jurisdictions.  
 
State and territory-based legislation also sets limits around POA drugs use in 
regard to the treatment of certain conditions, reporting of long-term treatment, and 
requirements for authorities for treatment in some instances. In Queensland, the Health 
(Drugs and Poisons) Regulation 1996 (Queensland Government, 1996) set out these 
requirements for use. Examples of these requirements are provided in Appendix B. 
 
Pharmaceutical preparations for human therapeutic use are also included under 
Australia’s Pharmaceutical Benefits Scheme (PBS), and a certain proportion of their 
cost is subsidised up to and within certain dosage and supply limitations (Medicare 
Australia, 2011). This scheme seeks to offset costs of widely used beneficial drugs in 
the treatment of certain conditions to the general population. 
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In Australia, most POA drugs are liable for subsidy under the PBS. This means 
that most of these drugs are available at a low cost. Furthermore, medical practitioners 
can also choose to prescribe drugs as non-PBS, or ‘private’ prescriptions, where 
treatment might be outside of PBS approval, and where the patients meets the full 
unsubsidised cost of the drugs. 
 
The policy context of the use of POA drugs in Australia is governed by three 
levels of control: one international, one national, and the other state and territory-
based. There are minor differences in regulation between states and territories, mostly 
based on different legislative frameworks. However, the Australian policy context in 
relation to POA drugs is similar to other similar jurisdictions, such as the United 
Kingdom under its Medical and Healthcare Products Regulation Agency (U.K. 
Department of Health, 2011), and the USA under its Food and Drug Administration 
(U.S. Department of Health and Human Services, 2011). 
 
Since 2009, a number of policy initiatives in Australia have been suggested to 
address this public health concern. The College of Physicians proposed a ‘Prescription 
Opioid Policy’ (Royal Australasian College of Physicians, 2009). The Pharmacy Guild 
of Australia proposed ‘real-time’ reporting of all dispensed POA drug prescriptions to 
allow for better monitoring (Pharmacy Guild of Australia, 2010). In response to these 
growing concerns the Australian Government commissioned the National 
Pharmaceutical Drug Misuse Framework for Action (Australian Government, 2012) 
that sets a range of strategic policy options to address this issues, that has been adopted 
in-principle by the state and territory jurisdictions. 
 
For health professionals such as doctors and pharmacists there are legal, 
professional and ethical obligations in regards to their treatment of patients. For POA 
drugs, a treatment provider could be subject to legal action if they provide drugs 
outside of the legal framework. In a treatment setting, health professionals are liable 
to actions against them by patients or the Courts should their treatment cause harm to 
a patient, and where that treatment was outside of established practice or was the result 
of demonstrable negligence. Where patients misuse or divert POA drugs outside of 
 40 Prescription opioid analgesic drug misuse: What can we learn from doctor-shopping behaviour 
treatment recommendations, it is less clear as to the responsibility of the treating health 
practitioner. Furthermore, a health practitioner denying treatment to a person without 
reasonable justification for doing so could also be subject to similar actions against 
them by regulators, patients, or the courts. Hence, the calls for comprehensive and real-
time prescription drug monitoring.  
 
In recognition of the growing concerns around the misuse of POA and other 
pharmaceutical drugs, the Australian Commonwealth Government commissioned the 
Australian National Pharmaceutical Drug Misuse Framework (2012-2015) (National 
Centre for Education and Training on Addiction, 2013) to provide strategic 
recommendations on how to manage these concerns. As with the NDS, each state and 
territory jurisdiction has agreed in principle to this framework and can choose to adopt 
recommended measures. 
 
2.3.3 Monitoring and Surveillance 
Medicare Australia collects information on all medications that are subsidised 
under the PBS – POA drugs being one class of such drugs. Medicare also conducts a 
‘Prescription Shopping Program’ (Medicare Australia, 2011) that can inform doctors 
of a patient obtaining drugs beyond a certain threshold or upper limit. Medicare’s focus 
is primarily to reduce inappropriate expenditure on PBS medication, and as such they 
have not pursued a broader research agenda into this area, particularly around POA 
drugs. The last population data produced by Medicare in this area was over 10 years 
ago (Health Insurance Commission, 1998). 
 
The overall monitoring of POA drugs across Australian jurisdictions is 
inconsistent, making it more difficult to ascertain accurate measures of use and related 
harms. While Medicare Australia monitors all prescription drugs subsidised under the 
PBS, ‘private’ prescriptions that do not attract a PBS subsidy are not monitored. Due 
to the reactive and inconsistent nature of monitoring prescriptions and limits to 
monitoring systems, there are few actual sanctions preventing individuals obtaining 
multiple prescriptions for large amounts of POA drugs from multiple doctors 
(Medicare Australia, 2011; Wilsey et al., 2010). 
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Each Australian state and territory has different legislation to regulate POA 
drugs as a class of ‘controlled drugs’. Queensland, Northern Territory, Tasmania, and 
South Australia all maintain a prescription monitoring system in some form that 
collates POA drug dispensing. New South Wales, Victoria, and the Australian Capital 
Territory have no such system in place.  
 
In Queensland, all POA drug prescription information – PBS and private – once 
dispensed at community pharmacies is transmitted to Queensland Health for input in 
to a central database. This information allows for the complete capture of the state’s 
POA drug prescribing in the general community, excluding hospital inpatients, and 
thus the identification of people engaged in doctor-shopping behaviour. 
 
The formation of the Medicines Regulation and Quality (MRQ) (formerly Drugs 
of Dependence Unit (DDU)) of Queensland Department of Health, in its present form, 
followed a recommendation for the creation of a discrete monitoring unit by the 1979 
Australian Royal Commission of Inquiry into Drugs (Williams, 1980). All state and 
territory governments established monitoring units in their respective health 
departments; however, not all decided to directly monitor prescription activity via 
prescription databases. 
 
To implement the Williams’ recommendations, Queensland began a manual 
monitoring system of POA drug prescriptions. This process was enhanced in 1983 by 
the introduction of a computer system, known as the Monitoring of Drugs of 
Dependence System (MODDS) database. The current version of the system has been 
in operation since 1996. MODDS collects all the information of controlled (Schedule 
8) drugs – of which most are POA drugs – dispensed by community pharmacies in 
Queensland. The MODD system also facilitates the provision of a state-wide 
confidential telephone enquiry service for medical practitioners and pharmacists.  
 
 42 Prescription opioid analgesic drug misuse: What can we learn from doctor-shopping behaviour 
The Australian National Pharmaceutical Drug Misuse Framework (2012-2015) 
(National Centre for Education and Training on Addiction, 2013) supported the 
establishment of real-time prescription drug monitoring programs within all 
jurisdictions as one of its recommendations. These jurisdictional systems were to be 
linked to each other and allow access to prescribing doctors and dispensing 
pharmacists.  
 
2.3.4 Rise of Prescription Drug-Monitoring Programs 
 
One of the key population level responses, especially in the USA and Canada, 
has been the implementation of prescription drug-monitoring programs (PDMPs) and 
‘real-time’ reporting of dispensed prescriptions (Clark, Eadie, Kreiner, & Strickler, 
2012; Finklea, Bagalman, & Sacco, 2013; Laura Morgan, 2013). The rationale behind 
this response is to provide appropriate and contemporary information to clinicians for 
managing patients, and regulators to monitor individual and population level patterns. 
 
Some 48 out of 51 USA states (Blumenschein et al., 2011) and the majority of 
Canadian provinces now have some form of jurisdictional prescription drug-
monitoring programs (PDMPs). Initial reviews of the effectiveness of these programs 
in the USA have returned mixed results (Blumenschein, et al., 2011; Paulozzi, 
Kilbourne, & Desai, 2011). It is suggested that these programs and the provision of 
information alone is not sufficient to address the broader issue of prescription drug 
misuse (Laura Morgan, 2013; Prescription Drug Monitoring Program Center of 
Excellence at Brandeis, 2013; Shand, Campbell, Hall, Lintzeris, & Degenhardt, 2013; 
Strassels, 2012).  
 
An Australian policy review – the National Pharmaceutical Drug Misuse 
Framework for Action (National Centre for Education and Training on Addiction, 
2013) – also supports real-time prescription monitoring along with range of other 
strategies, there needs to be appropriate workforce development, greater accessibility 
and availability to specialist treatment services, improved clarity of roles of programs 
as either regulatory or medicine management, appropriate regulation and policing 
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policies, and ongoing evaluation of the programs to evaluate their effects on misuse of 
POA drugs (Shand, et al., 2013). 
 
Real time PDMPs have many potential benefits. They can allow prescribers, 
dispensers and regulators, contemporaneous information about prescription usage on 
which to make treatment decisions.  As such they can prevent further prescribing or 
dispensing if a health professional has clear evidence of overuse or drug seeking. From 
a regulatory or oversight perspective they can allow for intervention to prevent further 
prescribing or dispensing, and potential actions against patients, and health 
practitioners if there are concerns about their prescribing. Overall, if they are effective 
in limiting misuse and dependence they should represent savings to a health budget. 
 
Some issues around the implementation and use of PMDPs need clarification as 
it is not clear that they are established or used in consistent ways across jurisdictions 
and this can influence their use. Firstly, whoever the authorising agency is will set the 
use of the PDMP. An enforcement agency, such as the USA’s Drug Enforcement 
Agency, will be potentially using a PDMP to detect criminal activity. Whereas a 
medical or pharmacy board might be seeking to regulate activities of registered health 
practitioners. Alternatively, a health agency might use a PDMP to integrate with, or 
supplement health treatment records to improve treatment. Secondly, the legislative 
environment can influence whether providing and accessing data is mandated or 
supported. The ease of use and ability to access, and level of access for certain users 
could also affect uptake and use by relevant practitioners.  The timeliness, quality and 
extent of information in PDMPs can also affect usage and utility. Real-time or close 
7to real-time information that was reliable and historically accurate would be ideally 
most useful. If PDMPs included other treatment information or regulatory advice or 
warnings these could potentially add to their value in clinical settings. Furthermore, 
changes in information systems and data exchange, such as electronic prescribing and 
dispensing and cloud based computing could also facilitate good systems. 
  
However, real time PDMPs could have some limitations, especially when they 
ae not linked to broader records of a person’s healthcare history. Most PDMPs are 
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focussed on monitoring POA drugs and misuse of other drugs that could interact with 
opioids would escape scrutiny. PDMPs are potentially expensive and complex to 
implement and could represent monies diverted from health treatment or preventive 
programs. Without appropriate guidance treatment providers might misinterpret 
legitimate prescription obtaining as drug seeking and cease treatment.  There have 
been some reports of a ‘chilling’ effect in some state of the USA when PDMPs have 
been implemented (Reisman, Shenoy, Atherly, & Flowers, 2009) . That is prescribers 
or dispensers default to a do not prescribe/dispense position if there are any concerns 
and potentially deny patients appropriate treatment. Alternatively prescribers might 
not recognise problematic or aberrant usage of POA drugs  
 
There is the risk of contention between prescribers and dispensers, as they might 
view the same information differently. A dispenser might choose to not dispense a 
prescription if they hold concerns about a person’s POA drug obtaining even if the 
prescriber had not formed the same views. Furthermore, regulatory or legal peril, 
prescribers or dispensers might have greater liability in patient outcomes. There appear 
to be potential issues in implementing PDMPs effectively in jurisdictions if the policy 
intent is not clear (Gilson, 2010a; Gilson, 2010b; Gilson, Maurer, & Joranson, 2007). 
 
However, regardless of the broader contextual concerns, PDMPs offer the 
opportunity to capture large volumes of objective information on a person’s drug 
prescription history over time. For health practitioners to make informed decisions 
based on this information to guide their treatment choices there needs to be 
understanding of appropriate clinical use of POA drugs in pain conditions and 
recognition of evidence of drug dependence and misuse with this class of drugs. This 
emerging public health area represents a complex problem for treatment providers with 
potentially conflicting or co-occurring clinical conditions. Appropriate use of 
prescription information within PDMPs could add valuable information to assist 
decision-making. 
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2.4 THE CLINICAL CONTEXT OF OPIOID DRUGS  
The greatest increases in POA drug prescribing is in the controlled-release 
preparations of oxycodone and morphine (Bell, 1997; Degenhardt, et al., 2006; 
Dobbin, 2009, 2010a; Leong, et al., 2009). These preparations are central to the public 
health concerns relating to POA drug misuse (Cicero, Inciardi, & Munoz, 2005; 
Cicero, et al., 2007). 
 
POA drugs are indicated for use in the treatment of chronic and acute pain, and 
are widely supported as an appropriate pain management therapy (American Academy 
of Pain Medicine & American Pain Society, 1996; Passik, 2009; Zacny, et al., 2003). 
In the case of short-term and acute pain conditions, a limited course of POA drugs can 
be provided and then ceased on the resolution of the pain condition (Rosenblum, et al., 
2008). Chronic pain conditions might last for many years, and long-term therapy over 
months or years might be required to provide an individual appropriate pain relief 
(American Academy of Pain Medicine & American Pain Society, 1996; Eriksen, 
Sjøgren, Bruera, Ekholm, & Rasmussen, 2006; Kahan, Srivastava, Wilson, Mailis-
Gagnon, & Midmer, 2006; Rosenblum, et al., 2008). 
 
Chronic non-malignant pain has multiple and complex causes, and can often 
involve extensive and expensive testing procedures such as X-rays, magnetic 
resonance imaging scans, and consultations with specialist medical practitioners such 
as physicians and neurologists (American Academy of Pain Medicine & American 
Pain Society, 1996; Zacny, et al., 2003). The other complexity for practitioners is the 
subjective nature of pain conditions. Although diagnoses and overt pathology can 
indicate possible causes of pain and verify actual injuries, an individual’s response or 
ability to manage pain is often idiosyncratic (American Academy of Pain Medicine & 
American Pain Society, 1996; Passik, 2009; Passik & Kirsh, 2008; Zacny, et al., 2003). 
Therefore, many of the aspects of pain management rely on patient’s self-reports to 
ascertain levels of pain, and success or otherwise of treatments (Zacny & Lichtor, 
2008b). 
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In general, immediate release preparations of opioids are used to treat acute pain 
or breakthrough exacerbations of pain in chronic conditions (American Academy of 
Pain Medicine & American Pain Society, 1996; National Prescribing Service, 2010; 
NSW Therapeutic Assessment Group, 2002). Extended release medications are used 
to primarily treat chronic conditions. However, most clinical guidelines suggest that 
POA drug therapy should only be undertaken and maintained if the pain appears to be 
opioid responsive; that is, there is an analgesic effect produced by administration of 
the drugs (Kalso et al., 2003; Nicholson, 2003; Schug, Merry, & Acland, 1991). 
Titrating the POA drug type dose to an appropriate level to achieve analgesic effects 
can be a complex process. Most clinical guidelines advise particular caution using 
POA drugs, and nominate adverse consequences of prolonged use such as dependence 
and abuse.  
 
As mentioned previously, the American Academy of Pain Medicine and the 
American Pain Society established clinical guidelines in 1996 in the USA. There are a 
variety of similar guidelines in Australia. Most state regulatory agencies publish some 
form of standard guideline (NSW Therapeutic Assessment Group, 2002), and these 
are mostly consistent with the USA guidelines. The National Prescribing Service 
(National Prescribing Service, 2011), a not-for-profit professional medicines group, 
provides standard guidelines on the use of POA drugs for medical practitioners in 
Australia (National Prescribing Service, 2006, 2010). 
 
A Cochrane review recently published a review of use of opioids in chronic non-
malignant pain (Noble, et al., 2010) and suggested that, “proper management of a type 
strong painkiller (opioids) in well-selected patients with no history of substance 
addiction or abuse, can lead to long-term pain relief (for) some patients with a small 
risk of developing addiction, abuse, or other serious side effects…” ((Noble, et al., 
2010). 
 
The major concerns with chronic use of POA drugs is that treatment could cause 
or lead to misuse. Patients who are inappropriately managed on these drugs could 
develop dependence (Bieber et al., 2007; Craig, Diana, & Maren, 2007; Fudin, 
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Levasseur, Passik, Kirsh, & Coleman, 2003; Kahan, 2006; Rosenblum, et al., 2008). 
Alternatively, patients who are drug dependent might seek to obtain prescriptions to 
maintain their dependence or divert to illicit drug markets (Inciardi, et al., 2010; 
Kraman, 2004; Martyres, et al., 2004). Furthermore, opioid dependent individuals 
might also suffer chronic pain conditions and require POA drug treatment (Fudin, et 
al., 2003; Markowitz et al., 2010; Moore & McQuay, 2005).  
 
It remains a significant challenge for clinicians using POA drugs to differentiate 
between appropriate therapeutic use and dependence. The complexity of presenting 
conditions (American Academy of Pain Medicine & American Pain Society, 1996; 
Becker, Sjogren, Bech, Olsen, & Eriksen, 2000; Noble, et al., 2010; Potter & Jones, 
1992), the lack of readily accessible specialist support (Becker, et al., 2000; Potter & 
Jones, 1992), and the nature of general models of therapeutic relationships rely on a 
bond of trust between practitioner and their patient (Bendtsen, Hensing, Ebeling, & 
Schedin, 1999; Bhamb, 2006). To further complicate matters, the underlying concepts 
of abuse and dependence are also contentious and problematic, particularly in relation 
to the chronic use of POA drugs. Illustrating this, in 2015 Degenhardt and others 
sought to classify a sample of long term POA drug using persons for problematic use 
disorders using version of current and past DSM and ICD classifications. The results 
found inconsistent levels of classification of problematic opioid use across different 
editions of the DSM and ICD (Degenhardt et al., 2015).  This is a particular concern 
for treatment providers in this area of treatment, many who are non-expert in diagnosis 
of substance use disorders and who are seeking to treat what are primarily presenting 
pain conditions. 
 
2.4.1  What are the harms caused by POA drugs? 
 
Conceptualising harms of prescription drugs has proven to be complicated. A 
generally popular dichotomy of hard drugs and soft drugs is often referred to in the 
media and colloquial accounts regarding drugs use. In illicit drugs, heroin might be 
referred to as hard drug and marijuana as soft drug. However, this dichotomy is limited 
when attempting to assess actual harms in a quantifiable method. For example, heroin 
is highly dependence-forming, can cause overdose deaths, can increase risks of 
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acquiring BBVs via unsafe injecting practices, but, a manageable dose has limited 
long-term deleterious physiological effects. In contrast, marijuana is less dependence-
forming, but has known physiological effects due to prolonged use, and if ingested by 
smoking has a significant increased risk of throat and lung cancers. Therefore, harms 
might be better described on different dimensions. 
 
Nutt et al, 2007 (Nutt, King, Saulsbury, & Blakemore, 2007) proposed that there 
are three main factors that together determine the harms associated with any drug of 
potential abuse (see Table 2.3). The three main factors are: physical harm of drugs, 
causing damage to organs or physical systems or having negative physiological effects, 
such as effects to respiratory or cardiac systems; dependence potential of a drug, 
related to the interaction between its pleasurable effects and its propensity to produce 
dependence behaviour or be abused; social harms, related to the various effects of 
intoxication, through damaging family and social life and associated costs with health 
care, social care and legal responses. 
 
Table 2.3 Assessment of drug harms (Nutt et al, 2007) 
Harm Parameter Description 
Physical harm 1 Acute 
 2 Chronic 
 3 Intravenous harm 
Dependence 4 Intensity of pleasure 
 5 Psychological dependence 
 6 Physical dependence 
Social harms 7 Intoxication 
 8 Other social harms 
 9 Healthcare costs 
 
 
2.4.2 What POA drugs cause harms and why? 
The overarching harms associated with POA drugs are outlined in Chapter 2, 
and these broadly relate to the harms associated with opioid drugs and their risk of 
causing abuse or dependence. This is largely due to the active opioid ingredient of 
these drugs. However, different types of POA drugs have been more subject to misuse 
than others over time.  
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Considering whether a POA drug is more associated with harms is a complex 
consideration as the drugs themselves have been shown to have a legitimate 
therapeutic use, and have met appropriate clinical and regulatory safety standards for 
use in treatment settings. Evidence to date suggests there is a paucity of knowledge of 
the abuse liability of prescription opioids or the features of certain POA drugs that 
make them more sought after by persons who suffer substance misuse disorders 
(Centers for Disease Control and Prevention, 2012; Zacny, et al., 2003). Therefore, the 
types of drugs sought by drug-seeking or doctor-shopping patients could indicate 
particular concerns. 
 
Dosage levels in particular preparations are a particular concern. For example, 
most POA drugs have varying dosage preparations to allow for moderation of 
treatment and dosages in response to a patient’s pain levels and effects of the drug. 
However, higher dose preparations have more immediate value to drug dependent 
persons, as they represent the highest dosages available, and these are also more 
readily saleable and return higher value (Centers for Disease Control and Prevention, 
2012; Cepeda, Fife, Kihm, Mastrogiovanni, & Yuan, 2014; Compton & Volkow, 
2006). 
 
There is some evidence across jurisdictions that high-dose oxycodone, morphine 
and fentanyl preparations are most sought by drug-seeking patients and are more 
associated with non-medical use (Cepeda, et al., 2014; Dart et al., 2015; Dreifuss et 
al., 2013; Pilgrim, 2015; Zacny, et al., 2003). Therefore, for meeting dependence needs 
and diversion value, higher dose preparations represent most value for a person 
engaged in drug-seeking behaviour. 
 
It appears that any opioid by virtue of its active ingredient can be potentially 
sought after by drug-dependent persons, and in certain circumstances persons with 
injecting drug use histories will seek to modify these drugs for injection (Black, 
Trudeau, Cassidy, Budman, & Butler, 2012; Degenhardt et al., 2013; Lankenau et al., 
2011)). It is not clear if aspects of the preparations of certain POA drugs as ampoules, 
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tablets, capsules, or transdermal patches are more associated with abuse or dependence 
formation. 
 
The other aspect of formulation that is of interest is the proliferation of the 
controlled-release preparations of morphine and oxycodone and, to a lesser extent, the 
matrix release patches of transdermal fentanyl. The controlled-release POA drugs 
offered a benefit in managing pain conditions by allowing doses to be released over 
longer time periods of 6 or 21 hours (Davis et al., 2003; Mucci‐LoRusso et al., 1998).  
 
A number of US, Canadian and Australian studies have now strongly suggested 
that controlled-release oxycodone (i.e. OxyContin™) is particularly associated with 
dramatic increase in POA drug misuse and related harms (Canadian Centre on 
Substance Abuse, 2010; Dunn, 2008; Rintoul, et al., 2010). The slow release nature of 
these classes of POA drugs has not proven to be a barrier to dependence formation 
even when taken orally. There is now ample evidence of their association with abuse 
and dependence (Butler, Black, Cassidy, Dailey, & Budman, 2012; Rafat & Sproule, 
2015). 
 
2.5 CONCEPTS AND THEORIES IN OPIOID ANALGESIC DRUG USE 
Opioid drugs are most commonly used for pain management, in medical 
treatments, and as drugs of dependence or abuse in non-therapeutic situations. This 
section seeks to outline the conceptual frameworks and underlying definitions around 
these different facets of opioid use to explain some of the common issues of opioid 
use. Some matters of contention between these areas are also discussed. 
 
There are concepts that underpin human reactions to opioid drugs that are 
pertinent to both pain management and drug dependence. These are discussed below 
as they are relevant to later discussions around conceptual frameworks in pain 
management and dependence in regard to opioid drugs. 
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2.5.1 Drug concepts 
 
The chronic or long-term use of opioid drugs, as with other dependence-causing 
substances, leads to certain physiological responses of the body. Increased tolerance 
to a substance is experienced over time, and chemical receptors in the brain undergo 
neuro-adaptation in the presence of high levels of opioids with long-term use. The 
individual will experience withdrawal symptoms on the cessation of use, or possibly 
when dose effects have dissipated (Gutstein & Akil, 2006; Zacny, et al., 2003). Table 
2.4 below sets out some established definitions of these concepts. 
 
With POA drugs, chronic use and cessation of use can induce some or all of the 
above physiological responses. This physiological response can occur regardless of 
whether a person is dependent on these drugs according to full diagnostic assessment. 
This issue is discussed further in the following sections. 
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Table 2.4. 
Concepts in drug dependence 
Concept Description 
Tolerancea 
 
Tolerance is a state of adaptation in which exposure to a drug 
induces changes that result in a diminution of one or more of 
the drug’s effects over time. 
 
Withdrawalb 
 
Physiological and psychological symptoms associated with 
withdrawal from the use of a drug after prolonged 
administration or habituation. The concept includes 
withdrawal from smoking or drinking, as well as withdrawal 
from an administered drug. 
 
Neuro-
adaptationb 
 
The complex biological changes that occur in the brain with 
repeated or chronic exposure to a drugs. With repeated 
exposure, the body and brain often adapt to the presence of the 
drug. Through homeostatic or ‘self-corrective’ mechanisms, 
the nervous system attempts to compensate for the effects of 
the drug. 
 
Physical 
dependencea 
Physical dependence is a state of adaptation that is manifested 
by a drug class specific withdrawal syndrome that can be 
produced by abrupt cessation, rapid dose reduction, decreasing 
blood level of the drug, and/or administration of an antagonist. 
 
 
Source: a - (American Academy of Pain Medicine & American Society of Addiction 
Medicine, 2001) & b- (Heather, 1998) 
 
 
2.5.2 Pain management 
 
The International Association for the Study of Pain defines pain as ‘an 
unpleasant sensory and emotional experience associated with actual or potential tissue 
damage or described in terms of such damage’ (Merskey & Bogduk, 1994).   
 
Pain is typically classified as either acute or chronic. Acute pain is most 
commonly characterized as the result of disease or injury, and the cause can often be 
diagnosed and treated. Acute pain is self-limiting and confined to a given time and 
severity (Gutstein & Akil, 2006; Wolfert, Gilson, Dahl, & Cleary). Chronic pain is 
pain that persists over a longer period of time, and generally resistant to most medical 
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treatments. Common chronic pain conditions can include: headache, back pain, cancer 
pain, arthritic pain, neurogenic and psychogenic pain (Merskey & Bogduk, 1994).  
 
The sensation of acute pain is the response to tissue injury by peripheral pain 
receptors and their specific nerve fibres (nociceptors). Chronic pain is believed to be 
the result of persistent activation of these fibres. This type of pain is known as 
‘nociceptive pain’. Chronic pain can also be caused by damage or dysfunction to the 
peripheral nervous system, and is known as ‘neuropathic pain’ (Merskey & Bogduk, 
1994).  
 
Opioid drugs cause certain inhibitory or excitatory neurochemical actions at 
various sites that can reduce the sensation of pain. Opioids are believed to have mild 
anti-inflammatory effects at injury site, act to reduce activity in the spinal cord, and 
have inhibitory excitatory on certain opioid receptors in the brain (American Academy 
of Pain Medicine & American Pain Society, 1996; Kahan, et al., 2006; Merskey & 
Bogduk, 1994). Figure 2-4 graphically describes this. 
 
 
Figure 2-4. Opioid sites of action in pain. From: . 
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Acute pain conditions are generally considered better treated by those opioids 
that rapidly reach the pain receptors (Kahan, et al., 2006; Merskey & Bogduk, 1994). 
This usually means preparations of opioids that are injected into the muscle or the 
blood stream, or tablet forms that immediately release the full dose on oral ingestion 
into the gastro-intestinal system (Merskey & Bogduk, 1994). This means the effect of 
the opioid is achieved in a short time and the effects rapidly leave the system after the 
dose release. Thus for acute pain, a short course of rapid-acting opioids is considered 
optimal, as they would reduce the pain over the length of the episode. 
 
For chronic pain conditions, the use of controlled-release opioids is the preferred 
method of treatment (Braden et al., 2008; Kahan, et al., 2006). This is because ongoing 
dosing can achieve a level of opioids maintained over a longer period of time, and 
provide improved pain control over the course of time to improve the functioning of 
an individual (American Academy of Pain Medicine & American Pain Society, 1996; 
Kahan, et al., 2006). 
 
The known side effects of opioid use include sedation, constipation, the 
development of tolerance, and physical dependence (Gutstein & Akil, 2006). 
Hyperalgesia is also a possible outcome of long-term opioid therapy. This refers to an 
increased response to a stimulus which is normally painful, due to continued opioid 
use (Merskey & Bogduk, 1994). 
 
It is not generally shown that exposure to opioids alone in pain management 
cases is sufficient to cause dependence (Noble, et al., 2010). However, it has been 
suggested that the risk factors commonly associated with development of dependence 
in individuals in general might be similarly related in people suffering pain conditions 
when exposed to opioids (Bieber, et al., 2007; Kahan, 2006; McCracken, Hoskins, & 
Eccleston, 2006; Rosenblum, et al., 2008). However, it is not well established as to 
what role pain conditions might play in mediating or moderating individuals' 
likelihood of developing dependence. 
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2.5.3 Dependence and abuse 
 
The two most widely accepted diagnostic criteria for defining substance abuse 
and dependence are the Diagnostic and Statistical Manual of Mental Disorders of the 
American Psychiatric Association (DSM-IV) (American Psychiatric Association, 
2000) and the World Health Organisation’s International Classification of Diseases 
(ICD-10) (World Health Organisation, 2007). 
 
Drug dependence is generally described as the set of maladaptive behaviour 
resulting from the inappropriate use of a substance, such that an individual 
demonstrates lack of control over their use of the substance, and that use assumes a 
significant priority in an individual's life to the detriment of their normal functioning. 
Dependence for both the DSM-IV and ICD-10 definitions requires the presence of 
behavioural, physiological and cognitive phenomena (American Psychiatric 
Association, 2000; World Health Organisation, 2007). The use of the term ‘addiction’ 
is not supported by either classification, but has been widely used in the field 
(American Psychiatric Association, 2010). For the benefit of this study the term 
‘dependence’ will be used in keeping with accepted definitions.  
 
Drug abuse or harmful use can be defined as inappropriate use for particular 
effects, but may or may not be associated with dependence. This is often characterized 
by patterns of use that are damaging to an individual’s health and includes episodes of 
heavy consumption or binges (American Psychiatric Association, 2000). 
 
The use of the diagnostic term ‘dependence’ – that includes physical and 
psychological aspects – has led to confusion across the domain, since the over-arching 
term ‘dependence’ has been adopted (American Psychiatric Association, 2010). This 
is particularly relevant in the area of POA drugs, given that chronic use can produce 
physiological symptoms such as tolerance and withdrawal, but not necessarily further 
psychological criteria for dependence (Banta-Green, Merrill, Doyle, Boudreau, & 
Calsyn, 2009a; Bieber, et al., 2007; Kahan, 2006; McCracken, et al., 2006; Rosenblum, 
et al., 2008). It has been suggested that the misuse of the term ‘dependence” has led to 
the potential misdiagnosis of dependence, where only physical dependence was 
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evident in many cases of chronic POA drugs use (Kahan, 2006; Zacny, et al., 2003). 
The current revision of the DSM-5 – the fifth edition – has considered this matter of 
particular relevance and re-introduced the term ‘addiction’ into the nomenclature for 
these disorders (American Psychiatric Association, 2010). However, of particular note 
is that the  DSM-5 has a definition of substance use disorders related to POA drugs 
sets out that tolerance and withdrawal are not indicators of use disorder if consistent 
with a treatment regime. However, these physiological indicators are to be considered 
counted in the context of ‘aberrant’ behaviour (Degenhardt, et al., 2015; Larance, 
Degenhardt, Lintzeris, Winstock, & Mattick, 2011) 
 
Drug dependence can be conceptualized in terms of the use of a substance for 
initially pleasurable experiences where no therapeutic use supports it, and then 
continued use despite increasing negative consequences. At a neurochemical level 
initial use acts to stimulate the release of the neouro-transmitter dopamine thought to 
be associated with increasing pleasurable experiences (Brownstein, 1993). This 
behaviour is intrinsically reinforcing and encouraging of continued use. With chronic 
use, tolerance develops, neuro-adaptation occurs, and greater doses of the substance 
are required to achieve the same pleasurable effects (Heather, 1998), and reduce the 
experience of withdrawal effects(American Psychiatric Association, 2010; Gutstein & 
Akil, 2006). 
 
The causes of dependence are best understood in the model of dependence that 
incorporates biological, psychological, and social and cultural influences, more 
commonly known as the ‘biopsychosocial model’. This model arose largely out of 
opposition to medical or disease models of dependence and addiction (Marlatt, Baer, 
Donovan, & Kivlahan, 1988; Sarafino, Caltabiano, & Byrne, 1990). The 
biopsychosocial model describes the genesis of drug dependence as being based on 
particular proximal and distal contributing risk factors. These factors include 
biological factors (such as genetic predisposition), psychological factors (such as 
constructs of sensation-seeking or expectancies and mental illness), and social factors 
(such as substance use in families and peer networks) (Marlatt, et al., 1988; Newcomb 
& Earleywine, 1996). The model also describes the symptoms of dependence, in that 
a person will experience biological symptoms, such as neuro-adaptation, and 
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psychological and social symptoms of their condition (Marlatt, et al., 1988; Newcomb 
& Earleywine, 1996). 
 
2.5.4 Drug dependence and pain management 
 
Chronic use of POA drugs for either chronic pain management or dependence 
reasons can promote neuro-adaptation, increased tolerance, and withdrawal on 
cessation of use. The above conceptual understandings of drug dependence and pain 
management have been discussed as discrete phenomena. However, drug dependence 
and chronic pain conditions might co-occur in an individual, thus making the 
assessment and management of their condition more complex. 
 
It is generally supported that where a chronic pain condition exists in an 
individual without drug dependence, or without particular risk factors for dependence, 
then appropriate treatment with POA drugs can be undertaken without risk of causing 
dependence (Noble, et al., 2010). However, there is considerable evidence suggesting 
that where drug dependence or particular risk factors for dependence co-exist with a 
chronic pain condition there is a greater risk of a person developing dependence on or 
misusing POA drugs (Bieber, et al., 2007; Fudin, et al., 2003; Rosenblum, et al., 2008). 
The particular complexity in these instances can be that an opioid-dependent person 
might exhibit hyperalgesia, and require higher levels of analgesia for pain management 
than an opioid-naïve individual (Catalano, White, Fleming, & Haggerty, 2011; 
Doverty et al., 2001). 
 
Similarly, a person with drug dependence or at risk of developing dependence 
without a therapeutic need for analgesia and who is exposed to long-term POA drugs 
use also has a high risk of developing dependence on these drugs (Catalano, et al., 
2011; Manchikanti, 2008). This situation could perhaps describe a misdiagnosed 
patient receiving POA drug therapy, or individuals exposed to POA drugs diverted to 
illicit markets. 
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The challenge for clinicians is in the assessment and management of persons 
thought suitable for POA drugs therapies to ensure appropriate pain management, and 
to reduce the possible risk of causing dependence and other harms. 
 
2.6 DETERMINING SUBSTANCE DISORDERS WITH POA DRUGS 
 
Diagnoses of abuse and dependence can only be authoritatively made by 
individual assessment of patients by clinicians using accepted diagnostic criteria. The 
two most widely accepted being DSM-IV-TR (American Psychiatric Association, 
2000) and ICD-10 (World Health Organisation, 2007) definitions of opioid abuse and 
dependence. It should be noted that the current edition of the DSM-5 – was released 
in 2012 during the course of this study. However, the DSM-IV-TR criteria were used 
for purposes of the first study as this was the most currently used and widely known 
version.  
 
A number of scales of opioid abuse and dependence are also used in clinical 
face-to-face assessment of a patient, or at least based on access to comprehensive 
clinical records. However, the majority of these scales are used in the context of illicit 
opioid use, not POA drugs use. Given the increasing understanding of the development 
of substance use disorder with prescription opioids in chronic pain management cases, 
a number of scales have been developed to detect the onset of, or susceptibility of 
patients to, substance use disorders on POA drugs (Banta-Green, et al., 2009a; Banta-
Green, Merrill, Doyle, Boudreau, & Calsyn, 2009b; Banta-Green et al., 2011; Wilsey 
et al., 2008).  
 
However, the vast majority of POA prescribing and treatment occurs in 
community settings (non-hospital/non-inpatient) and is provided by general 
practitioners (GP). The most common treatment scenario of concern would be that of 
a patient presenting with a pain condition and a GP deciding if POA drugs were an 
appropriate treatment option, and balancing the concerns of misuse or dependence. 
This study is to examine prescription database records that have been gathered for 
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regulatory purposes and this data cannot supplant a clinical measure, but can 
potentially serve a proxy for such. 
 
Furthermore, opioid dependence or abuse in regards POAs is complicated by the 
fact that treatment might have been initiated due to legitimate medical conditions. It is 
often difficult for GPs to detect, assess and manage opioid dependence or abuse in 
their patient populations. This is not a shortcoming of GP abilities or their treatment, 
and could in part be due to aspects of increasing workloads, shorter patient consultation 
times, inability to obtain timely specialist reviews, and patients who for any number 
of reasons might not reliably report their condition or drug use history. Further, it might 
be a matter of routine in a general practice setting for a doctor to apply a measure of 
substance misuse disorders in assessing or reviewing chronic non-malignant pain 
patients. Therefore, dispensed prescription information might be the most utilitarian 
and accessible potential proxy measure to inform of potential cases of concern. 
 
To compound this increasingly complex area, there are divergent views as to 
definitions of abuse and dependence (Minozzi, Amato, & Davoli, 2013; Rehm et al., 
2013; Volkow & McLellan, 2016) and what is appropriate CNMP management in 
relation to the use of prescribed medications (American Pain Society in Conjunction 
with the Americian Academy of Pain Medicine, 2009; Chou, et al., 2015; Kissin, 
2013). 
 
In relation to substance misuse disorders with POA drugs, this is largely due to 
two underlying issues in chronic use of these drugs. Firstly, chronic use will induce 
physiological dependence over time, such that cessation of treatment will induce a 
withdrawal state.  Secondly, general definitions of dependence include physiological 
and behavioural criteria to be met to satisfy a diagnosis of dependence. However, 
inappropriate pain by providing insufficient medication for pain management could 
also induce a withdrawal state, and/or behaviour that might be considered drug 
seeking. It should be noted that neither the DSM or ICD framework maintain that 
tolerance or withdrawal are necessary criteria for a diagnosis of a substance use 
disorder. This differentiation could be difficult for non-specialist clinicians. 
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Furthermore, the current DSM-5 now no longer retains a separate diagnoses of abuse 
and dependence but includes an overarching construct of ‘substance use disorder’. 
Larance and others (2011) also suggested concepts such as ‘non-adherence’, ‘extra-
medical use’, and ‘aberrant behaviour’ could also be useful concept of describing POA 
drug misuse (Larance, et al., 2011). 
 
The term ‘pseudo-addiction’ has been coined in the US (Greene & Chambers, 
2015) to describe this phenomenon. However, it is not a term widely used outside of 
the US, and has certain connotations that suggests this is either a less serious issue or 
that a patient might be deliberately misleading a doctor as to their condition or need 
for opioids. 
 
A number of issues are of interest arise in this question. Firstly, whether there is 
any difference between expert groups in how they might assess POA drug use and 
dependence. Secondly, testing views of experts on the importance of the criteria of 
tolerance and withdrawal. And lastly, whether there could be a reasonable conceptual 
association to link drug seeking to doctor shopping as important criteria for 
establishing a diagnosis of dependence or abuse in regards to misuse of POA drugs. 
 
Due to the significant public health concerns in this area, and the nature of the 
drugs involved, jurisdictional regulators have become involved in attempts to 
moderate prescribing practices and manage problematic drug procurement by patients. 
The monitoring of obtained and dispensed prescriptions can form crucial objective 
evidence as to the total drugs and drug-seeking behaviour of patients. The key response 
from many jurisdictions experiencing POA problems is to implement prescription 
drug-monitoring programs. 
 
2.6.1 Definitions of Dependence and Abuse 
Drug dependence and abuse in relation to prescription opioid misuse is a 
diagnosis that is subject to a range of opinions and some contention as to what level of 
use constitutes inappropriate use (Edlund et al., 2014; Garland & Black, 2014; Rehm, 
 61 Prescription opioid analgesic drug misuse: What can we learn from doctor-shopping behaviour 
et al., 2013). Increases in numbers of persons possibly seeking prescription opioids 
due to their substance abuse disorders or other non-medical reasons has become an 
increasing challenge for primary care providers and general practitioners. 
 
The two most widely accepted diagnostic guidelines are DSM-IV-TR (American 
Psychiatric Association, 2000) – now superseded by the DSM-5 (American Psychiatric 
Association, 2013) – and ICD-10 (World Health Organisation, 2007) that both contain 
definitions of opioid abuse and dependence. Noting, however that the DSM-5 has 
dispensed with the constructs of dependence and abuse in favour of the overarching 
construct of substance use disorder (Hasin et al., 2013). 
 
The ICD is a diagnostic system established by the World Health Organisation 
for the purposes of reducing disease burden across member countries. The DSM is 
produced and approved by the American Psychiatric Association and contains 
significant additional information around mental health disorders (APA, 2009).  
 
The DSM-IV-TR diagnostic criteria for substance dependence and abuse and the 
ICD-10 criteria for dependence syndrome and harmful use are set out in Appendix A. 
There are a number of similar criteria in both, but the DSM-IV-TR contains extra 
behavioural criteria. Andrews (1999) found that the DSM was the preferred diagnostic 
criteria for mental health disorders and that there was some lower agreement in 
diagnoses of substance dependence across DSM and ICD compared to other mental 
health disorders. The DSM-IV-TR criteria are have more widely used than the ICD-
10 criteria for clinical diagnosis purposes in Queensland via its advice to medical 
practitioners in guiding their assessment of drug dependence. The DSM-IV-TR 
diagnoses for substance abuse and dependence set out a total of four and seven criteria 
respectively.  
 
The diagnostic decision requires the meeting of one or more criteria in a 12-
month period for a diagnosis of abuse, and three or more criteria for a diagnosis of 
dependence. There is some contention about the use of the criteria of tolerance and 
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withdrawal in the case of prescription drug use. In the DSM-5, the constructs of 
dependence and abuse are now combined into an overarching diagnosis of substance 
use disorder (Hasin, et al., 2013) and the criteria of tolerance and withdrawal are not 
included as criteria that can be used to reach a diagnoses of a substance use disorder, 
but acknowledged as being relevant in the context of POA drugs (American 
Psychiatric Association, 2013). 
 
For the purposes of this study the diagnostic criteria used in the DSM-IV-TR 
(American Psychiatric Association, 2000) for drug dependence and abuse were used. 
This is because they were the accepted criteria at the time of study, and would have 
been familiar to the widest range of experts in the field for purposes of eliciting 
responses.  
 
2.7 POPULATIONS OF OPIOID DRUG USERS 
Research and information about this emerging trend in a new class of drugs of 
abuse is incomplete and inconsistent. A recent US review highlighted the lack of 
comparable international evaluations to POA drug prescribing practices, volumes, and 
associated drug harms due to different survey measures used (Manchikanti, 2008; 
Zacny & Lichtor, 2008b).  A significant Norwegian study in 2013 tracked a cohort of 
patients starting on POA drugs from their first exposure. This study found just over 
seven percent of patients were still on POA drugs after five years and over one third 
of these had doubled their original dose (Fredheim, Borchgrevink, Mahic, & Skurtveit, 
2013). Recent Australian research and reviews have also suggested research is required 
into monitoring and trends of pharmaceutical drugs misuse, and the phenomenon of 
doctor shopping (Drugs and Crime Prevention Committee, 2007; Fry, Smith, Bruno, 
O'Keefe, & Miller, 2007; Karanges, et al., 2016; Roxburgh, 2011; Royal Australasian 
College of Physicians, 2009) 
 
The dramatic increases in prescribing is exposing more of the population to POA 
drugs, and potentially to the risk of developing drug dependence (Manchikanti, 2007; 
Manchikanti, 2008). It is also suggested that given the issues of misuse following 
increased prescribing of POA drugs in the USA, Australia’s increased prescribing 
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could be facing similar concerns (Dobbin, 2009, 2010a). However, at this time in 
Australia there is limited evidence as to the extent of these harms. There is possibly an 
increasing prevalence of POA drug dependence and abuse hidden from scrutiny by the 
usual drug monitoring and surveillance systems in Australia (Elise Bailey, 2008; 
Manchikanti, 2008).  
 
There are potentially a number of sub-populations described by research to date 
that appear to be using POA drugs for legitimate and/or non-medical purposes. 
Broadly, there is the apparent dichotomy between those patients who are using drugs 
for therapeutic reasons, and those persons that are misusing them and suffer substance 
misuse disorders. Studies suggest these populations could be heterogeneous and 
dynamic, and not necessarily discrete. A brief analysis of the epidemiology of these 
hypothesised populations follows. 
 
Minozzi and others (Minozzi, et al., 2013) conducted a systematic review of 17 
studies involving a total of 88,235 participants and found the incidence of dependence 
developing following treatment with POA drugs ranged from 0 to 24% (median 0.5%); 
prevalence ranged from 0 to 31% (median 4.5%). They concluded that the available 
evidence suggests that opioid analgesics for chronic pain conditions are not associated 
with a major risk for developing dependence. However, in contrast, Edlund and 
colleagues (Edlund, et al., 2014) analysed the data of over half a million individuals 
with new chronic non-cancer pain episodes and found POA drug exposure was a strong 
risk factor for development of an opioid use disorder, with duration of treatment being 
more important than daily dose. 
 
It is hypothesised that some individuals, through exposure to POA drugs alone 
and initiated on legitimate therapeutic grounds, could develop substance misuse 
disorders, such as dependence or abuse. This has led to the suggestion that this group 
represent an emerging ‘hidden population’ (Dobbin, 2014). The hidden population are 
persons who are not coming to the attention of traditional alcohol and drug treatment 
services, are not largely engaged in the illicit drug milieu, do not identify themselves 
as drug misusers, and might not be recognised as such by their treating practitioners.  
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There also appears to be an emergent population of persons using POA drugs for 
‘non-medical’ purposes not derived from initial therapeutic exposure to POA drugs. 
Illicit opioid drug users might use POA drugs as substitutes, supplements or 
alternatives to heroin. Studies in the USA, Canada and Australia have found illicit 
POA drug has increased significantly over the last three decades. Investigations of 
these populations suggest there could be an emerging illicit POA drug-only sub-
population; a dynamic group of users who use illicit opioids and POA drugs equally; 
and an older heroin-only using subgroup (Fischer et al., 2008). It is not clear for this 
population whether they are obtaining POA drugs directly from prescriptions 
themselves or via supplies diverted from other patients.  
 
The reasons for this population using POA drugs has been suggested as 
influenced by shortages or disruptions in heroin supplies (Khosla, Juon, Kirk, 
Astemborski, & Mehta, 2011; Lankenau et al., 2012; Louisa Degenhardt, 2008; Zacny 
& Lichtor, 2008a), preferences for drugs of known quality and dosage, and the greater 
availability and access to POA drugs (Black, et al., 2012). It should also be noted that 
illicit drugs users might not be exclusively accessing prescription drugs, as many over-
the counter medications containing codeine and paracetamol have been abused. 
 
A further complexity in the illicit drug using population is that some of these 
individuals might require chronic pain management and treatment with POA drugs. 
Evidence is emerging that illicit opioid using persons maintain use of drugs throughout 
their life span and with the opioid substitution treatments are living longer than 
previously (Højsted, Nielsen, Guldstrand, Frich, & Sjøgren, 2010; Kahan, 2006). The 
complication here for patients is that appropriate disclosure of their histories might 
cause loss of access to treatment. The complication for treatment providers is 
managing a pain condition with POA drugs within the context of past or concurrent 
illicit drug use. 
 
Within the context of persons receiving prescriptions, there exist the possibility 
of those who obtain POA drugs and do not have medical conditions or suffer from 
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substance use disorders. This population would be difficult to estimate, as it is assumed 
that most prescribers would prescribe for perceived legitimate needs of patients. The 
numbers of prescribers reprimanded or de-registered for negligent prescribing remains 
low (Gilson, 2010a; Joranson & Gilson, 1996; Stratton Hill Jr, 1996). 
 
Figure 2.6 represents a proposed conceptual model of the populations of interest 
of POA drug users and how they might intersect or overlap. The proposed descriptions 
of these populations, their intersecting and discrete sub-populations, and those in 
which doctor-shopping behaviour might be expected to occur is described in the 
following sections. Populations and sections are not in proportion to any scale or size, 
and are only hypothetical at this stage. 
 
Figure 2-5. Conceptual diagram of possible POA drug using populations 
 
The three intersecting populations in Figure 2.6 are made up of three overarching 
populations represented by the groups A, B and C, which are: 
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A: Persons prescribed POA drugs – this is the population of persons who at any 
time are being prescribed opioid analgesic pharmaceutical drugs for any reason. This 
group is captured by a prescription drug-monitoring program. 
 
B: Persons dependent on illicit drugs – this is the population of persons who at 
any time are dependent on, or addicted to illicit drugs. For this study, it refers to 
persons primarily dependent on heroin, but is not necessarily limited to this illicit drug 
alone (see Note i).  
Note i: Illicit street drugs refer to non-pharmaceutical preparations such as 
heroin, amphetamine, or cocaine, etc. Although diverted POA drugs are also 
considered ‘illicit’ in these circumstances they are considered a distinct other class of 
illicit drugs, as their primary source is via doctors’ prescriptions, not larger-scale 
criminal operations. 
 
C: Persons dependent on POA drugs – this is the population of persons who at 
any time are dependent on POA drugs. This population might be typified as those 
whose drug using careers began with POA drugs, as opposed to illicit street drugs (see 
Note i). Further, this use might have commenced during treatment for legitimate 
medical conditions. 
 
It is proposed that there are four intersecting sections of these populations 
represented by the marked areas sub-populations 2, 4, 5 and 6, which are: 
 
Sub-population 2 – This sub-population are those illicit drug-dependent persons 
who are prescribed POA drugs at any given time, but not dependent on them. For 
example, this could be an illicit drug user who is receiving post-operative pain relief. 
This population would not necessarily be expected to engage in doctor shopping. 
However, exposure to POA drugs might increase the risk of drug-seeking for POA 
drugs (see Note ii)..  
Note ii: This population may require particular attention for their pain 
management needs as, if they are currently dependent on illicit drugs similar in action 
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to POA drugs, their tolerance for these drugs will be higher and they might require 
higher doses of POA drugs in comparison to an opioid naïve person (i.e. hyperalgesic). 
 
Sub-population 4 – This sub-population represents persons addicted to, or 
dependent on POA drugs who are receiving prescriptions, but who are not addicted or 
dependent on illicit drugs. There would conceivably be a risk of doctor-shopping 
behaviour to be found in this sub-population.  
 
Sub-population 5 – This sub-population represents persons dependent on POA 
and illicit drugs who are receiving prescriptions for POA drugs. This population might 
be most at risk of obtaining POA drug prescriptions for non-therapeutic reasons; that 
is, not having a medical condition apart from dependence that requires treatment with 
POA drugs. This sub-population could also potentially exhibit doctor-shopping 
behaviour. However, some persons might be treated for their dependence outside 
formal opioid substitution programs. 
 
Sub-population 6 – This intersection between illicit drug-dependent and POA 
drug-dependent populations represents those persons who are not receiving POA 
prescriptions. Persons in this sub-population would be obtaining POA drugs from 
sources other than prescriptions, such as black market suppliers or diversion from 
legitimate recipients. 
 
There are three discrete sections of the larger populations A, B and C that do not 
intersect with each other, and these are represented by the marked areas, 1, 3 and 7, 
which are: 
 
Sub-population 1 – This sub-population represents those persons receiving POA 
drug prescriptions who are not dependent on illicit or licit drugs. It would be expected 
the risk of doctor shopping should be low in this sub-population. If doctor shopping 
for prescriptions occurred in this population, it could represent: 
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• a person receiving inadequate treatment by their treating doctors (see 
pseudo-addiction) 
• a person not dependent on POA drugs but on-selling or diverting these 
medications, or engaged in some other criminal enterprise. 
 
Sub-population 3 – This sub-population represents those persons dependent on 
illicit drugs who do not receive any prescriptions for POA drugs. This would not 
preclude these persons obtaining POA drugs for reasons of their drug dependence; 
however, supply would be from non-prescription or diversion. As distinct from sub-
population C, these persons would be primarily dependent on illicit drugs. 
 
Sub-population 7 – This sub-population represents those persons dependent on 
POA drugs who are not dependent on illicit drugs, nor are they obtaining POA drug 
prescriptions. These persons could be doctor-shopping but being refused prescriptions 
for POA drugs by doctors, or are obtaining other prescription drugs (e.g. 
benzodiazepines, tramadol) or obtaining over-the-counter medications. These persons 
might also obtain POA drugs from other illicit markets or persons diverting them for 
other purposes. 
 
The more difficult behaviour to account for is where POA drugs could be 
diverted to other persons. Persons likely to divert prescribed POA drugs could be 
anyone, but more likely to be high dose, and/or doctor shopping persons. There is 
limited evidence of persons admitting to diversion of POA drugs. However, there is 
ample evidence from Australia (AIHW, 2012) and overseas (Alho et al., 2015; 
Dreifuss, et al., 2013; Nielsen et al., 2011) of persons’ admissions to drug treatment 
programs from POA drug SUDs where they have reported access from non-medical 
sources.  There is some evidence of police and crime reports (IDRS & Crime reports) 
of persons being prosecuted for offences of selling POA drugs and reports of pharmacy 
business thefts are also reported. 
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Persons like to divert POA drugs could fit in any particular category but 
assuming a person is obtaining POA drugs to meet a therapeutic or due to their SUD, 
then other POA drugs obtained above their personal needs could be diverted. 
Furthermore, a person with a history of illicit drug use might also be more likely to 
have associations with illicit drug use markets and greater opportunity to on-sell their 
POA drugs 
 
Table 2.7, represents a further description of the populations and sub-populations 
in Figure 2-5 and indicates those sub-populations that might exhibit doctor-shopping 
behaviour. 
  
 
 
 
 
 
 
Table 2.5 Doctor-shopping in proposed illicit drug and opioid analgesic drug-using populations 
 
Population* 
Persons 
prescribed 
POA drugs 
Person 
addicted/ 
dependent on 
illicit drugs 
Persons 
addicted/ 
dependent on 
POA drugs 
 
Doctor-
shopping 
Risk 
Sub-
population* 
(A) (B) (C)  
1 
 
+ - - Y 
2 
 
+ + - N 
3 
 
- + - N 
4 
 
+ - + Y 
5 
 
+ + + Y 
6 
 
+ + + N 
7 - - + N 
 
Note: Y- Yes; N-No;  
+ member of sub-population; - not member of sub-population 
* See Figure 2-5 
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The above model referred to in Figure 2-5 has the following assumptions and 
limitations. Firstly, the population boundaries might not be impermeable over time. A 
person’s drug use and dependence status can change; that is, individuals could move 
between populations or exit the model entirely due to death, treatment completion, or 
other reasons. Secondly, drug use other than POA drugs might be involved, 
contributing to, or resulting from, an individual’s dependence status, illicit drugs use, 
or doctor shopping.  
 
Furthermore, the notion of primary drug of dependence might need clarification. 
During the course of a person’s addiction/dependence they might change their primary 
drug of choice. This can happen for a number of reasons; for example, availability, 
price, or access. Primary dependence could refer to either initial drug use that leads to 
dependence, or drug of choice at a given time during an episode of dependence. This 
model does not suggest a temporal or causal relationship; that is, doctor shopping 
might result in dependence, or be due to a person’s dependence.  
 
Lastly, as previously discussed, other external or systemic factors might 
influence drug dependence or drug seeking; for example, heroin drought, lack of 
treatment places, policing or regulatory programs, prescription cost changes, new drug 
availability, GP/pharmacist training or programs, geographic location or other 
environmental variables. These proposed populations are hypothetical constructs at 
this time for potential testing in the study. It should be noted that members of these 
populations and their constituent sub-populations might change membership over 
time, or cease to be members of this group entirely. 
 
2.7.1 Individual Risk Factors 
 
Models of alcohol and drug dependence suggest that some individuals can 
possess risk factors that pre-dispose them to developing abuse or dependence. The 
biopsychosocial model of dependence states that there is a potential contributory and 
possible interaction between biological, psychological and social factors related to a 
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person’s risk of developing alcohol or drug dependence or abuse. By extension the 
same model should be applicable in populations of persons misusing POA drugs.   
 
The addictiveness of substances is a necessary a factor in formation of SUDs in 
persons. However, exposure alone to substances, does not necessarily lead to SUDs or 
problematic behaviour. The, biopsychosocial model has been applied to addiction as 
various biopsychosocial factors have been shown to be particularly relevant in 
predicting or accounting for susceptibility to developing SUDs when exposure occurs. 
 
Shaffer et al (Shaffer et al., 2004)describe addiction as a syndrome that 
“Although distinct expressions of addiction have unique elements, these different manifestations also share many neurobiological and psychosocial antecedents and consequents (Page 371). These antecedents are often difficult to measure, in regard to genetic and neurobiological variables; of for psychosocial factors prone to interpretative or social biases when relying on subjective measures.   In persistent pain management with POA drugs a population is being exposed to dependence forming substances, albeit for assumed therapeutic reasons and within certain controlled circumstances. (Fishbain, Cole, Lewis, Rosomoff, & Rosomoff, 2008) reviewed 67 studies of persistent pain patients under long-term POA drug treatment. The authors found an overall rate of abuse or addiction of 3.27 per cent; and when those with a history of abuse/addiction were excluded the percentage of abuse/addiction was 0.19 per cent Of these studies over 11 per cent of persons were reported as showing aberrant drug related behaviour, however, when excluding those with a history of abuse/addiction only 0.59 per cent person showed such behaviour.  
(Garland, Froeliger, Zeidan, Partin, & Howard, 2013) suggested that there is a 
“biobehavioral risk chain linking chronic pain, opioid analgesia, and addictive 
behaviours.” They propose addiction in this context could be caused by chronic pain 
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linked to negative affect, neurochemical effects of POA drugs in conjunction with 
other psychological and cognitive factors. 
 
However, studies to date have not conclusively identified biopsychosocial 
factors that are antecedents or consequents of POA drug related SUDs. This study 
seeks to explore the experts’ views on these matters. The role of PDMPs might also 
allow for capture of relevant factors to assist in clinical assessment of risk for 
development of POA drug SUDs. 
 
As PDMPs capture some demographic and other details of persons in receipt of 
POA drugs, some risk factors can be identified. The objective of this part of the study 
is to seek the views of experts as to what particular biological, psychological or social 
factors might be predictive of risk of POA drugs. These results could then be 
potentially tested in PDMP datasets based on relevant data items available. 
 
2.8 DRUG-SEEKING AND DOCTOR-SHOPPING BEHAVIOUR 
 
Medicare Australia in 1996/97 identified more than 10,000 persons as doctor 
shoppers for any class of drug and 9% of those drugs dispensed for doctor shoppers 
were for POA (Health Insurance Commission, 1998). Medicare defined ‘doctor 
shoppers’ as those people who saw 15 or more GPs in a year, had 30 or more Medicare 
consultations, and appeared to obtain more PBS medications than were clinically 
necessary. This equated to 1, 270 ‘doctor shoppers’ for every 1,000 general 
practitioners (Drugs and Crime Prevention Committee, 2007). It was estimated this 
cost the community over $31 million per year in unwarranted consultations and 
subsidised prescriptions. The socio-economic costs of persons developing drug 
dependence from POA, or not being effectively treated for a condition with POA is 
unknown. 
 
Drug dependence is a key indicator of inappropriate use of POA drugs. However, 
the defining of substance misuse disorders in a potentially heterogeneous population 
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is particularly complex. One proxy measure of drug dependence in this area could be 
that of drug-seeking behaviour or doctor shopping. This refers in a general sense to 
seeking multiple prescriptions for POA drugs from multiple prescribing doctors for 
drugs that might be in excess of expected therapeutic needs. Such behaviour could be 
suggestive of a person’s loss of control of their POA drug use and serve as a proxy for 
an assessment of substance misuse disorder. 
 
From a regulatory and clinical perspective, the challenge is to minimize public 
health and individual harms from the misuse of POA drugs in a manner that does not 
restrict individuals’ access to legitimate and appropriate treatment. Prescription drug-
monitoring programs offer an objective measure of some aspects of a person’s 
individual drug use, but also can establish some normative parameters of use across 
the wider population. 
 
PDMPs could offer valuable assistance to health practitioners to assist in their 
POA drug treatment decisions, as well as limiting the inappropriate flow of POA drugs 
that might be diverted for other purposes. This would then require some agreed upon 
definition of ‘doctor shopping’ and this is discussed as follows. 
 
2.8.1 Defining doctor shopping 
‘Doctor shopping’ refers to the behaviour of a person consulting multiple doctors 
for the purpose of attempting to obtain prescriptions for dependence-forming drugs. 
This is also known as ‘prescription shopping’, ‘double doctoring’ and other various 
terms (Sansone & Sansone, 2012).  
 
Doctor shopping represents a behaviour that could be indicative of a person’s 
misuse or dependence on prescription opioid medications. However, there are 
considerably varying definitions of what constitutes doctor shopping and even less 
evidence of an association between doctor shopping and prescription opioid drug 
problems.  
 
 74 Prescription opioid analgesic drug misuse: What can we learn from doctor-shopping behaviour 
There is a reasonably clear and established association between increased drugs 
use and development of abuse and dependence. For POA drugs, it could be reasonably 
assumed that a person obtaining increasing volumes of drugs is dependent on or 
abusing those drugs. What is less clear is what extent of drug seeking could indicate 
problematic misuse. 
 
The phenomenon of doctor shopping refers to persons who consult multiple 
medical practitioners for multiple prescriptions of medications that are in excess of 
their therapeutic requirements. In terms of POA drugs, doctor shopping particularly 
refers to persons who are obtaining large volumes of POA drugs in excess of 
therapeutic requirements. Doctor shopping has been identified as a concern in terms 
of its costs to the Commonwealth Government’s subsidised Medicare and 
Pharmaceutical Benefits Scheme (Medicare Australia, 2011); however, there is little 
known about the health implications of this phenomenon. 
 
Doctor shopping for POA drugs is possibly an indication of opioid dependence 
or abuse according to established diagnostic criteria (American Psychiatric 
Association, 2000; World Health Organisation, 2007). It has also been suggested that 
doctor shopping could be suggestive of persons who are under-treated for their pain 
conditions in some cases, also known as ‘pseudo-addiction (Zacny, et al., 2003). A 
recent Australian study of three state jurisdictions found there was little connection 
between POA drug obtaining and organised crime networks (Fry, et al., 2007). 
However, it is not entirely clear from the research to date as to whether persons doctor 
shopping might be obtaining drugs for pain management due to dependence, for abuse, 
for diversion to illicit markets, or for other purposes.  
 
Drug-seeking behaviour can be considered one of the possible diagnostic 
criterion, within the DSM-IV definition of dependence (American Psychiatric 
Association, 2010). In particular, the DSM-IV describes a criterion of drug dependence 
as where “a great deal of time is spent in activities necessary to obtain the drug, use 
the drug or recover from its effects.” (American Psychiatric Association, 2010).  
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Doctor-shopping behaviour is drug-seeking behaviour that is open to multiple 
interpretations, including possible drugs misuse. Therefore, doctor-shopping 
behaviour might serve as an indicator of possible POA drug dependence. However, 
any measure will need to have appropriate levels of sensitivity and specificity to 
capture the population in question, and not mislabel non-problematic behaviour. 
 
Prescription drug-monitoring systems present one means by which largely 
objective prescription information can be routinely monitored to detect patterns of 
aberrant drug-seeking or doctor shopping. This could allow timely and cost-effective 
interventions and ongoing collection of trend data to assist public health interventions 
and clinical practice. 
 
Converging evidence suggests that there is an increasing prevalence of misuse 
and dependence on POA drugs in Australia. However, a lack of consensus on many 
underlying issues has made it difficult to define the problem, understand the extent of 
misuse, and provide effective interventions.  
 
POA drugs have the potential for problematic use, and these same drugs have a 
place in conventional medical treatments. Appropriate levels of sensitivity and 
specificity are required to identify problematic use of POA drugs, and to ensure 
appropriate use of these drugs is not compromised. Prescription records held in central 
monitoring databases could provide some objective evidence as to a person’s drug-
seeking activity and potential aberrant use of POA drugs that might help make some 
of these issues clearer. 
 
Doctor shopping is widely held to be a behaviour of concern and associated with 
POA drug misuse and diversion. However, definitions of ‘doctor shopping’ are not 
well established nor is it understood what levels of drug obtaining might be 
problematic or indicative of substance use disorders. Regulators and clinicians are 
seeking to address the rising public health concerns around POA drug misuse. 
Strategic approaches to managing these concerns need to consider sound evidence 
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before making policy and treatment decisions. There is a considerable population of 
persons in the community with legitimate treatment needs and there could be 
significant implications in terms of unintended negative outcomes if regulatory or 
clinical policy decisions are made on a poor understanding of these issues. This study 
seeks to address this lack of knowledge. 
 
The aim of this research is to determine the definition of doctor shopping that 
can identify aberrant POA drug use; identify and describe the population of persons 
engaged in doctor shopping to determine if there is an emerging and increasing POA 
drug-misusing population in Queensland; and determine whether central database 
records of POA drug prescriptions can effectively help identify and monitor this issue. 
 
 
2.9 RESEARCH OBJECTIVES 
The objectives of this research are to: 
• Identify and describe the characteristics of the POA drug-misusing 
doctor-shopping population. 
• Evaluate the extent and nature of POA drug-misusing or doctor-shopping 
behaviour over time. 
• Consider the application of these findings to improve public health 
responses addressing current and possible emerging POA and other 
pharmaceutical drugs misuse problems. 
These objectives give rise to three particular research questions that are to be 
addressed in three studies that will constitute this project. 
 
The first study addresses the questions as to what level of drug-seeking 
behaviour would indicate inappropriate use of pharmaceutical opioids and when might 
that use constitute a clinical definition of abuse or dependence? That is, what 
definition, or definitions, of ‘doctor shopping’ behaviour in terms of prescriptions, 
dosage, drug type, frequency, and timeframe for POA drugs might indicate a person is 
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abusing, or dependent on, these drugs? This study will seek views of experts in the 
relevant fields to derive these definitions for testing in the subsequent studies. 
 
The second study relates to the first. If certain definitions of doctor shopping 
behaviour can be derived from the first study, what are the characteristics of this 
potentially drug-misusing population? What parameters describe this population, in 
terms of demographics, drug use, and behaviour and what discriminates doctor 
shoppers from other prescribing behaviour of persons receiving POA drugs? This 
study will seek to apply a definition of ‘doctor shopping’ derived from the first study 
in a prescription drug monitoring program dataset with a complete year of POA drug 
dispensed records for the State of Queensland. 
 
The final third study will examine historical aspects of doctor-shopping persons 
over previous years to investigate their prior prescribing patterns and to determine if 
historical drug use could be associated with current drug use patterns. Using the 
previously derived definition, the dispensing records of those persons identified as 
doctor shoppers will be examined over a 10 year period to examine antecedents to their 
POA drug use behaviour identified in Study 2. 
 
The discussion aspect of this study will draw together the finding of the three 
studies to consider the utility of central prescription activity databases in improving 
public health interventions and monitoring and surveying trends in POA drugs use. 
The implications for these findings for clinical and regulatory practice and areas of 
further study will also be discussed. 
Prescription opioid drugs misuse 
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Chapter 3: Study 1: Defining doctor 
shopping 
3.1 INTRODUCTION  
The aim of the first study is to examine aspects of various expert groups’ 
understanding of prescription opioid analgesic (POA) drugs misuse and doctor-
shopping behaviour to determine if agreement can be reached on criteria and 
definitions for these phenomena. These criteria and definitions are to be tested in 
prescription drug monitoring program (PDMP) in the second and third studies to test 
if they could be used to discriminate aberrant POA drug use. 
 
The objective of this study is to define problematic drug-seeking or doctor-
shopping behaviour and other possible factors that could be indicative of POA drug 
misuse by using drug dependence and pain management experts and specialists to 
derive criteria that can be tested in a PDMP. There are a number of issues identified in 
the literature review that are to be tested with the expert panel as these might add value 
to understanding prescription opioid misuse and drug seeking and could suggest 
testable criteria in a PDMP.  These issues can be categorised as definitions of drug 
dependence and abuse, aspects of particular POA drugs, characteristics of persons who 
might misuse these drugs, and the defining of doctor-shopping behaviour and when it 
might be indicative of misuse of POA drugs.  
 
The diagnosis of drug dependence and abuse is contentious in this area. Ideally, 
diagnosis should be undertaken as a clinical assessment in face-to-face consultation 
between a health practitioner and a patient. However, PDMP can offer objective 
information to assist in clinical assessment. Potentially some aspects of POA drug use 
could be more indicative of aberrant use than others. PDMPs can capture dispensed 
prescription drug details along with other limited demographic details. However, this 
data can still provide information types and preparations of drugs being used and the 
patterns of prescriptions sought over time. 
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This study will examine experts’ views on assessing substance use disorders for 
POA drugs, what types and features of particular POA drugs might be more likely 
associated with aberrant use, and what factors might be associated with POA drug 
misuse. Lastly, the experts definitions of ‘doctor shopping’ will be examined across 
all experts  to attempt to coalesce this into a single or unified definition. The following 
four sections discuss the above matters in more detail regarding the development of 
survey instruments to test understanding of these matters in a relevant expert group. 
 
The aim of this study was to attempt to derive a consensus from the expert panel 
of their ranking of importance of particular DSM-IV-TR criteria for abuse and 
dependence on POA drugs. This study seeks to poll experts across the various fields 
of addiction, pain management, and general practice to examine their understanding 
of POA drug misuse to see if there can be a convergent working definition of POA 
dependence and abuse. From these definitions is intended to develop criteria based on 
drug-seeking or doctor-shopping behaviour.  
 
3.2 METHODS 
A modified Delphi Technique (Iqbal, 2009; Skulmoski, 2007) was used as the 
methodology to determine an understanding of definitions of drug dependence and 
quantify levels of different aspects of doctor-shopping behaviour for testing in the 
population database in later studies. 
 
To examine these questions, experts were questioned on their views in a series 
of questionnaires using the methods of the Delphi Technique. This is where the views 
of a panel of experts are sought, and their collated views are  fedbackto them , in order 
for them to review and revise their views. This is done iteratively over multiple rounds, 
with the intention to move towards a convergence of views where experts might start 
with divergent views. 
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3.2.1 Overview of Delphi Technique 
The Delphi Technique is a research process that seeks to gain consensus across 
a range of experts by a series of questionnaires. Results of earlier rounds of 
questionnaires are fed back to the expert panel to see if they modify their responses 
based on the group’s overall response. By a process of iteration each round seeks to 
move the expert panel to a consensus or agreed position on the question under 
examination. 
 
Most applications of the Delphi Technique suggests an optimal number of 
between 30-50 panel members (de Meyrick, 2003; Iqbal, 2009; Linstone, 2002; 
Skulmoski, 2007) and that some level of participant attrition should be expected in 
follow-up rounds. Further, there is support for the use of a limited group of experts 
where the research topic is particularly specialised. 
 
This methodology has since been modified by drawing on all (Wang et al., 2003) 
or some (Gupta and Clarke, 1996; Robertson and MacKinnon, 2002) of the definition 
set out by Linstone and Turoff (1975) who define the Delphi Technique as a method 
for structuring a group communication process so that the process is effective in 
allowing a group of individuals, as a whole, to deal with a complex problem. 
 
This study is a variant of the classical Delphi Technique that is an iterative 
response-seeking expertise on a particular issue (van Zolingen and Klaassen, 2003). 
This study aims to arrive at a consensus across a panel of experts from different fields 
to achieve definitional criteria of a particular problem.  
 
Use of Delphi Method in health research 
The Delphi Technique has wide application, particularly in health-based 
research and has been used in over 1,000 published research papers since its 
development in the 1950s (de Meyrick, 2003). There has been less application to the 
use of this technique in the addiction and dependence field. This technique has been 
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used in similar and related studies in the development of assessment of clinical 
conditions where there is not necessarily an agreed position.  
Delphi techniques have been used in the development of scales or assessment 
measures by (Nekolaichuk, Fainsinger, & Lawlor, 2005) of pain classification systems 
in cancer patients. (Green et al., 2009) used a similar technique in assessing illicit drug 
users’ experience of drug-related effects, (Kingston et al., 2011) in developing 
strategies to help illicit drug users, and McBride et al to develop guidelines around 
access to controlled medications (McBride, Pates, Ramadan, & McGowan, 2003). 
 
3.2.2 Development of Survey Questions 
The broad objective of this study is to develop criteria to identify potentially 
drug-dependent or drug-abusing users of POA drugs from their profiles of POA drug 
obtainings in a prescription drug-monitoring program. Four topics areas were 
developed: what are the particular harms of POA drugs; what drugs and what aspects 
of POA drugs are most harmful; what is important in assessing substance use disorders 
in relation to POA drugs; and what might form an agreed definition of doctor shopping. 
 
Initial questions were piloted by sending them to two experts known to the author 
– one in the addiction field and one in the pain management field – for review of the 
readability and suitability of the questions. Neither expert was invited to participate in 
the actual study. The following first-round questions represent the outcomes of that 
consultation. This pilot testing led to the modification of a number of first-round 
questions in regards to phrasing of the questions and types of responses requested.  
 
Topics 1 and 2: What are the particular harms of POA drugs? What drugs and 
what aspects of POA drugs are most harmful? 
The levels of harm articulated by Nutt et al (Nutt, et al., 2007) set out sub-
categories of physical, dependence, and social harms (see Table 2.3). Initial pilot 
testing (see Section 3.2.2) found these parameters were not helpful in discriminating 
between different opioids and led to some lack of clarity in responses. However, the 
higher order concepts describing-levels of harm, in terms of physical, dependence, and 
social harms were understandable in pilot testing group and suggested as most likely 
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to encourage appropriate responses. Therefore, only three levels of harm, physical, 
dependence and social harms, were used in developing questions on opioid drugs 
harmfulness. 
 
Two further questions on what features of POA contribute or reduce their 
potential for harm were included. This was to assess what, if any, features of a POA 
drug might be linked to its misuse or lack of misuse (e.g., injectability and controlled-
release formulations). A further open-ended question was added to assess if there were 
any other reasons that the experts believed some POAs were more harmful than others. 
 
Table 3.1 
Question on harmfulness of pharmaceutical opioid drugs 
No Question 
1 What pharmaceutical opioid drugs do you believe are most prone to cause 
physical harm?  
2 What pharmaceutical opioid drugs do you believe are most prone to cause 
dependence? 
3 What pharmaceutical opioid drugs do you believe are most prone to social 
harms? 
4 What pharmaceutical opioid drugs do you believe are most prone to be 
abused? 
5 What do you believe are the features of pharmaceutical opioid drugs that 
might contribute to the potential for harm? 
6 What do you believe are the features of pharmaceutical opioid drugs that 
might reduce the potential for harm? 
7 What other reasons do you believe some pharmaceutical opioid drugs 
might be more harmful than others? 
 
 
In the first round experts were asked to suggest what opioid drugs, if any, were 
most harmful across the domains of physical harms, prone to cause dependence, most 
abused, caused social harms, and rate the features of POA drugs that might reduce or 
increase the potential for harms in free-text responses. The mentions of any listed POA 
drug was then counted from text analysis for the four domains of harm and resulted in 
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a total count for each drug under each domain of harm. For the benefit of this 
assessment only the active drug, not the type of formulation of drug, was counted. For 
example, controlled-release oxycodone (Oxycontin™) and immediate-release 
oxycodone preparation (Endone™) were both counted as oxycodone. 
 
The second part of this questionnaire was to query experts on what aspects of 
POA drugs might make them more or less prone to misuse. The responses were given 
as free text and due to the range and variability of responses and lack of consistent 
terminology the results did not lend themselves to standard text count. For example, 
many experts rate the sustained-release preparations in either response; however, the 
terms used included: slow, controlled, length of half-life. 
 
For the first round, respondents were able provide free-text responses to the 
questions in Table 3.1. The responses were then compiled to generate ranked lists of 
particular responses. For the second round, respondents were presented with the 
ranked list of responses from the first round and were then asked whether they agreed 
with the ranking or, if not, they could re-order the rankings. Furthermore, respondents 
could still add free-text to any items at this point. 
 
Topic 3: What is important in assessing substance use disorders in 
relation to POA drugs? 
Based on the biopsychosocial model of dependence the following questions (see 
Table 3.2) were developed to seek experts’ views as to what particular biological, 
psychological and social factors were most associated with dependence or abuse of 
POA drugs. The first round of questions were free-text questions to garner the broadest 
responses. 
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Table 3.2 
Questions based on individual risk factors under biological, social and cultural domains. 
No Question 
1 What biological factors do you believe are most relevant in the 
development of a substance misuse disorder related to pharmaceutical 
opioid drugs? 
2 What psychological factors do you believe are most relevant in the 
development of a substance misuse disorder related to pharmaceutical 
opioid drugs? 
3 What social or cultural factors do you believe are most relevant in the 
development of a substance misuse disorder related to pharmaceutical 
opioid drugs? 
4 What other factors do you believe are most relevant in the development of 
a substance misuse disorder related to pharmaceutical opioid drugs? 
 
 
For the first round, the experts provided free-text responses. For the second 
round, the most common responses for each question were compiled. Respondents 
were presented with the un-ranked list of responses under each category above and 
were asked to rank their level of importance. The respondents could still add free-text 
to add any items at this point. 
 
Topic 4: Definition of substance use disorders on POA drugs 
These questions were developed using DSM-IV-TR criteria for substance abuse 
and dependence as set out below in Table 3.3. For each criterion a question was 
developed to solicit a rating on the importance of each criterion in reaching diagnosis. 
This led to 11 questions of phrased variants of DSM-IV criteria of abuse and 
dependence. 
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Table 3.3 
DSM-IV-TR criteria and derived survey questions 
 DSM-IV TR criteria for substance use 
disorders. 
Question 
 Substance dependence – three or more 
occurring in a 12 month period. 
 
1 Tolerance as defined by either of the 
following: - A need for markedly 
increased amounts of the substance to 
achieve intoxication or desired effect;  
Markedly diminished effect with 
continued use of the same amount of the 
substance. 
How important is evidence of tolerance in 
assessing person for substance use disorders on 
pharmaceutical opioid drugs? 
2 Withdrawal, as manifested by either of 
the following: The characteristic 
withdrawal syndrome for the substance; 
Taking the same (or a closely related) 
substance to relieve or avoid withdrawal 
symptoms 
How important is evidence of withdrawal 
symptoms in assessing a person for substance use 
disorders on pharmaceutical opioid drugs? 
3 Use of a substance often in larger 
amounts or over a longer period than was 
intended. 
How important is the amount of the drug being 
taken, in assessing a person for substance use 
disorders on pharmaceutical opioid drugs? 
4 Persistent desire or unsuccessful efforts to 
cut down or control substance use 
How important are attempts to reduce or control 
drug use, in assessing a person for substance use 
disorders on pharmaceutical opioid drugs? 
5 Spending a great deal of time spent in 
obtaining, using, or recovering from the 
effects. 
How important is time spent in obtaining drugs, in 
assessing a person for substance use disorders on 
pharmaceutical opioid drugs? 
6 Social, occupational, recreational 
activities given up or reduced because of 
use 
How important are the effect of drug use on 
social, occupational, or recreational activities, in 
assessing a person for substance use disorders on 
pharmaceutical opioid drugs? 
7 Continued use despite social, legal, 
medical, psychological, and other 
problems 
How important are social or interpersonal 
problems, in assessing a person for substance use 
disorders on pharmaceutical opioid drugs? 
 Substance abuse – a maladaptive pattern 
of substance use indicated by at least one 
of the following occurring in a 12 month 
period 
 
1 Recurrent use resulting in a failure to 
fulfil major role obligations at work, 
school, or home 
 
How important are the drug use effects on work, 
school or home obligations, in assessing a person 
for substance use disorders on pharmaceutical 
opioid drugs? 
2 Recurrent use in situations in which use is 
physically hazardous (e.g., driving while 
intoxicated) 
How important is drug use in hazardous 
situations, in assessing a person for substance use 
disorders on pharmaceutical opioid drugs? 
3 Recurrent substance-related legal 
problems 
How important are drug-related legal problems, in 
assessing a person for substance use disorders on 
pharmaceutical opioid drugs? 
4 Continued use despite a persistent or 
recurrent social, occupational,  
psychological, or physical problem that is 
caused or exacerbated by the  
substance use 
How important is continued drug use despite 
health or psychological effects, in assessing a 
person for substance use disorders on 
pharmaceutical opioid drugs? 
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For the first round, respondents were requested to rate each response on a 5-point 
Likert-type scale from ‘Very important’ to ‘Unimportant’. A free-text section was 
provided to allow for the inclusion of any other criteria participants believed were 
relevant. 
 
For the second round, respondents were presented with the ranked list of criteria 
that resulted from the first round and were then asked whether they agreed with the 
ranking or, if not, they could re-order the rankings. 
 
Doctor-shopping behaviour 
The main aim of this study was to determine an appropriate definition of the term 
‘doctor shopping’ and determine threshold levels of POA drugs use or drug-seeking 
behaviour for objective dispensing criteria. This was to allow for identification and 
possible prediction of persons of interest from monitoring and regulatory standpoints 
and provide assistance in clinical decision-making to assist in treatment and 
prescribing decisions. 
 
Table 3.4 below sets out the questions used in this part of the survey. As 
described above the term ‘doctor shopping’ has a wide and varied application and 
multiple meanings so all experts were asked their opinions of this definition. This was 
to ascertain if there was actual disparity amongst the expert community and to see if a 
unified definition could be derived. 
 
The second questionnaire asked the experts what criteria suggested a person 
might be suffering a substance use disorder. This included criteria derived from 
literature searches, such as frequency of consultation, number of prescriptions 
obtained, and timeframe of behaviour. Again, this was designed to garner views across 
the expert panel to work towards a possible range of objective criteria that could be 
tested in the database. The final question was a further free-text question to assess if 
any other criteria could be considered relevant in assessing doctor shopping.  
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Table 3.4 
Questions on drug-seeking behaviour 
No Question 
1 What do you understand by the term ‘doctor shopping’ or ‘prescription 
shopping’ in the context of potential misuse of pharmaceutical prescription 
medications? 
2 What extent (frequency of consultations, prescriptions obtained, volume of 
drug obtained, over what time period) of doctor/prescription shopping do 
you believe would suggest a person is suffering from a substance use 
disorder? 
3 Are there any other features of doctor/prescription shopping that you 
believe are relevant in considering whether a person is suffering from a 
substance use disorder? 
 
 
For the first round, experts were asked their general understanding of the term 
‘doctor shopping’, measureable variables that might describe doctor shopping, and for 
any other relevant factors. The initial responses from the first round sought to force 
respondents to suggest particular levels of prescriptions obtained, doctors consulted, 
pharmacies dispensing, and average daily dose in morphine equivalent milligrams that 
might suggest a substance misuse disorder. This led to a number of respondents 
suggesting that in a clinical assessment any element of drug seeking could be 
indicative of problems. 
 
In the second round the question was amended further to have respondents 
indicate what levels of drug seeking might indicate either no cause for concern (green 
light), some heightened levels of concern (amber light), or definite concerns (red light). 
 
3.2.3 Participants 
A panel of experts were drawn from the fields of chronic pain management, 
addiction and dependence, the general practitioner community, and across both 
Australian and international domains (see Table 3.5). This was to obtain the various 
stakeholders in both definitional issues and actual clinical management of these 
conditions.  
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Table 3.5 
Proposed class of experts by speciality and nationality to be recruited for Delphi study 
 Specialty Australia International Total 
Pain management 15 15 30 
Addiction/Dependence 15 15 30 
General practice 30 - 30 
Total 60 30 90 
 
 
International experts were mainly drawn from the USA and Canada due to the 
similar prescription opioid issues in these jurisdictions to Australia and each country’s 
adoption of prescription drug-monitoring programs. However, other experts from the 
published literature were not excluded if they were from other jurisdictions. 
 
Searches were conducted via the internet for professional pain management and 
addiction associations and bodies where members were involved in clinical treatment 
of patients or where a clinical qualification was a prerequisite of membership. A full 
list of organisations is attached in Appendix C. Emails were sent to organisations to 
seek their involvement and distribution via membership pathways. Where requested, 
details of ethical approval and study protocol was provided if the organisation required 
prior review before distributing to their members.  
 
Literature searches were also conducted of PubMed, Ebsco Scholar, Google 
Scholar and other internet search engines on authors published on prescription opioids 
and pain management topics. Searches were conducted using the search terms: 
• prescription, pharmaceutical, opioid, drug, abuse, dependence, misuse, 
addiction 
• chronic, persistent pain management, drug seeking, doctor shopping, 
prescription shopping, double doctoring,   
 
Authors were then reviewed based on their published curriculum vitaes, if 
available, to determine those who indicated clinical qualifications. Experts were 
chosen by their known contribution to their respective fields as published authors in 
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the area of POA drug misuse. Australian general practitioner participants were 
recruited via approaches to the alcohol and drug or chronic pain interest groups that 
accepted membership from non-specialists, such as the Australian Pain Society and 
the Australian Professional Society on Alcohol and Drugs (see Appendix C). 
 
Initial introductory emails were then sent to a number of organisations to request 
distribution of information about the study to members. This included email address 
details for interested participants to respond to. Similarly, initial email invitations were 
issued to individuals of interest identified via literature and web-based searches.  
 
3.2.4 Survey media and distribution 
To provide ready access to the expert panel the survey questions above were 
constructed in the online survey poll, Survey MonkeyTM (Survey Monkey Inc., 2011). 
Survey Monkey allows construction of online questionnaires, access to users over the 
internet, and compilation of responses into various formats of files for export and later 
statistical analysis. 
 
Survey Monkey (Survey Monkey Inc., 2011) also allows for tracking of survey 
respondents as individual participants can be given unique links to access the survey. 
This means appropriate follow-up can be done to encourage non-responders. 
Furthermore, for this application of the Delphi Technique, the responses to the second 
iteration of the study could be linked to the initial responses in the first round of the 
study.  
 
Two rounds of the questionnaires were conducted and the reasons for this are 
discussed later in the Results section. The questionnaire rounds were uploaded to the 
Survey Monkey (Survey Monkey Inc., 2011) website and password protected. The full 
versions of Version 1 and Version 2 of this survey are provided in Appendix D as they 
appeared online in Survey Monkey and includes the full versions of the first and 
second round surveys. 
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Survey Monkey (Survey Monkey Inc., 2011) is widely used as a survey or data 
collection tool across social science and academic research. There are some limitations 
and concerns around the use of online surveys. Buchanan and Hvizdak (2009) 
identified concerns around security and storage of data, design of questions, anonymity 
of responses, and ability to verify appropriate respondents completing surveys 
(Buchanan & Hvizdak, 2009). 
 
In regards to security of data, this study largely used responses linked to a set of 
named respondents with email addresses in the actual Survey Monkey program. A full 
paid subscription was procured for the purposes of the study to allow for use of the 
full range of program features, thus limiting unauthorized access from other parties.  
 
The Survey Monkey program does limit the format of questions and responses 
to a set repertoire of variations. Once initial questions were conceived and constructed 
they were appropriately modified. Initial modifications were minor and the actual 
initial questions and form of response (Likert type scales, free text or ranked lists) did 
not substantially alter the nature of the questions. Survey questions in the Survey 
Monkey form were also piloted with a test group of two experts and, based on their 
responses, further minor amendments were made to some of the wording of questions 
for improved ease of comprehension. 
 
The respondents were advised that their responses would be anonymous for the 
purposes of reporting the outcomes of the study. However, they were also informed 
that their email addresses were linked to individual web links to Survey Monkey for 
purposes of follow-up and later rounds of the study. Respondents were informed of 
this in the preliminary background information on the study and offered further details 
of the research protocol if required. Once information gathering was completed data 
was removed from the site. All analysis and reporting did not use any identifying 
information. Verification of respondents was achieved by preliminary contacts by 
email in the first instance.  
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On receipt of the results from Round 1 each of the questionnaire categories were 
assessed and collated to develop a second-round questionnaire to feedback to the 
expert panel the compiled results. The responses from Round 1 are described in the 
following sections. The results from Round 1 were fully compiled before the second 
round of questions were re-issued to all of the original respondents who agreed to 
further participation. 
 
3.3 RESULTS  
3.3.1 Participants 
 
Sixty-one recipients responded to the first round of the survey. Of the first-round 
participants, 29 reported as male, nine as female, and 23 didn’t report gender. Eighty 
per cent of respondents were from Australia and New Zealand, and 20% were from 
Canada and the United States of America.  
 
Of the self-nominated area of speciality, where reported, 32 (52%) self-
nominated as primarily working in drug dependence, 21 (34%) as primarily working 
in pain management, with 4 respondents reporting working in both fields. The 
remaining four participants reported as being primarily researchers and did not report 
a primary field of work. 
 
Almost half of the respondents (n=30) were medical practitioners and 9 reported 
as being nursing or allied health professionals. Twenty-one persons reported as having 
research roles in universities with 6 participants reporting having PhDs. Over a quarter 
(n=17) reported working in hospitals. 
  
Just under half the respondents (n=27) responded to the second round of the 
survey. A summary of the differences between Round 1 and 2 respondents is shown 
in Table 3.6 with the classification of respondents by gender, country and primary 
speciality area reported to show the level of attrition in participation across the two 
rounds. 
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Table 3.6 
Details of responding participants for Round 1 (n=61) and Round 2 (n=27) of Delphi Study 
  
Round 1  
 
Round 2 
 
  
n % N % 
Gender 
     
Male 
 
29 48% 20 74% 
Female 
 
9 15% 7 26% 
Missing 
 
23 38% 0 0%       
Primary field 
    
Drug dependence 32 52% 16 59% 
Pain management 21 34% 7 26% 
Both 
 
4 7% 2 7% 
Neither 
 
3 5% 2 7%       
County of origin 
    
Australia 
 
39 64% 21 78% 
New 
Zealand 
 
10 16% 1 4% 
USA 
 
9 15% 2 7% 
Canada 
 
3 5% 3 11% 
 
 
The Round 2 had a higher proportion of female respondents and more Australian 
respondents engaged in this round. However, the proportion of participants by primary 
field of work appeared to remain similar across both rounds of the study. It should be 
noted that for Rounds 1 and 2 not all participants responded to all questions, and the 
numbers of actual item responses are reported in the results. 
 
3.3.2 Response to Delphi Study 
The results are reported for Round 1 and 2 for each section of the survey in the 
following results.  
 
What are the harms of POA drugs and what drugs cause harm and why? 
Table 3.7 and Table3.8 show the results of experts’ views over two rounds of the 
Delphi Study for particular POA drugs they agree as being the most harmful.  
 
 94 Prescription opioid analgesic drug misuse: What can we learn from doctor-shopping behaviour 
Table 3.7 
Round 1 - Harmfulness of POA drugs combined ranking by experts by category of harm for each POA 
drug type (n=61)  
POA Drug Physical 
Harm 
Dependence 
causing 
Abuse 
prone 
Social 
harms 
Oxycodone 17 22 22 12 
Morphine 14 15 12 7 
Fentanyl 8 8 5 1 
Hydromorphone  3 3 1 1 
Methadone 2 2 1 0 
Pethidine 4 5 4 0 
Codeine 2 4 4 2 
Buprenorphine 3 0 3 0 
Any Opioid 9 7 3 1 
 
 
Table 3.7 shows the experts’ rankings from Round 1 of the survey where they 
ranked drug type for each of the dimensions of harm. For each type of harm, the two 
most commonly available POA drugs – oxycodone and morphine – are listed as the 
two most harmful for each dimension. 
 
After the first round of surveying, the question was modified to combine all 
dimensions of harm into a question on the overall ranking of what was the most 
harmful of all POA drugs. Using the results of Round 1, a proposed ranking of POA 
drugs in the order set out in Table 3.7 was presented and respondents able to alter the 
rankings.  
 
Table 3.8 shows the list of the most harmful of the POA drugs reduced to those 
most commonly used and accessible – oxycodone and morphine – being ranked first 
and second respectively.  
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Table 3.8 
Round 2 - Harmfulness of POA drugs overall combined ranking by experts for each POA drug type 
(n=27)  
Drug Minimum Maximum Mean SD Mode 
Oxycodone 1 4 2 0.84 1 
Morphine 2 5 3 0.82 2 
Fentanyl 1 5 3 1.08 3 
Hydromorphone 2 5 4 0.81 4 
Any opioid 1 5 4 1.76 5 
 
 
Experts were also asked about particular aspects of POA drugs that could 
potentially increase or reduce harms. In Round 1 this was asked as an open question 
with a free-text response. The resulting responses classified under commonly reported 
themes are shown in Table 3.9. Interestingly, similar themes of extended release, high 
potency, rapid onset and injectability were reported as aspects that could increase and 
decrease harms. 
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Table 3.9 
Round 1 – Harmfulness of POA drugs – Aspects of POA drugs that might increase or decrease harms 
combined responses of all experts (n=61)  
Aspects of POA drug Description 
Increasing harm  
Extended release - extended release preparations being linked to misuse   
- ease of adulteration of preparations for other routes of 
administration 
- increased access and availability 
High potency - high dose preparations and high volumes of drugs 
being prescribed 
Injectable preparations - injectable preparations such as pethidine 
Injectability - ease of transformation of table/capsule preparations to 
injectable forms, lack of “limiter” antagonist 
medications such as naloxone in newer POA 
preparations 
Rapid onset - immediate onset formulations can induce dependence, 
encourage abuse due to increased euphoric effects, 
full agonist action 
 
Reducing harm 
 
Extended release - sustained release also mentioned as reducing harms, 
improved pharmacokinetics and transdermal patch 
preparations 
High potency - improved pain management, limiting access with 
fewer prescriptions, lower volumes of drugs 
prescribed 
Injectable/injectability - tamper resistance, harder to convert to usable 
injectable preparations, inclusion of antagonist 
medications activated on adulteration of drug 
Rapid onset - appropriate short-term use or immediate release 
preparations 
  
  
 
 
In Round 2 the results of Table 3.9 were reduced to unranked options for 
increasing and decreasing harms and the expert respondents were requested to rank 
them accordingly. Table 3.10 shows the resultant rankings based on the Round 2 
responses. The results show experts ranked injectable and high-dose preparations as 
aspects most likely to cause harms, and extended release and high-dose preparations 
as most likely to reduce harms in POA drugs. 
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Table 3.10 
Round 2 - Harmfulness and protective features of POA drugs combined responses of all experts 
(n=27) 
POA drug feature Minimum Maximum Mean SD Mode 
Increase harmfulness 
     
Injectable preparations (ampoules, 
vials) 
1 5 2.30 1.35 1 
High potency/dose formulations 1 5 2.74 1.10 2 
Rapid onset/immediate release 
preparations 
1 5 3.30 1.30 3 
Injectability of preparations 1 5 2.93 1.21 4 
Extended/controlled/slow release 
preparations 
1 5 3.52 1.81 5 
      
Decrease harmfulness 
     
Extended/controlled/slow release 
preparations 
1 4 1.52 1.12 1 
High potency/dose formulations 1 4 2.07 0.47 2 
Injectable 
preparations/injectability of 
preparations 
1 4 2.67 0.92 3 
Rapid onset/immediate release 
preparations 
2 4 3.56 0.70 4 
 
 
Individual risk factors  
In Round 1 respondents were requested to nominate in a free-text response any 
particular biological, psychological or cultural factors that might predispose a person 
to risk of developing a POA drug SUD. The respondents provided the list of free-text 
responses to the classes of individual risk factors and the most commonly reported 
responses were grouped in like classes under each category. These are reported in 
Table 3.11 and examples of indicative responses are provided. 
 
 98 Prescription opioid analgesic drug misuse: What can we learn from doctor-shopping behaviour 
Table 3.11 
Round 1 – Individual risk factors under biological, psychological and cultural classes that might 
predispose persons to SUDs with POA drugs as reported by experts (n=45)  
Class of Individual risk factor Indicative responses 
Biological  
- Genetics - Genetic predisposition, vulnerability 
- Age - Young persons 
- Biology - Metabolism 
- Chronic pain - Comorbid pain and dependence 
- Family history - Family history of substance dependence, 
Psychological  
- Mental health issues - Mood, anxiety disorders, PTSD, impulse control 
issues, personality disorders, psychoses 
- Low self-efficacy - Poor self-efficacy related to pain 
- Expectancies/beliefs - Beliefs about harms effects 
- History of dependence - Links to street drug culture, exposure to illicit drugs 
Cultural  
- Peer use - Acceptance amongst subgroup, social availability 
- Lack of social support - Dislocation from family or significant others, 
normative influences, social isolation, poor social 
networks 
- Low socio-economic 
status 
- Poverty, unemployment, disability 
- Availability of POA 
drugs 
- Poor prescribing practices, lack of guidelines, 
pharmaceutical promotion 
- Poor 
parenting/upbringing 
- Poor normative influences, learnt behaviour from 
family 
  
  
 
 
The responses from Round 1 in Table 3.11 report a broad range of factors under 
each category. These summarised sub-factors for each class of individual risk were 
then presented to the experts in Round 2 in un-ranked list and the respondents were 
requested to rank the list from highest to lowest level of risk within in each factor of 
biological, psychological and social. 
 
Table 3.12 below shows the expert respondents from the Round 2 of the study. 
The rankings of the compiled risk factor reported in Round 1 for each of the classes of 
risk factors that are considered most related to a POA substance misuse disorder were 
ranked as number 1 through to higher-numbered lower-ranked risk factors.  
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Genetic predisposition, concurrent mental health issues and peer use were ranked 
as the highest risk factors, under biological, psychological, and cultural categories of 
risk respectively for the risk of developing a SUD with POA drugs. Interestingly, 
chronic pain and a previous drug dependence history were not highly ranked in the 
biological and psychological factors respectively.  
 
Table 3.12 
Round 2 – Ranks of individual risk factors for development of SUDs with POA drugs under biological, 
psychological and social classes as ranked by experts (n=27). 
Risk Factor Minimum Maximum Mean SD Mode 
Biological 
     
Genetics 1 5 1.67 1.24 1 
Age 0 5 2.67 1.30 2 
Individual biology 
(absorption/metabolism) 
1 5 3.11 1.01 3 
Chronic pain conditions 1 5 3.63 1.18 4 
Family history 1 5 3.74 1.40 5       
Psychological 
     
Mental health issues 1 4 1.63 0.88 1 
Low self-efficacy 0 3 2.26 0.76 2 
Expectancies/beliefs 3 4 3.48 0.51 3 
Previous history of dependence 1 4 2.48 1.37 4       
Social/cultural 
     
Peer use 1 5 1.93 1.21 1 
Lack of social support 1 4 2.48 0.70 2 
Low socio-economic status 1 5 3.37 1.01 3 
Availability of prescription drugs 1 5 2.74 1.51 1 & 4 
Poor parenting/upbringing 0 5 4.30 1.38 5 
 
 
Definitions of substance use disorders on POA drugs 
In Round 1 experts were presented with the list of criteria for drug dependence 
and abuse from the DSM-IV-TR (American Psychiatric Association, 2000) and were 
requested to rank them according to their potential importance in determining SUDs 
with POA drugs. Table 3.13 and Table 3.14 show the results of the responses after 
Rounds 1 and 2 of the Delphi Technique for ranking the importance of particular 
criteria for drug dependence and abuse. 
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The results from Round 1 are shown in Table 3.13 with the initial ranking of 
each criteria, from 1 – highest-ranked or most important – to 11 – lowest ranked or 
least important.  
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Table 3.13 
Round 1 - Ranked DSM-IV-TR substance abuse and dependence criteria ranked by experts in order of 
importance in determining SUDs with POA drugs (n=48) 
DSM-IV-TR Criteria Min Max Mean SD Rank 
How important are the drug-use effects on 
work, school or home obligations, in 
assessing a person for substance use disorders 
on pharmaceutical opioid drugs? 
 
1 4 1.73 0.84 1 
How important are the effects of drug use on 
social, occupational, or recreational activities, 
in assessing a person for substance use 
disorders on pharmaceutical opioid drugs? 
 
1 4 1.77 0.88 2 
How important are social or interpersonal 
problems, in assessing a person for substance 
use disorders on pharmaceutical opioid drugs? 
 
1 4 1.92 0.92 3 
How important is the amount of drug being 
taken in assessing a person for substance use 
disorders on pharmaceutical opioid drugs? 
 
1 4 2.25 0.93 4 
How important is time spent in obtaining 
drugs in assessing a person for substance use 
disorders on pharmaceutical opioid drugs? 
 
1 5 2.17 0.95 5 
How important are attempts to reduce or 
control drug use in assessing a person for 
substance use disorders on pharmaceutical 
opioid drugs? 
1 5 2.02 1.00 6 
How important is continued drug use despite 
health or psychological effects in assessing a 
person for substance use disorders on 
pharmaceutical opioid drugs? 
 
1 5 1.77 1.02 7 
How important is evidence of tolerance in 
assessing a person for substance use disorders 
on pharmaceutical opioid drugs? 
 
1 4 2.15 1.03 8 
How important is drug use in hazardous 
situations in assessing a person for substance 
use disorders on pharmaceutical opioid drugs? 
 
1 4 1.98 1.04 9 
How important is evidence of withdrawal 
symptoms in assessing a person for substance 
use disorders on pharmaceutical opioid drugs? 
 
1 4 2.27 1.07 10 
How important are drug-related legal 
problems, in assessing a person for substance 
use disorders on pharmaceutical opioid drugs? 
 
1 5 2.19 1.14 11 
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These results were then presented in Round 2 to the experts in the ranked order 
from Table 3.13 and respondents were able to adjust the ranks accordingly based on 
their particular views. Table 3.14 shows the results of the second ranking. 
 
Table 3.14 
Round 2 - Ranked DSM-IV-TR criteria for substance abuse and dependence (n=27) 
DSM-IV-TR Criteria Min  Max  Mean SD Mode Rank 
Effects on social, occupational, or 
recreational activities 
1 7 2.2 2.04 1 1 
Effects on work, school or home 
obligations 
1 8 3.1 2.07 2 2 
Continued use despite health or 
psychological effects 
1 8 3.1 1.54 3 3 
In hazardous situations 3 10 4.6 1.67 4 4 
Social or interpersonal problems 4 11 5.8 1.62 5 5 
Attempts to reduce or control use 2 7 5.1 1.55 6 6 
Drug-related legal problems 0 11 7.3 2.25 7 7 
Time spent in obtaining drugs 1 11 7.3 2.16 8 8 
Evidence of tolerance 0 11 7.8 2.91 9 9 
Evidence withdrawal symptoms 0 11 8.1 3.13 10 10 
Amount of drug taken 1 11 9.3 2.46 10 11 
 
 
It appears that the experts ranked behavioural and social problems as most 
important in considering substance use disorders related to POA drugs (see Table 
3.14). They also agreed the evidence of tolerance and withdrawal symptoms was least 
important along with amount of the drug taken. The time spent in obtaining drugs was 
overall ranked eighth of all the criteria. 
 
Doctor shopping behaviour 
First, experts in Round 1 were asked a general question to elicit their broad 
definition of doctor shopping. The general consensus amongst experts in Round 1 in 
response to the first question was agreement for most (n=40) that doctor shopping was 
behaviour of persons seeking multiple prescriptions from multiple doctors. A number 
of experts (n=6) qualified this definition to include an element of deceptiveness on the 
part of the patient such that prescribers would be unaware of other prescriber’s 
activities. Two experts suggested that doctor-shopping behaviour suggested a person 
might be dependent or have lost control of their drug use. A further four experts noted 
that doctor-shopping behaviour could be linked to on-selling or illicit sales of drugs. 
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Second, the experts were asked to describe a level of doctor shopping by 
nominating a particular number of prescriptions obtained, prescribers consulted, 
dispensing pharmacists seen, and an estimated average daily dose in oral morphine 
milligrams equivalent in a given time period that would indicate a person is suffering 
a SUD with POA drugs. This included a free-text field for further explanation. 
 
In Round 2 in the second question the experts gave responses suggesting that 
obtaining a prescription within the prescription period of a previous prescription from 
another doctor could be cause for concern. There was a considerable range of 
responses for the number of doctors (ranging from 2 or more to multiple); numbers of 
prescriptions (any extra prescription from another doctor to up to four per year from 
multiple doctors); and the obtaining of maximum doses or any unsanctioned doses. 
Experts varied in their views that the behaviour could be taking place in time periods 
ranging from a week to a year. 
 
Given the range and variability of the responses it was decided to change the 
second questions in Round 2 in an attempt to facilitate responses. The Round 2 
questions requested the numbers of prescriptions obtained, prescribers consulted, 
dispensers involved and milligram dosage obtained over a two-month period; two 
months emulating the reporting requirements for long-term treatment in Queensland 
under the relevant legislation(Queensland Government, 1996).  
 
Furthermore, the question was varied to request the respondents to nominate the 
lowest levels of doctor shopping by these criteria in three different categories. These 
categories were explained using a traffic light system: a green light meant there was 
no concern to continue prescribing; an amber light meant a prescriber exercise caution 
before further prescribing; and red light was where a prescriber might choose not to 
prescribe. 
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Table 3.15 
Round 2 – Traffic light criteria for categories of doctor shopping based on prescriptions, prescribers, 
dispensers and average daily dose (OME-mg) consumed over any two-month period (n=27) 
Doctor shopping criteria Min Max Mean SD Mode 
Green light           
Prescriptions obtained 1 12 2.9 2.42 2 
Doctors consulted 1 5 1.6 0.96 1 
Pharmacies dispensing 1 5 1.6 1.05 2 
Average daily dose*  5 400 124.3 120.46 60       
Amber light 
     
Prescriptions obtained 1 13 4 2.88 2 
Doctors consulted 1 8 2.6 1.4 2 
Pharmacies dispensing 1 8 2.5 1.48 2 
Average daily dose*  10 700 161.6 159.72 60 &  
100* 
Red light 
     
Prescriptions obtained 1 24 6.2 5.22 3 
Doctors consulted 1 10 3.7 1.7 3 & 
4* 
Pharmacies dispensing 1 10 3.5 1.77 3 
Average daily dose**  20 800 222.8 233.22 60 & 
120* 
** multiple modes 
     
 
 
Table 3.15 above sets out the responses in Round 2 to the amended questions on 
what criteria for doctor shopping they would consider to continue to prescribe (green 
light), prescribe with caution (amber light), and not prescribe (red light). Experts 
appeared to support that some level of drug-seeking – consulting more than one 
prescriber and dispenser, and obtaining approximately three prescriptions with a dose 
of up to 120 mg per day oral morphine equivalent (OME) – would not necessarily be 
a barrier to further prescription of POA drugs. However, up to five prescriptions and 
more than two prescribers and pharmacists, and consumption of up to 220 milligrams 
(OME) would raise concerns, and levels beyond that further prescribing should not 
proceed. 
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3.4 DISCUSSION 
The results of the Delphi Technique study over two rounds with the expert panel 
presented mixed outcomes. The experts agreed that oxycodone and morphine POA 
drugs are most associated with harms. However, it is less clear what aspects of these 
POA drugs might make them more or less harmful. The experts agreed that injecting 
use and high-potency preparations were the most harmful features. However, they 
suggested that controlled-release and high-potency preparations could be protective 
features. Overall, this suggests that the participants are knowledgeable in this area and 
are aware of the association between the increased accessibility of oxycodone and 
POA drug-related harms in Australia and the USA. There is some inconsistency in this 
response, given that most oxycodone use is in the controlled-release preparations; a 
feature that experts agreed was protective. 
 
There was an apparent contradiction in the results in the experts’ assessment of 
sustained release preparations being viewed as both increasing and reducing harms.  
This is potentially reflective of two contradictions. Firstly, there is real potential for 
sustained release preparations to improve pain management and reduce inadvertent 
dependence in compliant persons adhering to their dosage. On their introduction in the 
late 1990s and early 2000s, sustained release preparations were superior to other 
immediate release preparations that then were most available on the market(Butler, et 
al., 2012; Hallinan, Osborn, Cohen, Dobbin, & Wodak, 2011). However, with 
increasing use there was widespread diversion of the sustained release preparations. 
Drug dependent and abusive users then discovered means to subvert the sustained 
release mechanism in the preparations to obtain effects similar to immediate release 
preparations (Fischer, Nakamura, Ialomiteanu, Boak, & Rehm, 2010; Okie, 2010; 
Shram et al., 2010).  
 
In determining individual risk factors across biological, psychological and 
cultural domains the experts agreed that genetics was the most important biological 
factor; mental health issues, exclusive of SUDs, the most important psychological 
factor; and peer use the most important cultural factor. It is noted that experts did not 
highly rate a chronic pain condition as a risk factor for developing a SUD with POA 
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drugs. Overall, the listed factors do not appear markedly different from generally 
reported risk factors across the drug dependence literature for the development of any 
SUDs. Potentially the questions in these parts of questionnaire were too broad.  
Perhaps the questions were open to alternative interpretations did not allow experts to 
readily discriminate between those persons on POA drugs long term for pain 
management purposes in comparison to those persons who might be obtaining POA 
drugs from non-medical sources. 
 
The experts’ ranking of the DSM-IV-TR SUD criteria in order of importance 
over the two rounds found agreement in social and behavioural criteria as most 
important. The criteria for tolerance and withdrawal were ranked lowest, with the 
exception of one. This supports the changes in the newly-released DSM-5 in regards 
to sub-classification of opioid use disorders, where tolerance and dependence are now 
not supported as the most salient diagnostic criteria. This again supports the fact that 
the experts in the study are knowledgeable of the field. 
 
The experts also set criteria for doctor shopping that might indicate whether a 
person is suffering a SUD with POA drugs. A traffic light system was used to 
effectively force the experts to nominate a level of doctor shopping in which they had 
no concern about further prescribing (green light); some concerns (amber light) and 
the level at which they would not recommend further prescribing of POA drugs (red 
light). This suggested a range of prescribing above four prescriptions from more than 
two different prescribers, and two different dispensers for a mean daily dose of over 
160 milligrams (OME) would cause initial concerns. The experts also agreed that at a 
level of prescribing above six prescriptions from more than three different prescribers, 
and three different dispensers for a mean daily dose of over 220 milligrams (OME) 
they would consider not further prescribing.  
 
These results appear to be consistent some of the review results in the recent 
Centers for Disease Control  Safe Opioid Prescribing Guidelines (Dowell, et al., 2016). 
The review found that patients on daily doses of greater than 100 milligrams OME 
were almost at twice the risk of a fatal overdose and over three times the risk of any 
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overdose of those patients prescribed between 50-100 milligram OME. Similarly the 
review found overdose mortality rates rose rapidly up to doses of 200 milligram OME 
per day.  These results seem to suggest some validity to the experts’ categorisation of 
different levels of concern.  
 
Overall, this use of a modified Delphi technique was helpful in drawing on a 
range of experts in different domains across different countries. This also allowed for 
the testing of a number of complex questions over an iterative process to allow experts 
to moderate their views based on the larger group’s response. Where the responses 
accessed areas with established or related research they were consistent with 
knowledge in the field, supporting that the expert selection was sound and that the 
Delphi Technique was effective in extracting this consensus information. 
 
There are some limitations to acknowledge. The first is the expert panel 
recruitment did not achieve anticipated numbers, and many participants that did 
respond did not quite fit the exclusive classification of either drug dependence or pain 
expert. Therefore, the study could not analyse differences in understandings between 
these fields. 
 
There was also an almost 2:1 ratio of self-nominated drug dependence experts 
to pain experts, so any results might reflect a bias towards the views of drug 
dependence experts. Furthermore, there was significant atrophy of participants across 
the two rounds, with an over 50% loss of participants from Round 1 (n=61) to Round 
2 (n=27). Also, the non-participating respondents completed all parts of the survey in 
either of the rounds they contributed to. This leads to some caution interpreting the 
results of a reasonable representation of pain and drug dependence experts, and the full 
respondents to only Round 1. It should also be noted some questions developed in 
Round 1 were used to derive materials for the next round’s rankings. For these 
questions, only one round of expert ranking was effectively undertaken in Round 2. 
Further iterative rounds were not undertaken given the significant loss of participants 
between the two rounds. 
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The DSM-IV-TR criteria for the use of a substance in larger amounts over longer 
periods is related to the construct of impaired control. This is perhaps related to a 
substance use disorder with POA drugs. However, this could also conceivably be 
associated with aspects of poor pain management or tolerance over different time 
periods. As such this criterion as set out in the questionnaire might have been open to 
multiple interpretations by the experts. 
 
It should also be noted that DSM-IV-TR diagnostic criteria for abuse and 
dependence state in overarching statements that they require consideration of “a 
maladaptive pattern of substance use leading to clinically significant impairment or 
distress …” (American Psychiatric Association, 2000). This statement was not 
included in the survey nor directly operationalised in questions in Delphi study, as the 
design was to examine the importance or contribution of each criterion.  However, the 
criterion ‘how important are the drug use effects on work, school, or home obligations 
in assessing a person for substance use disorders on pharmaceutical opioid drugs” is 
arguably more conceptually closer to describing ‘clinically significant impairment or 
distress’ than the other criteria. This similarity might have influenced this choice by 
the experts. 
 
 
3.4.1 Conclusion 
The results of this study suggest that defining substance use disorders with POA 
drugs, understanding the aspects of harms and the harmful characteristics, 
understanding what characteristics predispose persons to develop SUDs, and what 
levels of doctor-shopping or drug-seeking suggest problematic use are complex 
questions. In regards to the different POA drugs, it appears oxycodone and morphine 
are the two most likely to be associated with problematic use. However, it is less clear 
based on the formulations and routes of administration of POA drugs which would be 
ranked more highly. The experts rated injectability as the feature most likely to be 
associated with harms, and extended release the feature most likely to be a protection 
against misuse. This suggests a contradiction as the most common forms of oxycodone 
and morphine are controlled-release preparations, and are the drugs driving most of 
the increased consumption in Australia (Vowles, et al., 2015). In relation to the 
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question of the type of POA drug and characteristics associated with misuse, it should 
be noted the increased use and access to oxycodone, especially in a controlled-release 
formulation, could confound any ability to isolate a particular POA drug or its 
characteristics as more likely to be misused, as the prescribing and treatment 
environment does not allow equal access to all the different drug types and 
formulations. Furthermore, it is largely now known that controlled release oxycodone 
is readily able to be re-purposed and used in injectable forms. 
 
The experts’ ranking of individual characteristics that predispose a person to develop 
a SUD with POA drugs suggest, in most cases, characteristics that predispose someone 
to develop a SUD with any dependence-forming drug. From the point of view of the 
larger study, there are limited factors that might be accessible from the information in 
a PDMP. Of particular interest is the rating of younger persons, persons with a chronic 
pain condition, and persons with previous SUDs as likely risk factors for developing 
SUDs with POA drugs. Potentially these characteristics can be captured in dispensed 
prescription data held in a PDMP. 
 
There is also some difficulty in potentially using higher order concepts in 
PDMPs as they currently stand. At present most PDMPs are limited to, at best, 
including age and gender information. PDMPs are not clinical management tools per 
se, given the reasons for their development. However, potentially future iterations 
might consider information as important supporting information to assist in clinical 
and medical decision making. However, it is suggested that evidence and research 
should drive data collection, as expansion of system is costly, might not add value and 
could compromise use by clinicians. Perhaps consideration of linkage to other systems 
is more relevant, however the use of these concepts given current results are not readily 
able to be used in the following studies.  
 
Doctor shopping is not an unlawful activity under most State and Territory legislation 
in Australia. At its most basic form it could represent a person exercising freedom of 
choice in order to choose another health practitioner. At worst, it might represent overt 
criminal activity to obtain drugs for illicit markets. The issue for the implementation 
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of real-time monitoring is to provide information to prescribers and dispensers about 
a person’s POA drugs use history when they are making treatment decision and before 
a prescribing or dispensing decision is made. 
 
Doctor shopping in its pejorative sense is broadly defined as a person seeking 
prescription drugs from multiple doctors for purposes other than therapeutic needs. 
This implies the person seeking the drugs is either obtaining them for their use due to 
a SUD or that they are diverting them for other purposes. However, other explanations 
could account for a person’s apparent POA drug-seeking. For instance, a person whose 
pain was undertreated could seek further drugs from other prescribers . This is the 
phenomenon of ‘pseudo-addiction’ used in USA literature (Fellers, 2016; Robinson & 
Reiter, 2016). Alternatively, in palliative care situations or aged care scenarios, a 
person might be receiving prescriptions from multiple prescribers for high doses of 
drugs for legitimate treatment needs. 
 
Defining set criteria for doctor shopping by the experts, given this diversity for 
use in Study 2 to test in a PDMP therefore could not produce clear guidance or 
definitive definitions for person’s POA drug use that might be indicative of a person 
suffering a SUD. This does raise some issues for consideration in the progress towards 
developing real-time PDMPs at significant cost to the health budget. If there is a lack 
of general agreement across experts in defining doctor shopping from objective 
prescription information, then this might be also a challenge for the broader 
community prescribing community. 
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Chapter 4:  Study 2: The doctor-shopping 
population 
4.1 DEFINING DOCTOR SHOPPING 
This study examines whether doctor-shopping behaviour could potentially 
identify POA drug abuse or dependence within a regulatory prescription drug 
monitoring program (PDMP) database. In Study 1 there was a lack of agreed 
definitions for what described doctor shopping or aberrant drug-seeking of prescription 
opioids. The only agreed position was, at a minimum, that any amount of extra drug-
seeking beyond a person’s primary prescriber could be considered an indicator of 
concern. Overall, experts also did not rate drug-seeking behaviour highly as an 
important diagnostic criterion in assessing what criteria might be important in 
assessing person for SUDs on POA drugs. 
 
This finding of varied definitions of doctor shopping is consistent with previous 
research in the field (Cepeda, Fife, Berlin, Mastrogiovanni & Yuan, 2012; Han, Kass, 
Wilsey & Li, 2014; McDonald & Carlson, 2013; Nordmann et al., 2013; Peirce, Smith, 
Abate & Halverson, 2012; Wilsey et al., 2011; Worley, 2012; Worley & Hall, 2012)) 
that suggests there are multiple definitions of what might constitute doctor shopping. 
The general definition discussed in Chapter Two (see Section 2.8.1) is that doctor 
shopping is seeking prescriptions from multiple doctors and obtaining dosages in 
excess of what might be needed for therapeutic reasons. The results from Study One 
suggest that any drug-seeking behaviour meeting that criteria could be indicative of a 
SUD, depending on the individual circumstances. 
 
The common data elements that appear to define ‘doctor shopping’ are the 
number of doctors (or prescribers) consulted, the number of prescriptions obtained 
and/or number of dispensers used, and the time period during which the activity has 
taken place (see Section 2.8). Furthermore, there is an actual and implied element in 
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these definitions that the actual drug dose being obtained is in excess of therapeutic 
need. 
 
Study 2 aims to determine if levels of doctor shopping – as determined by the 
numbers of prescribers consulted, numbers of prescriptions obtained, numbers of 
dispensers seen, and volume of drug consumed – indicate different patterns of POA 
drugs usage that might discriminate aberrant or problematic drug seeking from non-
problematic drug seeking. The study also aims to determine if aberrant patterns of drug 
seeking could provide evidence supporting a substance misuse disorder, such as 
dependence or abuse. 
 
Potentially, the diagnostic criteria of the DSM-IV-TR for dependence could be 
tested within prescriptions records. The criterion of ‘substance taken in larger amount 
and for longer period than intended’ and ‘much time/activity to obtain, use, recover’ 
(American Psychiatric Association, 2000) suggest elements of dosage that is greater 
than therapeutic doses and extended periods of time engaged in drug seeking. 
Potentially, doctor-shopping activity that involves seeing greater numbers of 
prescribers, obtaining large volumes of prescriptions, and attending high number of 
dispensers over longer time periods could be more indicative of dependence than 
activity that was of lesser duration. 
 
Furthermore, the DSM-IV-TR criteria of ‘substance taken in larger amount and 
for longer period than intended’ and ‘tolerance (marked increase in amount; marked 
decrease in effect)’ (American Psychiatric Association, 2000) suggest that increasing 
or high dosage is also associated with drug dependence, especially in association with 
drug-seeking behaviour. Possibly, high or increasing dosage of POA drugs obtained 
by doctor shoppers could be a proxy for diagnostic criteria associated with 
dependence. Potentially, POA drug dosages that are greater than accepted therapeutic 
levels in association with doctor-shopping activity suggest converging evidence of 
drug dependence. 
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There is generally accepted evidence suggesting that there is limited efficacy of 
dosages of POA drugs at over 100-120 mg per day of Oral Morphine Equivalent 
(American Pain Society in Conjunction with the Americian Academy of Pain 
Medicine, 2009). Further, doses above 120 mg per day have also shown to be 
correlated with an increased risk of death (Gomes, Mamdani, Dhalla, Paterson & 
Juurlink, 2011). Dosages greater than 200mg per day are considered high dosages by 
the American Academy of Pain Medicine Opioid Guidelines (Chou, Fanciullo, Fine, 
Adler, Ballantyne, Davies, Donovan, Fishbain, Foley & Fudin, 2009). 
 
It has been reported that the risk of death increases for person on doses between 
200-400mg per day OME (Gomes, Juurlink, et al., 2011). Guidelines in determining 
high-risk dosages across the population consider levels of low, medium and high 
dosage to inform clinicians. The American Pain Socity suggests a low dose is 100mg 
OME per day, a medium dose between 100-200 mg OME per day, and a high dose 
greater than 200mg OME per day ((Chou et al., 2015)). A person engaging in doctor 
shopping might be at greater risk of harm at higher levels of consumption than a non-
doctor shopping person, as the consumed dose would not be that sanctioned by their 
treating doctor. 
 
Shorter-term aberrant POA drug doctor-shopping could indicate drug abuse 
under DSM-IV criteria. Doctor shopping in only one or two quarters of a year might 
not necessarily indicate a person has developed tolerance. This pattern might suggest 
a person is prepared to continue drug seeking despite there being possible legal 
consequences of this behaviour. This is not a definitive definition, nor does it meet any 
more than one criteria of the DSM-IV TR definition of abuse. However, for the 
purpose of this study, this concept of short-term aberrant POA drug doctor-shopping 
is proposed to serve as an approximation of a definition of drug abuse. 
 
For both definitions of doctor shopping, it should also be noted that a high dosage 
of POA drugs over a certain time period does not necessarily correlate with 
dependence or abuse. Within the population of persons being prescribed POA drugs, 
many will be on high dosages over lengthy periods of time for ostensibly legitimate 
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persistent or acute pain management conditions. This study is not examining whether 
pain management treatment provided in the non-doctor shopping context is appropriate 
or not. 
 
A further complexity in investigating this population is that a person might also 
drug seek or doctor shop infrequently, for short time periods across a year, and have 
periods of either no POA drug seeking (but still obtain POA drug prescriptions below 
a defined doctor shopping threshold) or obtain no POA drugs. These patterns are open 
to multiple interpretations. Short-term use POA drugs with low levels of drug seeking 
could represent successful acute pain management. Longer-term or persistent use of 
POA drugs with limited evidence of doctor shopping could suggest inadequate chronic 
pain management where a person might be supplementing drugs from other 
prescribers. 
 
Therefore, this study considers describing doctor shopping in terms of its 
constituent elements – prescriptions, prescribers, dispensers and volumes of drugs 
obtained – as well as the frequency and persistence of this behaviour. Furthermore, 
describing levels of POA drugs dosage and the frequency or persistency of POA drug 
prescribing over time might assist in discriminating aberrant use from legitimate use, 
and potential dependence from abuse, with the prescription database records. 
 
It is suggested that amongst a larger population of potential doctor-shopping 
patients there might be distinct sub-population of persons suffering drug dependence 
or abuse, poorly-managed pain management patients, or persons involved in diverting 
POA drugs for other purposes. These potential sub-populations are described in 
Chapter Two (Section 2.7). It is hypothesised an examination of doctor-shopping sub-
populations should allow discrimination between potentially different categories of 
POA drugs users (Queensland Government, 1996)based on their levels of doctor 
shopping as described by the numbers of prescribers consulted, prescriptions obtained, 
dispensers seen, dosages obtained, and the frequency of that behaviour over time. 
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4.2 METHODS 
This section sets out the description of the MODDS database and the 
operationalisation of the data elements of interest. The methods of extracting the study 
datasets and the methods of describing and analysing these are also discussed. 
 
4.2.1 Description of the MODDS database 
Data is collected by the Department of Health (DoH) of the Queensland 
Government for the purposes of state legislation (Queensland Government, 1996), and 
Medicare data is collected by the Commonwealth Government for the purposes of 
administering payments under the Pharmaceutical Benefits Scheme (PBS). Medicare 
collects all prescribed and dispensed drug data, of which POA drugs are, in part, liable 
for PBS subsidies. The DoH collects all POA drugs data that are Schedule 8 drugs 
under the SUSMP, and includes all PBS and private prescriptions dispensed 
community pharmacies. This does not capture treatment for patients in hospital or 
when POA drugs are provided to patients on discharge from hospital. 
 
Under Queensland legislation (Queensland Government, 1996) community 
pharmacies are required to submit records of dispensed controlled (Schedule 8) drug 
(i.e. POA drugs) prescriptions to the DoH on a monthly basis. Since 1996 the DoH has 
maintained a PDMP known as the MODDS database to collate and store this 
information and undertake its regulatory compliance functions. Appendix F shows 
details of a sample prescription and the information elements represented. This is also 
set out in The highlighted elements of the prescription are those entered into the 
MODDS database as data elements that describe a dispensed prescription event. 
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Table 4.1 
MODDS database summary data elements 
 
Category Variable name Example 
Drug details Drug name  Oxycodone controlled-release 
 Formulation Tablets 
 Drug formulation dose 80mg 
 Total quantity prescribed 20 
Patient details Name  Mr John Citizen 
 Date of birth 20 August 1985 
 Gender Male 
 Address 20 Brown Street, Corinda 
QLD 4006 
Prescriber 
details 
Name Dr Jenny Brown 
 Address Corinda 7 Day Medical 
Centre, 34 Corinda Rd 
Corinda 4011 
Pharmacy 
details 
Name  Mr Han Solo 
 Address Corinda Amcal Pharmacy, 22 
Sherwood Rd, Corinda QLD 
4006 
 
The system is regularly screened for data quality issues and has a regular process 
at data input to detect possible patient aliases. A range of business processes are 
employed to maintain data quality and ensure accurate matching of new data against 
the correct patient and doctor records. 
 
The MODDS database is on an Oracle Database platform (Oracle Corporation, 
2011) and is comprised of a number of interrelated data tables. The system has an over-
arching interrogation application, ‘Oracle Discover’ (Oracle Corporation, 2011), that 
allows for the production of ‘flat’ data files that can be extracted for the purposes of 
statistical analysis. 
 
The DoH has currently developed a ‘doctor shopper’ query for monitoring 
purposes. However, the DoH has not developed a single definition for ‘doctor 
shopping’. It is proposed to further develop this query tool to assist in producing 
appropriate datasets for the following studies. This query is designed to identify doctor 
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shopping by the user input variables as to the number of prescriptions and the number 
of different doctors consulted over a certain time period. For example, a user could 
interrogate the system to examine those patients who had seen 10 doctors or more and 
obtained 50 prescriptions or more over a set six-month period, where start date and 
end date parameters are entered. 
 
The MODDS database also records details of patients’ admission and discharge 
to formal opioid substitution treatment programs, and other administrative data related 
to legislative functions of the DoH. A person is then classified within the system based 
on whether certain regulatory or administrative actions have occurred. 
 
Details of the operation of the DoH and the MODDS database is subject to 
intellectual property limitations for Queensland Health and the claim of ‘public interest 
immunity’ as an exception to Queensland’s Right to Information Act 2009 
(Queensland Government, 2009). This means that some aspects of the system cannot 
be revealed, as DoH functions involve regulatory activity and public availability of 
that knowledge could compromise the DoH’s activities. Therefore, only those 
elements relevant to this study are discussed. 
 
Queensland Health data is also subject to provisions of confidentiality under the 
Public Health Act 1991 and the Health Services Act 1991. The MODDS database and 
its data code and structure are a Queensland Health asset and intellectual property and 
are subject to restriction from full public disclosure. Therefore, full operational 
structure of the database cannot be revealed. The relevant data elements that are used 
to extract the study population and derive data items for the study are discussed in the 
following section. 
 
4.2.2 Prescription opioid drugs in the MODDS database  
Data from MODDS includes all POA drugs that are Schedule 8 drugs or 
controlled drugs (Queensland Government, 1996; Schedule 8 (Commonwealth of 
Australia, 2010) dispensed at community pharmacies. This excludes some POA drugs, 
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such as tramadol that are Schedule 4 drugs, and some forms of codeine that in some 
doses are Schedule 3 and 4 drugs. This study examines opioid drugs only, so all non-
opioid controlled drugs were excluded in data extraction. This excluded all controlled 
psychostimulant drugs (dexamphetamine and methylphenidate) and benzodiazepines 
(flunitrazepam and alprazolam) that are captured by the MODDS database. The opioid 
substitution treatment drugs of methadone syrup and liquid and buprenorphine and 
buprenorphine-naloxone tablets and sub-lingual film were retained as they are opioids. 
However, they are discussed further in the course of the study as patients in receipt of 
these drugs have been formally admitted to opioid treatment programs. 
 
The opioid drugs are classified in the MODDS database under ‘Drug IDs’ and 
‘Drug Group IDs’. All drugs with a particular dosage formulation are allocated 
individual ‘Drug IDs’. For example, different dosage forms of morphine slow-release 
tables, capsules and sachets each have individual ‘Drug IDs’ However, all would have 
the same ‘Drug Group ID’ as they are all forms of the same drug class. Appendix G 
shows the full list of drugs in the MODDS databases. 
 
4.2.3 Prescribers (doctors) 
The number of prescribers consulted is intrinsic to a definition of doctor 
shopping. If all prescriptions are undertaken by the same doctor, then such an episode 
of supply is outside the parameters of interest for this study as this does not involve 
multiple prescribers; hence, does not quality as an example of doctor shopping. There 
can still be questions as to the appropriateness of supply of POA drugs in these 
circumstances which could be related to the professional practice of the prescriber. 
 
If it is assumed that a standard prescription is issued for a month or 28-day 
supply, then a single doctor issuing one prescription in a month might be considered 
legitimate supply. Two or more doctors prescribing to a person could be explained by 
in a number of ways that might also constitute legitimate supply of drugs. For example, 
two doctors at the same practice might see the same patient; possibly there might 
another specialist doctor also involved in treating the patients with the general 
practitioner, and prescriptions can overlap over month period. Furthermore, different 
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combinations of drugs might be required at different times for patient. For example, 
short acting POA drugs are often prescribed for ‘breakthrough’ pain in concert with 
controlled release POA drugs. Patients can also lose drugs and might also be travelling 
or moving across a jurisdiction and consult multiple doctors in their travels. 
 
At the lowest threshold of possible doctor shopping, more than one prescribed 
event with different prescribers within the same 28-day period of another prescribed 
event – especially where doctors were at different practices – could be indicative of 
doctor shopping over a set time period, dependent on the number of prescriptions and 
amount of drugs obtained. 
 
It should be noted that in this definition only consultations with prescribers that 
result in a dispensed prescription can be captured by the database; that is, if a person 
consults multiple doctors to obtain prescriptions that are not issued, they could be 
doctor shopping but not obtaining prescriptions. 
 
4.2.4 Prescriptions 
If a person consults at least two doctors in a set period, they could have obtained 
at least two prescriptions. From the information in the MODDS database, a 
prescription event will equate to a doctor consultation. However, some prescriptions 
from the same doctor might be ‘repeat’ prescriptions. These are prescriptions written 
for multiple dispensing at some future time period, usually 28-day intervals, without 
the need to return to consult the prescribing doctor. 
 
Some USA studies examine prescription supply that has occurred within the 
intended period of supply of a prescription (Johnson, McFarland, Corelle & Woodson, 
1994; Tanskanen et al., 2014)); that is, if a prescription is written for a 28- day supply, 
then a second dispensing event of another prescription after the initial dispensing event 
could constitute an incident of aberrant obtaining. However, the MODDS database 
does not capture this information and it is anticipated actual obtained dosage of drugs 
is a better measure and more likely to be correlated to problematic use. For defining 
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doctor shopping the baseline threshold will be that a person must have at least four 
dispensed prescriptions within a three-month period. This is one more prescription 
than might be expected in a one prescription per month (28-day period) in a non-
aberrant treatment regimen. The MODDS data only contains details of dispensed 
prescriptions; that is, those events where the prescribed medicines are actually supplied 
to a patient by a pharmacist in a community pharmacy. This includes all POA drug 
dispensed prescriptions, including those subsidised under the PBS, as well as those 
non-subsidised or private prescriptions. 
 
The MODDS dispensing information does not include: 
• POA drugs provided to persons as part of hospital inpatient care or those 
POA drugs that might be provided on discharge from hospital 
• Attempts at obtaining prescriptions that were refused by prescribers; and  
• Non-filling of obtained prescriptions by persons who had obtained 
prescriptions. 
 
It is possible that details of consultations captured by Medicare Australia under 
funding arrangements could give some indication of unsuccessful attempts to obtain 
prescriptions. Further, the MODDS database includes doctor enquiries and this 
information might allow for an estimate of drug seeking that did not result in a 
prescription being issued.  
 
4.2.5 Dispensers (pharmacists) 
The number of pharmacists a person consults to have prescriptions dispensed is 
a potential indicator of problematic drug obtaining. For instance, if a person obtains 
multiple prescriptions from multiple prescribers and has them filled at different 
pharmacies, there is concern this could suggest a method to conceal their obtainings 
from a single pharmacist who might question such activity. At the least the behaviour 
suggests poor health management as a single dispensing pharmacist would not be in a 
position to give any medication management advice as they would not have a complete 
medication history within their pharmacy records. 
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A number of US studies have used different pharmacies dispensings as an 
indicator of doctor shopping (Peirce, Smith, Abate, & Halverson, 2012; Yang et al., 
2015). However, in the Queensland context there is no regulatory or other mechanism 
to limit a person to a single pharmacy business. Even repeat prescriptions can be 
dispensed at different pharmacies. There is limited evidence in the Australian context 
to suggest that patients routinely confine their medication dispensing to single 
pharmacy as they might to a single medical practitioner or practice ((Nielsen, 2015)). 
 
Therefore, while multiple pharmacy dispensing could be a factor it might be 
more appropriately used as a secondary or latent factor to better discriminate within a 
proposed doctor shopping population. 
 
4.2.6 Time period 
Doctor-shopping definitions are based on some measure of multiple 
consultations of doctors and obtaining of prescriptions that imply the drugs obtained 
are in excess of therapeutic needs. This raises the question as to over what period of 
time in which prescriptions are obtained and dispensed is of interest to reliably capture 
the behaviour. 
 
Such a time period needs to be short enough to adequately capture a supply of 
drugs that could indicate possible misuse. However, the period of time over which 
drugs are being obtained should be long enough to capture use that might reflect a 
pattern of chronic behaviour, rather than aberrant single events. Furthermore, the time 
period should be of sufficient length to allow for calculation of average daily dose that 
might reflect actual consumption – assuming that the drugs obtained are consumed by 
the person prescribed. 
 
The longest dispensing period for a opioid analgesic drugs is 28 days, due to 
both pack sizes of medications (MIMS), funding or approval requirements for PBS 
subsidised items, and the general principles of appropriate clinical governance of these 
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medications by prescribers in not allowing patients too many drugs at any one time 
and general recommendations suggesting a monthly review of a patient’s treatment 
(National Prescribing Service, 2006, 2010; Royal Australasian College of Physicians, 
2009). 
 
Shorter time periods, less than a month, could potentially not capture 
prescription obtainings of concern. For example, in a single month, prescriptions 
dispensed on the last days of the previous month would not be counted even though 
the medication dispensed might be consumed in the month of interest and in 
conjunction with prescriptions obtained in this month. Similarly, prescriptions 
dispensed at the end of a calendar month could represent medications to be consumed 
fully or partly in the next month. Therefore, a single month is considered too short a 
period to examine for this behaviour. 
 
The American Pain Society (2009) in its comprehensive guidelines for treatment 
of chronic pain with POA drugs suggested that short-term treatment was treatment 
lasting less than three months, and, where conditions were long-term, the preiod is 
greater than three months (American Pain Society in Conjunction with the Americian 
Academy of Pain Medicine, 2009; Chou et al., 2015). 
 
In the regulatory context, most Australian jurisdictions have set reporting or 
permit requirements for treatment of a patient that is to extend beyond 8 weeks 
(Queensland Government, 1996). Continuous treatment for more than three months 
with a POA drug would seem to indicate a person suffering from a persistent or chronic 
pain condition. There is less evidence to suggest what time period would suggest a 
person was dependent or abusing POA drugs. 
 
In assessing abuse and dependence, the DSM-IV-TR and DSM-5 defintions set 
out that a number of criteria need to be met over a 12-month period (American 
Psychiatric Association, 2000, 2013). In terms of prescription and illicit opioid use this 
does not necessarily give guidance as to how long a period of time someone might 
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need to be exposed to opioids to develop dependence. Dependence suggests that the 
definition can be met in any timeframe within a year. 
 
There is some support in the pain management literature that pain that is not 
resolving after more than two months of treatment with opioids might not be 
appropriate for continued opioid treatment (Chou, Fanciullo, Fine, Adler, Ballantyne, 
Davies, Donovan, Fishbain, Foley, Fudin, et al., 2009). Furthermore, treatment beyond 
two months might suggest at least some level of tolerance or neuroadaptation in 
response to opioid consumption. 
 
However, a two-month period might not adequately capture opioid consumption 
that continues beyond a two-month threshold. An optimal time period would capture 
any standard prescribing practice of supply greater than two months of prescriptions 
at the most sensitive level of prescribing. Therefore, a prescribing interval of interest 
would necessarily need at least to be over a three-month period to capture the minimum 
level of prescribing that went beyond a two-month period. 
 
In Australia, most jurisdictions recognise long-term prescribing as prescribing 
for greater than two months or eight weeks (Hua, Shen, & Ge, 2015). This is usually 
the threshold at which a treatment provider is required to notify or seek authority from 
the relevant jurisdictional health department. Furthermore, there is some evidence that 
acute pain conditions or post-procedural pain management usually resolve in the six 
weeks after injury or procedure (Burke, 2016; Huxtable, Roberts, Somogyi, & 
Macintyre, 2011). Chronic pain conditions are often described as those conditions 
lasting beyond a six week period (Access Economics Pty Ltd, 2007; American 
Academy of Pain Medicine & American Society of Addiction Medicine, 2001; Ospina 
& Harstall, 2002; Rosenblum, et al., 2008). There is no consistent evidence in the 
literature that exposure to opioids for periods of two months or longer are associated 
with development of SUDs with POA drugs. However, consistent and long-term use 
of POA drugs is a necessary criterion for considering a diagnosis of dependence. 
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In Australia many drug preparations are prescribed and dispensed in 28 days 
periods and packaged as packets of 28 tablets. This means in many cases prescriptions 
are usually for 28 day or close to one calendar month. Two prescriptions could 
arguably represent two months of treatment for most of the main forms of POA drugs 
– morphine and oxycodone – that come in 28-tablet packages. 
 
This study aims to detect doctor shopping or drug seeking that could be related 
to aberrant POA drugs use and a substance use disorder. A greater than two-month 
period suggests a timeframe that is of interest to regulators and possibly indicative of 
chronic treatment. However, to adequately capture treatment extending beyond a two-
month period, a minimal timeframe of interest was set at three months to better capture 
POA drug use. In using a three-month time period the study can better capture apparent 
aberrant drug obtainings. For a three-month period, long-term prescribing could be 
represented by at least three prescriptions in that time period: one prescription for each 
month, assuming most prescriptions are written for a 28-day supply. Obtaining two or 
less prescriptions in a three-month period suggests possibly short-term treatment and 
less likelihood of aberrant POA drug use. 
 
Doctor shopping is broadly defined as a person seeing multiple doctors for more 
POA drugs that would appear required. In a three-month period this could be three or 
more doctors for four or more prescriptions. This sets a minimal and sensitive lower 
threshold of possible doctor shoppers. Two doctors in this period could reasonably 
represent a GP and a specialist or two GPs at the same practice, or another locum 
doctor, so is too sensitive a criterion. Three doctors in three months was set as the 
lower threshold for the number of prescribers. Four prescriptions over three months 
could represent one more prescription than would be expected in most routine 
treatment settings. Therefore, the criterion for dispensed prescriptions was set at four 
prescriptions over any three-month period. 
 
Longer time periods, six or twelve months, were considered as possible study 
intervals. However, using these longer time periods was more difficult to reliably 
detect possible doctor shopping. For these longer periods the numbers of prescriptions 
were more stretched and less able to be shown as greater than the expected therapeutic 
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need. Potentially the longer timeframes might have not been sensitive to short-term 
doctor-shopping activities.  For the purposes of the study annual figures were also 
calculated to allow for comparisons with the three month time periods. 
 
4.2.7 Drug consumption levels – approximation of daily 
dosage 
There is considerable inconsisitency across the literature in recommending what 
dosages of POA drugs might be hamful or problematic for individuals. This variability 
in tems of patient needs and complexity of pain management has led to many clinical 
guidelines around POA drug use not setting dose thresholds. Guidelines tend to focus 
on appropriate assessment and titration of dosage levels and patient monitoring to 
determine effects in initiating POA drugs treatments. 
 
There is generally accepted evidence that there is limited efficacy of dosages of 
POA drugs at over 100-120 mg per day of Oral Morphine Equivalent (Holliday, Hayes 
& Dunlop, 2013). Guidelines to determine risky dosages consider levels of low, 
medium and high dosages to inform clinicians. The American Pain Society suggests a 
low dose was 100mg OME per day, a medium dose was between 100-200 mg OME 
per day, and a high dose was greater than 200mg OME per day. 
 
Calculation of consumption at daily dosage level for most mediciations in the 
course of treatment assume a single practitoiner, coordinated treatment management, 
and that patients are consuming drugs as prescribed. However, for the population of of 
interest for this study – that is, potentially drug-seeking, drug-dependent, or abusing 
patients seeking drugs from multiple doctors – that can not be assumed. For example, 
a doctor-shopping patient can receive mulitple prescriptions from multiple prescirbers 
for different POA drugs with overlapping or discrete dispensing dates. Further, the 
instructions of a prescriber on any given prescrption could vary from ‘take as needed’ 
to a daily consumption regime. 
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There is also concerns that high-volume obtaining patients might be onselling or 
diverting some or part of the medications. Alternatively, there could be parties 
involved in organised criminal enterprise obtaining POA drugs under false IDs for 
direct diversion to illicit markets. Another potential issue is that patients could be 
prescribed short term courses of extra POA drugs for ‘breakthrough’ pain, that is short 
of acute exacerbations of pain within the context of persistent pain management.  This 
could create apparently higher doses in some periods of dispensing. However, short 
course breakthrough prescribing is generally limited to less than a few weeks at a time 
in most longer time periods.  
 
An approximation of daily dosage consumption levels could be useful in 
classifying persons as potentially drug-dependent, drug-seeking, or otherwise 
consuming POA drugs at beyond accepted therapetic levels. A proxy measure of daily 
drug consumption was developed to allow classification within the sub-population of 
potential doctor-shoppers that correlates with actual consumption levels. For each 
three-month quarter the total drug dosage by oral morphine equivalent milligrams 
(OME) was obtained for all POA drugs dispensed in that quarter. The total OME per 
quarter was then divided by the number of days in that quarter to give an approximation 
of a daily dose of OME milligrams. This gives an approximate daily dosage figure, 
and from this a person could be classifed as either Low, Medium or High dose levels 
as shown in Table 4.2 below. 
  
Table 4.2 
Estimation of approximate daily dose from actual quarter POA drugs dispensed 
(Oral Morphine Equivalent – mg) 
Dose level Actual volume POA drug 
dispensed/quarter 
Approximate daily 
dose 
Low  <9000mg <100mg/day 
Medium 9000-18000mg 100-200mg/day 
High >18000mg >200mg/day 
 
 
This measure is an approximation to allow for comparison across each of the 
different drug types and to allow for each person in each quarter but does have certain 
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limitations. This measure assumes consistent consumption across the dosing period, 
which might be applicable for long-acting medications. This assumption can not 
universally be held for immediate-release preparations, such as oxycodone (Endone™) 
tablets. These preparations are often take on an ‘as needed’ basis. 
 
The measure cannnot account for drugs obtained before the commencent of that 
quarter. This could lead to an underestimate of daily dosage. Secondly, drugs obtained 
towards the end of a quarter that might be consumed in the following quarter are 
included, potentially inflating a daily dosage estimate. However, for persons obtaining 
drugs across all four quarters of the study period this variability will be reflected in all 
quarters of the study period, potentially evening out these estimates. Given these 
limitations, and that other established measures of daily dosage might not be applicable 
in high-volume drug-seeking patients, this measure is used as the best approximation 
across all persons to allow for classification. 
 
4.2.8 History of drug dependence 
The MODDS database has a number of classifications based on DoH regulatory 
actions and confirmed diagnoses of drug dependence or notifications of long-term 
treatment with POA drugs. These classifications are set out in Table 4.3. 
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Table 4.3 
MODDS Classifications 
 
Classification Description 
Regular A person has been in receipt of at least one POA drug 
prescription, but not subject to any regulatory action* 
Report A person has had a long-term treatment report submitted to the 
Department of Health by a treating medical practitioner to 
meet legislative obligations 
Approval A person has had an approval issued to a medical practitioner 
to treat them with controlled drugs as they have been 
diagnosed as drug dependent** 
Program A person has been admitted to the Queensland Opioid 
Treatment Program for management of their drug dependence 
by a medical practitioner. 
 
* Note – Classification of a person in the MODDS system starts as ‘Regular’ once a 
prescription event generates a person within the system. The classification status is 
then changed to either report, approval or program based on the above described 
events.  
**Note – Drug dependence here refers to a legislative definition; however, the 
Department does refer to DSM or ICD diagnostic criteria in providing advice to 
medical practitioners. 
 
 
A ‘Program’ classification includes those persons who have had or are currently 
registered in a formal opioid treatment program (OTP) for their opioid dependence and 
are receiving opioid substitution drugs, such as methadone or buprenorphine (Subutex 
and Suboxone). As such, the extracted records capture a range of persons who have 
been diagnosed by medical practitioners as drug dependent. 
 
Once a person is admitted to the OTP, their classification remains ‘Program’ 
regardless of subsequent discharge or other reports or approval events. The Report, 
Approval, and Program status represent an increasing order of classification, such that 
a person once classed at one level cannot have their classification regress to the lower 
level classification, but they can be classed at the next level higher in the event of 
actions described in the table. 
 
Furthermore, those persons classified as ‘Approval’ status have had a formal 
legal instrument granted to a doctor to treat them with POA drugs because that doctor 
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‘reasonably believed they were drug dependent’ as required under the relevant 
legislation (Queensland Government, 1996). Drug dependence in these situations 
usually refers only to the use of POA drugs and not illicit or injecting drug use. This 
is different from persons determined as candidates for OTP treatments whose use of 
opioids usually involves illicit drugs, either heroin or illicitly obtained POA drugs, and 
whose use of these drugs might involve injection. 
 
For the benefit of this study, in considering issues of drug dependence on POA 
drugs, the above classifications give three initial categories of interest; those persons 
with admissions or potential admissions to OTP treatment; those persons who are 
considered dependent on POA drugs, but not suitable for OTP treatment; and those 
persons who have not been considered dependent on opioids at present.  The ‘Report’ 
status refers to legal requirements of doctors to report patients who have received two 
or more months of treatment with POA drugs to the DoH. All other persons who were 
other ‘nil-reports’ status were categorised as having no current or previously known 
drug dependence, nor any prescribing doctor notifying the Department they were 
undertaking long-term treatment of that person. These two classifications – ‘nil 
reports’ and ‘report’ – were combined into a single category of ‘unclassified’ as they 
represent that sub-population with no formal assessment of drug dependence. 
 
4.2.9 Extract of possible doctor-shopping population 
The definition of ‘doctor shopping as seeing multiple prescribers and obtaining 
multiple prescriptions was used to extract the population of interest. 
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Table 4.4  
Criteria for defining minimal definition of doctor shopping 
 Extraction variable  Criterion 
1 Number of prescribers  >2 in any one quarter 
2 Number of prescriptions dispensed  >3 in any one quarter 
3 Time period of activity Each 3-month calendar quarter 
 
 
The following discussion sets out the reasons for the numbers of doctors, 
prescriptions, and time periods used to extract the study population. The Oracle 
Discover queries were developed to extract potential doctor-shopping persons and 
their relevant details from the MODDS database for the 2013 calendar year. These 
queries sought to extract any persons who had been dispensed three or more 
prescriptions from three or more different prescribers in any one calendar quarter 
(three-month period) of the year (see Table 4-2). 
 
 
Table 4.5 
Calendar year quarters for extraction of doctor shoppers 
Quarter 1 
 
Quarter 2 
 
Quarter 3 
 
Quarter 4 
 1 January – 
30 March  
1 April – 
30 June 
1 July –   
30 
September 
1 October -  31 
December 
Q1 Q2 Q3 Q4 
 
 
An Oracle Discoverer query was run for each quarter of 2013 based on the above 
criteria, and four separate files were created. Each file contained the person’s 
demographic and classification details and summary of details of numbers of 
prescribers, prescriptions, and dispensers. The four files were then unified into a single 
file by linking them with the unique person PPID. This produced records of the 
person’s POA drug prescriptions across all quarters of 2013. This file included one 
case per person per line of data. 
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Data was extracted in four individual files for each quarter and then combined 
in a single, longer file for each quarter via the Merge File add Cases SPSS function. 
This file was now restructured using the SPSS Restructure function to create a file for 
each individual person and the four quarters of their prescribing history was included 
in each case record. 
 
Based on the persons identified in the above database queries another set of 
queries was developed to extract details of the prescriptions dispensed for each person 
in each quarter. This data allowed for full details of each prescription, including type 
and class of drug and total milligrams dispensed for that drug. This file included 
multiple lines per persons to account for all prescriptions dispensed to the person in 
that quarter. 
 
These prescriptions were not unified due to the complexity of the data, where a 
person’s ID had multiple prescription details listed against them for each quarter. 
However, this data was summarised to create a total dosage dispensed by Oral 
Morphine Equivalent (OME) milligrams. This summary figure for each quarter was 
then added to the original prescription summary files to give a total OME dosage 
dispensed per quarter for each person.  
 
The use of set three-month quarter periods (e.g. January to March, April to June) 
across the study captured all persons who met the study’s doctor-shopping criteria in 
those time periods (see Table 4.5). However, it is possible that some persons meet the 
doctor-shopping criteria for three-month periods within 2013 that are not captured 
within the quarter set for the study. For example, a person could meet the doctor-
shopping criteria in the three months from March to May. That person’s prescription 
activity might not have met the doctor-shopping criteria in either of the quarters 
January to March or April to July. Therefore, the study would not capture potential 
doctor-shopping persons and thus underestimate the number of persons engaged in 
doctor-shopping activity in the study year. 
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To verify if there were any non-identified doctor-shopping persons, all three-
month periods within 2013 were investigated to determine if further persons were not 
captured in the quarters set out in Study 2. Table 4.6 below shows other possible three-
month periods that occur in the year, in the column ‘Other Quarters’. 
 
Table 4.6 
All possible three-month periods in 2013 for doctor shopping analysis via MODDS database. 
Month Study 
Quarter 
Other Quarters 
January Quarter 1   
February  Quarter 1a  
March  Feb-Apr Quarter 1b 
April Quarter 2   Mar-May 
May  Quarter 2a  
June  May-Jul Quarter 2b 
July Quarter 3  Jun-Aug 
August  Quarter 3a  
September  Aug-Oct Quarter 3b 
October Quarter 4   
November    
December    
 
To generate this data Oracle Discoverer queries were executed for all the periods 
set out in Table 4.6. All the relevant data elements were extracted in the same manner 
as the procedure set out above for the previous data extraction described in this section. 
 
4.2.10 Frequency of doctor shopping 
The extent or frequency of doctor shopping and drug obtaining, in the absence 
of the criteria for doctor shopping, could potentially discriminate between drug-
seeking behaviour, indicative of a substance use disorder (SUD) and legitimate 
therapeutic treatment regimens. 
 
It could be considered that low-level of POA doctor shopping might resemble 
abuse, and longer-term doctor shopping resemble dependence. Also, short-term 
exposure to POA drugs, in the absence of doctor shopping, suggests acute pain 
management treatment, and longer-term treatment with POA drugs, in the absence of 
doctor shopping, suggests treatment of a chronic or persistent pain condition. A 
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proposed model of how level of doctor shopping and frequency of POA drug 
obtainings might relate of pain management or SUDs and consumed dosage levels is 
show in Table 4.7 and Table 4.8, respectively. 
 
Table 4.7 
Proposed model combining levels of doctor shopping and drug obtaining – possible diagnoses 
 Frequency of POA drug 
obtaining  
 
Doctor Shopping  Low  High 
Low Acute pain management Chronic pain 
management  
High Abuse Dependence 
 
 
Table 4.8 
Proposed model combining levels of doctor shopping and drug obtaining – dose levels 
 Frequency of POA drug 
obtaining  
 
Doctor Shopping  Low  High 
Low Low-Medium dose Low-Medium dose 
High High dose High dose 
 
 
As set out in Table 4.7 above the following relationship between the levels of 
doctor shopping and frequency of doctor shopping behaviour are hypothesised. A high 
level of doctor shopping could be characterised as behaviour of a person obtaining 
large numbers of prescriptions, from a large number of different prescribers, and being 
dispensed at multiple different dispensers. A low level of doctor shopping could be 
characterised as behaviour of a person obtaining lesser numbers of prescriptions, from 
a lesser number of different prescribers, and being dispensed at multiple different 
dispensers. In considering the frequency of doctor shopping over time, a low frequency 
low level doctor shopper might represent a person seeking extra pain relief for an acute 
pain condition; and a low level doctor shopper with a high frequency of activity over 
time, could represent a person seeking ongoing extra pain relief for a chronic pain 
condition. In contrast, a high level doctor shopping patient, displaying low frequency 
of this behaviour over time, might represent a response with the SUD of abuse; 
 134 Prescription opioid analgesic drug misuse: What can we learn from doctor-shopping behaviour 
whereas a high level doctor shopper exhibiting high frequency behaviour might 
represent a person with a dependence type of SUD. 
 
The extracted data is described and analysed to investigate if the 
abovementioned variables can be used to discriminate or identify doctor-shopping 
persons that are more likely to have potential SUDs from those persons who might be 
in receipt of long-term POA drug treatment. 
 
4.3 ANALYSIS 
 
All analyses were performed using SPSS (IBM Corporation, 2011) to identify 
potentially distinct groups within the sub-population of unclassified persons that met 
the criteria of a potential doctor shopper in any one quarter of 2013. A two-step cluster 
analysis was performed as this technique can classify large datasets and is robust to 
violations of assumptions of normality, independence between variables, and can 
manage outlying variables effectively (Norusis, 2008). 
The analysis of similarity between the clusters was determined using the log-
likelihood method, as this method is supported as being able to account for both 
continuous and categorical variables – which are intended to be used in the analysis of 
doctor shopping. Determination of the optimal number of clusters was performed 
automatically in the procedure selecting the Bayesian Information Criterion (Norusis, 
2008).  
Table 4.9 
Variables for entry in two-step cluster analysis for unclassified population for unclassified persons 
 Variable 
1 Mean unique prescribers consulted each quarter* 
2 Mean prescriptions dispensed per quarter* 
3 Mean unique dispensers dispensing per quarter* 
4 Mean volume of OME (mg) dispensed per quarter* 
5 Total quarters doctor shopped  
6 Total quarters POA prescriptions dispensed 
7 Mean dose level quarter dispensed 
*for each quarter where POA drugs only were dispensed 
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Measures included in the analyses are described previously and include those 
listed in Section  4.2 above. All measures were those potentially related to prescribing 
activity, such as unique prescriber, unique dispensers, and prescription volumes. Other 
drug consumption variables include volumes of drugs obtained, dose level, and other 
time-related variables of quarters where minimal doctor shopping was met, as well as 
total quarters in which POA drugs were dispensed. 
 
Differences in the proportions across clusters were assessed with Chi-square 
tests. The clusters were then compared using one-way analysis of variance with 
Scheffe’s post-hoc tests and Chi-square tests. The level of significance was set at 
p<.05. 
 
4.4 RESULTS 
 
 
4.4.1 Persons who received a POA drug prescription 
The records of total population of adults (18-80 years) who received any POA 
drugs in 2013 was extracted from the MODDS database by Oracle Discover Query 
and then exported into SPSS for further analysis. 
 
The data extracted was for each quarter and reported details of each person who 
had prescriptions dispensed in that quarter of their demographic details (date of birth 
and sex) and a summary form of dispensing records (number of prescribers, number 
of prescriptions, number of dispensers, date of first and last dispensing, days between 
first and last dispensing dates, and the MODDS classification at the time of extract). 
Records were extracted from the MODDS database using Oracle Discoverer Queries 
to extract all records of any individuals receiving opioid prescriptions for each quarter 
(three-month period) for 2013. 
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A total of 248,389 persons, almost 5.3% of the Queensland population 
(Australian Bureau of Statistics, 2006) received at least one prescription and in total 
received 1,589,933 POA drug prescriptions in 2013. 
 
All persons under 18 years of age (n=3,579) and over 80 years (n=26,049) of age 
were excluded from this study. Non-adults under 17 years were excluded as they are 
unlikely to be independently seeking POA drugs and there is limited evidence to date 
that this demographic is the subject of drug-seeking behaviour for this class of drugs 
by doctor shopping. Furthermore, much of the epidemiological evidence discussed in 
Chapter 2 refers to the adult population. Also in Australia, Medicare and subsidy 
arrangements often have children included under parents Medicare cards and health 
insurance policies, where they are co-habiting. Persons under 18 years who are drug 
seeking or on longer term POA drugs, might be more likely to be distinct from the 
adult population. The study is primarily examining adults who are not in aged care 
situations. As such persons over 80 years of age were also excluded as these persons 
are more likely to be receiving POA drugs for terminal illnesses, unlikely to be 
ambulatory and drug-seeking by doctor-shopping behaviour. Furthermore, multiple 
prescribers in this older age group might be indicative of a mix of care providers in 
aged care facilities or other situations and could be misclassified as doctor shopping 
patients. 
 
There were 218,761 persons aged between 18-80 years of age (Mean 
age=51.98+16.52 years), and this represents 6.7% of the Queensland population for 
this age group. Where gender was known, 37.2% (n=81,352) were female, and 26.2% 
were male (n=57,236). Persons between 18-80 years of age were prescribed a total of 
1,313,897 POA drug prescriptions for this year. Any person who has seen three or 
more doctors and obtained four or more prescriptions in any one quarter in 2013 was 
selected under the most conservative definition of potential doctor shopping. The 
following section examines the prescription activity of the potentially doctor-shopping 
population within each quarter, or three-month period, of 2013. 
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A secondary data query was performed to extract all persons who might have 
been potential doctor shoppers for any other three month periods as described in Table 
4.6. This was to test for any potential doctor shopping persons not captured in the 
initial extraction above. The Principal Personal Identification numbers (PPIDs) for all 
cases from this extracted data set were compared against the PPIDs extracted for the 
four calendar-month quarters from described earlier. The results of the matching 
process found there were no new cases identified in the secondary extractions for the 
other three-month periods that were not in the originally extracted cases. This means 
that the cases originally extracted include all persons in 2013 that meet a potential 
doctor-shopping criteria at any time in the year. 
 
4.4.2 Potential doctor-shopping population 
Based on MODDS-extracted data of summaries of prescription records, 15,545 
persons met the criteria for possible doctor shopping (consulted three or more 
doctors and obtained four or more prescriptions) in at least one of any of the four 
quarters of 2013. As shown in Table 4.10, this included 15,545 persons and this 
represents 7.1% of the adult Queensland population, 18-80 years of age who received 
a POA drug prescription in 2013 (0.005% of the entire Queensland adult population 
of the same age range) and accounted for over 27% of all POA drugs prescriptions in 
this year.  
 
Table 4.10 
Total persons and POA prescriptions x potential doctor shopping status 
Doctor shopping Persons (%) Prescriptions (%) 
Non doctor-shopping 203179 92.9 953621 72.6 
Possible doctor-shopping 15545 7.1 360515 27.4 
Total 218761 100 1313897 100 
 
 
Of the potential doctor-shopping population, where gender was known, 7905 
(50.85%) persons were female, and 7054 persons (45.38%) were male and the mean 
age for the entire population was 54.23+15.1 years. In comparison, the Queensland 
population projection for 2013 for persons aged 18 to 80 years reports 50.22% females 
 138 Prescription opioid analgesic drug misuse: What can we learn from doctor-shopping behaviour 
and 49.78% males (Australian Bureau of Statistics, 2014). Table 4.11 sets out the age 
categories for the potential doctor shoppers, and shows almost 60% of these persons 
were aged between 40 and 60 years of age. 
 
Table 4.11 
Persons by age category for all potential Queensland doctor shoppers in 2013 (n=15,545) 
Age range  Frequency % 
 
18-20 years 64 .4 
21-30 years 906 5.8 
31-40 years 2084 13.4 
41-50 years 2795 18.0 
51-60 years 3011 19.4 
61-70 years 2966 19.1 
71-80 years 2538 16.3  
Missing 1181 7.6 
 
Total 15545 100.0 
 
 
 
4.4.3 Doctor shoppers by drug-dependence status 
Table 4.12 sets out the MODDS classification of this population and shows almost 
three-quarters of the population (72.3%) were ‘Nil report’ patients, meaning those 
persons had not been subject to any regulatory action by Queensland Health nor had 
they been reported to the Department for their long-term POA drug treatment. Less 
than 4% had ever been or were currently on formal opioid treatment programs for 
dependence. Approximately 20% (3132 persons) had been reported in receipt of 
lengthy treatment, almost 4% (587 persons) were under drug treatment approvals, and 
another 4% (583 persons) had OTP histories. For the benefit of later analysis, all ‘Nil 
report’ and ‘Report’ persons are grouped as a broader ‘Unclassified’ category 
(n=14,378) representing all persons who have not previously been classified as drug 
dependent. This unclassified category represents over 92% of all potential doctor 
shopping persons. 
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Table 4.12 
MODDS classification of potential Queensland doctor shoppers in 2013 (n=15,545) 
 Classification Frequency Per 
cent  
Nil report 11,246 72.3 
Report 3132 20.1 
Approval 585 3.8 
Program 582 3.7 
Total 15,545 100.0 
 
 
4.4.4 POA drugs prescribed for potential doctor shoppers 
The second extracted file linked drug types and dosage dispensed for each of the 
individual prescriptions for each of the doctor-shopping persons prescribing 
summaries so that this drug type and dosage information could be amalgamated to 
show each person’s more detailed prescription records. A total of 360,515 POA drug 
prescriptions were dispensed in 2013 for this population and this was 387,001,476 
milligrams based on Oral Morphine Equivalent (OME) conversions for all the drug 
types (Nielsen, Degenhardt, Hoban, & Gisev, 2014). Table 4.13 sets out all the POA 
drug dispensed and the volumes and proportions of prescriptions and OME 
(milligrams) accounted for by each drug type. 
 
Oxycodone prescriptions account for almost two-thirds of prescriptions issued 
and almost 60% of drugs by volume dispensed. The next most commonly used POA 
drug was morphine slow-release preparations that accounted for almost 8% of 
prescriptions, almost 15% of volume of drugs dispensed. This is in keeping with 
known data from Australian prescribing trends (Degenhardt, et al., 2006; Dev, 
Loveday, Ballantyne, & Kemp, 2010; Dobbin, 2010a; Leong, et al., 2009). 
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Table 4.13 
POA drugs dispensed by prescriptions and OME milligrams in 2013 (n=15,545) 
Drug name Rxs % OME(mg) % 
Alfentanil Injections 1 0.000 140 0.000 
Buprenorphine + Naloxone Sub-
Lingual 
2530 0.007 17082862.5 0.044 
Buprenorphine Patches 27351 0.076 398445.6 0.001 
Buprenorphine Sub-Lingual 646 0.002 2655447.75 0.007 
Codeine Oral 3020 0.008 695371.3 0.002 
Fentanyl Injections 113 0.000 85.26 0.000 
Fentanyl Patches 32914 0.091 2281833.08 0.006 
Fentanyl Sub-Lingual 388 0.001 1963.6 0.000 
Hydromorphone Extended Release 
Oral 
9269 0.026 22768960 0.059 
Hydromorphone Injections 485 0.001 3307710 0.009 
Hydromorphone Oral 1282 0.004 2654910 0.007 
Methadone Injections 13 0.000 60075 0.000 
Methadone Liquid 2948 0.008 17612208.95 0.046 
Methadone Oral 6099 0.017 16769788 0.043 
Morphine Injections 3556 0.010 3751305 0.010 
Morphine Oral 4913 0.014 7174630 0.019 
Morphine Slow Release Oral 28369 0.079 56606695 0.146 
Oxycodone Hcl Controlled Release 
Oral 
94762 0.263 165603195 0.428 
Oxycodone Hcl; Naloxone Hcl 
Dihydrate 
30131 0.084 29125417.5 0.075 
Oxycodone Injections 9 0.000 2400 0.000 
Oxycodone Oral 107785 0.299 36619522.5 0.095 
Oxycodone Suppositories 731 0.002 724320 0.002 
Pethidine Injections 3133 0.009 992540 0.003 
Pethidine Oral 1 0.000 200 0.000 
Remifentanil Injections 1 0.000 10 0.000 
Tapentadol 65 0.000 111440 0.000 
Total 360515 1.000 387001476 1.000 
Note: Rxs-prescriptions, OME – oral morphine equivalent. 
 
4.4.5 Prescribing and doctor-shopping activity across the year 
A person of interest for this study could have met the study criteria for doctor 
shopping in any one of the four quarters of 2013. Many persons who might have met 
these criteria for less than four quarters may have also obtained prescriptions in the 
other quarters, and/or had no POA drugs dispensed in the other quarters. The measure 
of how many quarters a person met the doctor shopping criteria, and how many other 
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quarters they received POA drugs, are of interest in potentially separating drug-seeking 
behaviour from ongoing legitimate long-term therapy. 
 
The frequency and chronicity of doctor-shopping activity and POA drug-
prescribing allows for assessment of how prolific a person’s drug-seeking activity is, 
in regards to possible doctor shopping, and also how extensively they are exposed to 
POA drugs in terms of their continuity of prescribing across the year. For this 
population, persons could have met the criteria for doctor shopping in one, two, three 
or four quarters of 2013. Table 4-10 below sets out how many persons meet the doctor-
shopping criteria in how many quarters. Also included are the volumes of prescriptions 
and total milligrams dispensed for those persons, and the proportions they account for 
of total prescriptions and volumes of POA drugs dispensed. For example, 74% of 
persons in the study only met the doctor-shopping criteria in any one quarter of 2013, 
and this group accounted for almost 60% of all prescriptions and volume of POA drugs 
dispensed in 2013. 
 
Table 4.14 
Total doctor shopping quarters POA drugs dispensed by persons by prescriptions and by volume of 
drugs for possible Queensland doctor shoppers in 2013 (n=15,545) 
Quarters Persons 
 
Rxs 
 
OME(mg) 
 
 n % n % n % 
1 11,504 74.0 211,913 58.8 223,719,506.2 57.81 
2 2784 17.9 89,236 24.76 98,080,209.52 25.34 
3 925 6.0 39,761 11.03 43,393,141.82 11.21 
4 332 2.1 19,490 5.41 21,808,618.46 5.64 
Total 15,545 100.0 360,400 100.0 387,001,476 100.0 
 
 
Table 4.15 below shows the total numbers of quarters the study population 
received any POA drugs and included the percentage of prescriptions and volumes of 
drugs dispensed for each group. From this perspective, over half of the study 
population received prescriptions for all four quarters of the year, and this group 
accounted for over three-quarters of all prescriptions and over 80% of total volume of 
drugs dispensed. 
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Table 4.15 
Total quarters POA drugs dispensed by persons by prescriptions x volume of drugs for possible 
Queensland doctor shoppers in 2013 (n=15,545) 
Quarters Persons % Rxs % OME(mg) % 
   n %   n % n % 
  1 2392 15.4 15,987 4.44 8,841,157.66 2.28 
2 2667 17.2 31,235 8.67 22,485,750.53 5.81 
3 2348 15.1 42,733 11.86 34,020,908.2 8.79 
4 8138 52.4 270,445 75.04 321,653,659.6 83.11 
Total 15545 100.0 360,400 100.0 38,700,1476 100.0 
 
 
Combining the number of quarters a person doctor shopped by the study criteria 
by total quarters in which they had been dispensed POA drugs can describe in greater 
detail different levels of drug seeking in the context of long-term treatment not 
characterised by drug-seeking behaviour.  That is a person’s doctor shopping and non-
doctor shopping access to POA drugs can be examined over the study year. This allows 
examination of how frequently a person might have doctor shopped and also the oterh 
quarters in which they might have obtained POA drugs. 
 
The following three tables (Table 4.16, Table 4.17, and Table 4.18) show a 
matrix of persons classified by number of drug-seeking quarters and number of 
quarters prescribed for 2013, and the volumes of prescriptions and OME (milligrams) 
dispensed for each sub-group. The tables also include the proportion by percentage 
that that cell accounts for of the entire number or volume of that table. 
 
For example, 2,392 (15.4%) of persons in the study population appeared to doctor 
shop in one quarter and did not obtain POA drugs in any other quarter (Table 4.16) 
and accounted for almost 4.5% of all the prescriptions dispensed by number (Table 
4.17) and over 2% of OME milligrams volume of total POA drugs dispensed. 
Further, almost one-third of all persons in the study group seemed to doctor shop in 
one quarter and received POA drugs in the other three-quarters of the year (  
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Table 4.18). This group accounted for over 40% of all prescriptions and volumes 
of drugs dispensed. 
Table 4.16 
Total quarters doctor shopped for all quarters dispensed POA drugs – number of persons and 
proportion of total persons per category for all possible Queensland doctor shoppers in 2013 
(n=15,545) 
    Quarters dispensed         
1 2 3 4 Total 
Quarters 1 2,392 2,317 1,695 5,100 11,504 
Doctor  
 
15.4% 14.9% 10.9% 32.8% 
 
Shopped 2 - 350 528 1906 2784   
- 2.3% 3.4% 12.3% 
 
 
3 - - 125 800 925   
- - 0.8% 5.1% 
 
 
4 - - - 332 332   
- - - 2.1% 
 
  Total 2,392 2,667 2,348 8,138 15,545 
 
Table 4.17 
Total quarters doctor shopped x all quarters dispensed – POA drug prescriptions dispensed and 
percentage of total prescriptions for all possible Queensland doctor shoppers in 2013 (n=15,545) 
 
       Quarters dispensed        
1 2 3 4  Total 
Quarters 1 15,987 24,646 26,819 144,461  211,913 
Doctor  
 
4.44% 6.84% 7.44% 40.08%  
 
Shopped 2 - 6,589 11,846 70,801  89,236   
- 1.83% 3.29% 19.65%  
 
 
3 - - 4,068 3,5693  39,761   
- - 1.13% 9.90%  
 
 
4 - - - 19,490  19,490   
- - - 5.41%  
 
  Total  15,987 31,235 42,733 270,445  360,400 
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Table 4.18 
Total quarters doctor shopped x all quarters dispensed – OME(MG) of POA drugs dispensed and 
proportion of total volume of drugs dispensed for all possible Queensland doctor shoppers in 2013 
(n=15,545) 
      Quarters dispensed        
1 2 3 4 Total 
Quarters 1 8,841,157.66 16,952,353.55 20,673,766.26 177,252,228.8 223,719,506.2 
Doctor  
 
2.28% 4.38% 5.34% 45.80% 
 
Shopped 2 - 5,533,396.98 9,536,928.332 8,3009,884.2 98,080,209.52   
- 1.43% 2.46% 21.45% 
 
 
3 - - 3,810,213.6 39,582,928.22 43,393,141.82   
- - 0.98% 10.23% 
 
 
4 - - - 21,808,618.46 21,808,618.46   
- - - 5.64% 
 
  Total 8,841,157.66 22,485,750.53 34,020,908.19 321,653,659.6 387,001,476 
 
 
4.4.6 Approximate levels of POA drugs consumption 
An approximate measure of daily dosage of POA drugs by OME milligrams can 
allow classification of persons into low, medium and high dosage to describe 
consumption level. Based on the method set out in Section 4.4.6 an approximate level 
was calculated for each persons and averaged across the number of quarters in which 
they received POA drugs in the year.  
 
Table 4.19 shows how many persons in the study were in each dosage category 
and the volume of prescriptions and total OME milligrams of drugs dispensed for each 
group. Over three-quarters (77.6%) of all potential doctor-shopping persons had an 
average drug consumption of less than 100 milligrams per day (OME) per quarter 
prescribed in 2013. Further, this group accounted for just over 60% of all prescriptions 
dispensed; however, this was less than one-quarter (23.4%) of the total volume of 
drugs by milligrams OME. In contrast, the high-dose persons, consuming on average 
more than 200 milligrams OME in any quarter, were only 11.1% of all persons 
receiving almost one-quarter of all prescriptions (22.4%) but accounting for over a half 
(56.5%) of the drug consumed by volume of milligrams OME. 
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Table 4.19 
Mean approximate daily dosage levels per quarter dispensed for all possible Queensland doctor 
shoppers in 2013 (n=15,545) 
Daily dose 
estimate  
Persons   Prescriptions Volume of 
drugs 
  
 
N % n % Sum % 
Low dose 
(<100mg/day) 
12,065 77.6% 21,9008 60.8% 90,325,153.11 23.4% 
Medium dose 
(100-200mg/day) 
1,755 11.3% 60,740 16.9% 77,864,201.10 20.2% 
High dose (> 
200mg/day) 
1,725 11.1% 80,652 22.4% 218,812,121.81 56.5% 
Total 15,545 100.0% 360,400 100.0% 387,001,476 100.0% 
Note: mg=oral morphine equivalent dosage 
 
 
4.4.7 Drug dependence status of potential doctor shoppers 
The particular sub-population of interest for this study are those persons who 
have not been already identified as drug dependent, either as being on a formal opioid 
treatment program (e.g., OTP status) or under a legally-approval issued by the 
Department to a treating doctor (e.g., Approval status). As set out in Table 4.20 these 
persons will be referred to as ‘Unclassified’ persons and subject of further analysis for 
this study. The reason for this is that these persons are of most interest to monitoring 
and surveillance methods as they are being prescribed POA drugs by doctors 
frequently, or at least to meet the minimal doctor-shopping criteria; however, they have 
not been assessed as drug dependent at this time. The ‘Unclassified’ persons also are 
being dispensed over 90% of all prescriptions and accounting for 88% of the volume 
of OME (mg) being dispensed for 2013 for this sub-population (see Table 4-16). 
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Table 4.20 
Numbers of POA drug prescriptions and OME (mg) dispensed for potential doctor-shopping patients 
by drug-dependence classification (n=15,545) 
  Persons % Prescriptions % Total 
OME(mg) 
% 
Classification 
      
Unclassified  14,378 92.5% 317,166 88.0% 301,625,878.4 77.9% 
Approval 585 3.8% 25,449 7.1% 41,013,279.55 10.6% 
OTP 582 3.7% 17,785 4.9% 44,362,318.11 11.5% 
Total 15,545 100% 360,400 100% 387,001,476 100% 
 
 
Table 4.21 below sets out the differences in the variables of interest for each of 
the classifications of drug dependence. A one-way ANOVA was performed comparing 
the means for each of the variables of interest and all were found to be significantly 
different from each other at levels p<.001. The levels for the ‘Unclassified’ persons 
across all variables are lower than either of the ‘Approval’ or ‘OTP’ persons. The 
Unclassified category also accounted for over 92% of all potential doctor shoppers. 
This suggests that this population includes a wide range of prescribing behaviour, 
much of which might not be aberrant or representative of any substance misuse 
disorders. Therefore, the following analyses focus on the ‘Unclassified’ population to 
further examine this issue: these persons’ dependence status was indeterminate, and it 
would be expected this sub-population would include both legitimate therapeutic use 
and aberrant use. 
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Table 4.21 
POA drug prescription use and demographic variable x drug dependence status for all potential doctor shoppers for all possible Queensland doctor shoppers in 2013 
(n=15,545) 
  Unclassified    Approval    OTP     Test statistic 
  (n=14,378)     (n=585)     (n=582)         
POA drug prescription use  
        
F 
 
Prescriptions per quarter 
           
    Mean & SD 7.05 ± 4.83 11.78 ± 8.86 8.84 ± 6.59 267.57 ** 
    Range 1.75 - 124.00 1.75 - 76.33 2.25 - 81.25 
  
Prescribers per quarter 
           
    Mean & SD 2.56 ± 0.94 2.87 ± 1.42 2.72 ± 2.33 28.98 ** 
    Range 1.50 - 29.50 1.50 - 12.50 1.50 - 49.75 
  
Dispensers per quarter 
           
    Mean & SD 1.81 ± 1.03 2.72 ± 1.66 2.84 ± 2.32 395.34 ** 
    Range 1 - 29.75 1 - 14 1 - 44.75 
  
OME (mg) per quarter 
           
    Mean & SD 6186.45 ± 11117.39 18467.35 ± 19173.83 20765.66 ± 20125.44 684.44 ** 
    Range 12.60 - 262732.50 34.65 - 168637.50 42.00 - 122250.00 
  
Quarters doctor shopped 
           
    Mean & SD 1.34 ± 0.67 1.71 ± 0.93 1.46 ± 0.75 87.11 ** 
    Range 1 - 4 1 - 4 1 - 4 
  
Quarters obtained prescriptions 
          
    Mean & SD 3.01 ± 1.16 3.60 ± 0.82 3.38 ± 0.92 103.94 ** 
    Range 1 - 4 1 - 4 1 - 4 
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Demographic characteristics 
          
Gender 
           
Females 7445.00 
 
(54%) 241.00 
 
(41.3%) 219.00 
 
(52.8%) 
  
Males 6349.00 
 
(46%) 343.00 
 
(58.7%) 362.00 
 
(47.2%) 
  
Mean age 55 ± 15 45 ± 11 39 ± 10 
  
    Range 18 - 80 19 - 75 19 - 80     
**p <.001 
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4.4.8 Descriptive analyses of variables of interest 
 
The variables of interest for further analysis were examined using IBM SPSS for 
Windows (IBM Corporation, 2011) to investigate for assumptions of normality, 
identification of outliers, and independence. It is expected that this sub-population will 
include a large majority of cases that are unremarkable and representative of normal 
treatment regimes or slight variations from these. However, it is also expected there 
will be a small proportion of persons at the extreme ranges of variables due to high-
levels of drug-seeking. This means there is expected to be violations to the assumptions 
of normality in the variables of interest. 
 
It is noted that all variables of interest relate to a dispensing event, such that a 
prescriber, prescription, dispenser and dose amount are all elements of a dispensing 
event, so it is expected there is a violation of assumption of independence. Table 4.22 
below shows means and standard deviations for all prescription level variables of 
interest and Table 4-19 shows the skewness and kurtosis description of each variable.  
 
Table 4.22 
Means of variables of interest – Unclassified population of all possible Queensland doctor shoppers in 
2013 (n=14,378)  
 Variable Mean SD 
Mean Prescriptions x Quarter 7.05 4.83 
Mean Prescribers x Quarter 2.56 .94 
Mean Dispensers x Quarter 1.81 1.03 
Mean drug volume (OME-mg) x Quarter 6,186.45 11,117.38 
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Table 4.23 
Skewness and kurtosis –variables of interest – Unclassified population (n=14,378)  
  Skewness SE Kurtosis  SE 
Mean Prescriptions x Quarter 4.45 0.02 51.59 0.04 
Mean Prescribers x Quarter 4.64 0.02 75.42 0.04 
Mean Dispensers x Quarter 4.23 0.02 60.59 0.04 
Mean drug volume (OME-mg) x Quarter 5.68 0.02 62.17 0.04 
Total quarters prescribed -0.65 0.02 -1.14 0.04 
Total quarters doctor shopped 2.08 0.02 3.92 0.04 
 
 
 
The following four histograms (see Figure 4-1, Figure 4-2, Figure4-3, Figure 
4-4) show the distribution for each of the prescription level variables with the overlay 
of a normal distribution. 
 
 
 
 
Figure 4-1. Histogram of mean prescribers by quarter for Unclassified population – normal distribution 
overlaid (n=14,378)  
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Figure 4-2. Histogram of mean prescriptions by quarter for Unclassified population – normal 
distribution overlaid (n=14,378)  
 
 
Figure 4-3. Histogram of mean dispensers by quarter for Unclassified population – normal distribution 
overlaid (n=14,378)  
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Figure 4-4. Histogram of mean (OME) mg obtained by quarter for Unclassified population – normal 
distribution overlaid (n=14,378)  
 
 
Initial univariate descriptive analyses of individual continuous variables of 
prescriptions obtained, prescribers consulted and OME milligrams reported above 
obtained suggested small numbers of outliers or extreme values in each variable. To 
further analyse outliers in these variables scatter plots distributions were generated of 
combinations o undertaken using SPSS of Windows to investigate these cases. 
Scatterplots were constructed using Chart Builder function with selection of 
Scatterplots. 
 
To examine for outliers in regard to the volume of POA drugs obtained, scatterplots 
were constructed for each of the variables, mean prescribers, prescriptions, and 
dispensers per quarter as the Y – Axis, and mean OME milligrams per quarter as the 
X – Axis (Figures 4.5 to 4.7). A further scatterplot was also constructed with total 
prescriptions for the year (Y-Axis) and total OME milligrams obtained for the year  
(X Axis) as shown in Figure 4.8.  Results were further investigated using SPSS 
descriptive statistics to describe the volume and extent of potential outliers based on 
visual inspections of the scatterplots to determine the limits of each variable that 
appeared to contain the majority of cases. 
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The first scatter plot distribution examined the mean prescriptions per quarter and 
mean oral morphine equivalent in milligrams (OME) obtained in each quarter of 2013 
for the unclassified doctor shopping patients (See Figure 4-5). In this distribution over 
99 per cent of persons obtained 20 or fewer prescriptions on average each quarter and 
obtained a mean of less than 50,000 milligrams OME in each quarter they were 
prescribed. These persons accounted for 98.3 per cent of all prescriptions dispensed 
and 90 per cent of the volume of OME milligrams dispensed for the year. Of this 
distribution there were 122 cases or less than one per cent of total cases, that obtained 
more than 20 prescriptions and more than 50,000 milligrams OME on average for 
each quarter. Of note in this analysis, this group of outliers representing just over one 
percent of potential doctor shoppers obtained ten per cent of the total volume of OME 
milligrams dispensed to this population for the entire year. 
 
 
Figure 4-5. Distribution of total oral morphine equivalent in milligrams by mean prescriptions per 
quarter of 2013 for all potential doctor shopping persons (n=14,378) 
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The second scatterplot in Figure 4-6 describes the mean prescribers per quarters and 
mean prescriptions per quarters for all unclassified doctor shopping persons. The 
distribution of cases indicates 99 per cent of persons obtained 20 or fewer 20 
prescriptions per average each quarter and saw five or less different doctors per 
quarter. These persons accounted for 98.7 per cent of the total prescriptions dispensed 
and 98.9 per cent of the total Oral Morphine Equivalent (OME) in milligrams 
dispensed for these potential doctor shopping patients. A total of 155 persons (one per 
cent) of this sub-population obtained more than 20 prescriptions per quarter and were 
prescribed by more than 5 different doctors per quarter but obtained less than two 
percent of the volume of prescriptions dispensed in number and OME milligram 
volume.  
 
 
Figure 4-6. Distribution of total oral morphine equivalent in milligrams by mean prescribers per 
quarter of 2013 for all potential doctor shopping persons (n=14,378) 
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A further scatter plot distribution, as shown in Figure 4-8, was performed to describe 
mean OME in milligrams per quarter associated with the mean number of dispensers 
seen each quarter for all doctor shopping persons in 2013. Similar to the previous two 
figures, 98 per cent of potential doctor shopping persons saw 5 or less unique 
dispensers on and obtained 50,000 OME milligrams on average each quarter in 2013. 
The outlying or extreme just over one per cent of cases (n=148) consulting more than 
five different dispensers on average per quarter and obtaining more than 50,000 OME 
milligrams accounted for less three per cent of prescriptions dispensed and just over 
14 per cent of the volume of OME milligrams dispensed in 2013. 
 
 
Figure 4-7. Distribution of total oral morphine equivalent in milligrams by mean dispenser per quarter 
of 2013 for all potential doctor shopping persons (n=14,378) 
 
A final scatterplot distribution was produced for total OME milligrams by total 
prescriptions dispensed for all potential doctor shopping patients in 2013 (see Figure 
4-8). More than 99 per cent of persons obtained 100 prescriptions or less and received 
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200,000 milligrams of OME milligrams over the calendar year of prescribing activity.  
However, in total volumes obtained the less than one percent of outlying cases 
accounted for 1.7 per cent of prescriptions dispensed in number and over ten percent 
of total volume of OME milligrams supplied. 
 
 
Figure 4-8. Distribution of total oral morphine equivalent in milligrams by total prescriptions per for 
full year of 2013 for all potential doctor shopping persons (n=14,378) 
 
Figure 4-9 below shows the numbers of persons for each mean approximate dose 
levels for all ‘Unclassified’ persons for all quarters where POA drugs dispensed in 
2013. 80.7% of ‘Unclassified’ persons received low-level doses (less than 100mg 
OME) of POA drugs for all quarters they were dispensed prescriptions in 2013. 80.7% 
of Unclassified persons received on average 100 milligram or less per day of POA 
drugs, this accounted for almost two-thirds of all prescriptions dispensed (65.2%) but 
less than one-third of volume of OME milligrams (28.1%). For those 8.6% of 
Unclassified persons consuming on average over 200 milligrams OME per day, this 
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accounted for almost one-fifth of all prescriptions (18.2%) and almost one-half of the 
volume of OME milligrams (49.5%) dispensed. 
 
 
 
Figure 4-9. Histogram of frequency of persons mean dose level OME(mg) for all quarters dispensed 
for Unclassified population (n=14,378)  
 
 
Table 4.24 below shows means and standard deviations for all prescription level 
variables of interest and Table 4.25 shows the skewness and kurtosis description of each 
variable. For this sub-population, each person seems to be being prescribed for three-
quarters of the year but only doctor shopping for 1.3 quarters of the year.  
 
Table 4.24 
Means of variables of interest – Unclassified population (n=14,378)  
 Variable Mean SD 
Total quarters prescribed 3.01 1.16 
Total quarters doctor shopped 1.34 0.67 
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Table 4.25 
Skewness and kurtosis –variables of interest – Unclassified population (n=14,378)  
Variable  Skewness SE Skew Kurtosis  SE Kurt 
Total quarters prescribed -0.65 0.02 -1.14 0.04 
Total quarters doctor shopped 2.08 0.20 3.92 0.04 
 
 
The distribution of frequencies of quarters in which persons doctor shopped was 
negatively skewed. Figure 4-6 shows the numbers of persons by frequency of quarters 
doctor shopped in 2013. Most unclassified persons appeared to have only met a doctor 
shopping criteria in any one quarter of 2013 and fewer persons doctor shopped in two 
quarters, and less in three and four quarters. 
 
The distribution of frequencies of quarters a person is prescribed POA drugs are 
positively skewed, such that most persons appear to be receiving prescriptions across 
all four quarters, with similar numbers of persons receiving prescriptions in one, two or 
three quarters (see Figure 4-7). 
 
 
 
 
Figure 4-10. Histogram quarters doctor shopped for Unclassified population (n=14,378)  
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Figure 4-11. Histogram quarters dispensed for Unclassified population (n=14,378)  
 
Table 4.26 reports the correlations between all variables of interest and shows 
that all variables are significantly correlated with each other. The highest correlation 
(.790) is between Mean OME (mg) per quarter and Mean prescriptions per quarter, 
which is an expected relationship. However, there are two negative correlations 
between mean quarters prescribed and mean prescribers per quarter (-.423) and mean 
dispensers per quarter (-.093). This suggests as prescribing becomes more frequent, 
numbers of unique prescribers and dispensers reduces. 
 
Table 4.26 
Bivariate correlations for all variables of interest – Unclassified population for all possible 
Queensland doctor shoppers in 2013 (n=14,378)  
  Variable 1 2 3 4 5 6 
1 Mean prescribers per quarter       
2 Mean prescriptions per quarter 0.284      
3 Mean dispensers per quarter 0.503 0.341     
4 Mean OME (mg) per quarter 0.113 0.790 0.180    
5 Mean quarters prescribed -0.423 0.151 -0.093 0.185   
6 Mean quarter doctor shopped 0.368 0.320 0.216 0.193 0.318   
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Note: All correlations are significant p<0.01 (2-tailed)    
 
The description of the above variables of interest suggests some violations of the 
assumptions of normality for all continuous variables and lack of independence 
between variables. The variables of prescriptions, prescribers, dispensers, mean OME 
(mg) consumed appear to be highly-kurtosed and negatively skewed. This shows that 
the majority of cases in this population have low values, suggesting most cases might 
not represent aberrant patterns of use. There are a small number of extreme outliers 
particularly in mean prescriptions and mean OME (mg) consumed. 
 
4.4.9 Doctor-shopping cluster analysis 
 
The reporting of the Cluster Analysis following is based the recommendations of 
(Clatworthy, Buick, Hankins, Weinman, & Horne, 2005) for use of the technique in 
health psychology studies. Clatworthy et al (2005) suggested reporting on the computer 
program, the similarity measure, the cluster method, the procedure use to determine the 
number of clusters and the evidence for the validity of clusters. The full output of the 
SPSS for Windows two- step cluster analysis is reported in Appendix H. 
 
The similarity measure chosen the ‘log-likelihood’ which is named ‘distance 
measure’ in IBM SPSS for Windows (IBM Corporation, 2011). Two similarity 
measures are available ‘log likelihood’ and ‘Euclidean’. Clatworthy et al (2005) 
recommend squared Euclidean distance as the optimal distance measure to use in cluster 
analysis where groupings might be based on elevation of scores. However, Norusis et 
al (2008) state that if analysis included continuous and categorical variables then only 
‘log-likelihood’ distance measure can be used. This analysis then used ‘log likelihood’ 
distance measure for the operation of the cluster analysis. 
 
The cluster method chosen was the 2 Step Cluster Analysis in SPSS For Windows 
(REF) option under Classification methods. Two other cluster analysis methods, 
Hierarchical and K-Means are also available as options in SPSS for Windows (IBM 
Corporation, 2011). The 2 Step Cluster Analysis is the only method that can form 
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clusters where the variables are a mix of continuous and categorical (Norusis, 2008) as 
is the case with this study. As such the 2 Step Cluster Analysis method was chosen as 
the most appropriate means of analysis. 
 
The 2 Step Cluster Analysis method in SPSS allows for user to set a maximum 
upper limit of the number of clusters, or specify a fixed number of clusters. SPSS also 
includes two options for clustering criteria for assessing the cluster model’s fit to the 
data, Bayesian and Akaike Information Criterion. The 2 Step Cluster Analysis was run 
using both Information Criterion and there were no differences in models generated, so 
the default settings of Bayesian Information Criterion was retained and reported on in 
the following results. 
 
The 2 Step Cluster Analysis also allows for continuous variables to be 
standardised if they have different scales and means. The analysis was run with 
standardised and non-standardised continuous variables, and the same cluster models 
was produced. Standardisation of the continuous variables is the default setting, and as 
such was retained and the following reported results are based on this setting. 
 
Treatment of outliers can also be undertaken in the 2 Step Cluster Analysis and it 
is anticipated outliers will exist in the study population and could have an undue 
influence on cluster models formed. In IBM SPSS for Windows outliers can be 
nominated at as certain percentage level and this can lead to creation of a particular 
cluster for those outliers. The analysis was undertaken with outliers, with percentages 
set at the top five, ten and 20 per cent levels. This is lead to solutions with a large 
number of clusters between six and ten, and all reported as ‘poor’ solutions on cluster 
quality measure of cohesions and separation. Furthermore, no clusters in these solutions 
were found to be good representations of outliers in any of the contributing variables. 
As such no treatment for outliers was undertaken as per the default settings of the 
analysis and the reporting on the results following reflects this. 
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The validity of the cluster structure was tested by randomly diving the data set in 
two halves and repeating the cluster analysis as suggested by Clatworthy and others 
(2005). This testing was undertaken and reported the same outcomes in terms of cluster 
models for example population half sample. 
 
The cluster analysis produced two distinct groups based on the seven prescription 
activities on the salient characteristic of each group: non-aberrant and aberrant POA 
drug use groups. Table 4.27 below sets out the difference between both clusters on 
variables of interest. The largest cluster, the normal POA drug-use group, consisted of 
11,536 persons (80.2% of the unclassified persons) and has more females than males. 
As the group name suggests, this group has lower levels of POA drug activity and 
consumption across all variables, particularly in mean volume of prescriptions 
dispensed and POA drugs consumed per quarter which equated to low-level POA drug 
consumption of less than 100 milligrams OME per day. This group was named the 
‘Non-aberrant’ group for further descriptive purposes and discussion. 
 
The total population (n=11,536) of the non-aberrant use cluster all were in the 
low mean dose level per quarter dispensed; whereas the aberrant use clusters were 
predominantly spread in the medium-level, 1,533 (53.9%), and high-level doses, 12,355 
(43.5%), with only 74 persons (2.6%) within the low dose group  
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Table 4.27 
Differences in POA drug prescription use and demographic variable for all potential ‘Unclassified’ doctor shoppers by two-step cluster solutions (n=14,378) 
  Normal  
use  
  Aberrant 
use 
    Test statistic 
  (n=11,536)     (n=2,842)         
POA drug prescription use  
     
F 
 
Prescriptions per quarter 
        
    Mean & SD 5.95 ± 2.96 11.52 ± 7.59 3,834.04 ** 
    Range 1.75 - 29.00 2.5 - 124  
 
Prescribers per quarter  
 
  
 
  
 
    Mean & SD 2.52 ± .78 2.74 ± 1.42 119.67 ** 
    Range 1.57 - 7.0 1.5 - 29.5  
 
Dispensers per quarter  
 
  
 
  
 
    Mean & SD 1.72 ± .82 2.17 ± 1.56 441.29 ** 
    Range 1.0 - 7.0 1.0 - 29.75  
 
OME (mg) per quarter  
 
  
 
  
 
    Mean & SD 2,365.43 ± 2260.93 21,696.37 ± 17,457.99 13,245.06 ** 
    Range 12.60 - 9,020 636.48 - 262,735.50  
 
Quarters doctor shopped  
 
  
 
  
 
    Mean & SD 1.27 ± .59 1.63 ± .88 674.23 ** 
    Range 1 - 4 1 - 4  
 
Quarters obtained prescriptions 
 
  
 
  
 
    Mean & SD 2.88 ± 1.17 3.52 ± .92 725.905 ** 
    Range 1 - 4 1 - 4 
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Demographic characteristics 
Gender 
           
Females 6157 
 
(55.9%) 1288 
 
(46.3%)    
  
Males 4854 
 
(44.1%) 1495 
 
(53.7%)    
  
Mean age 56 ± 15 52 ± 14    
  
    Range 18 - 80 19 - 80        
**p <.001 
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The smaller group comprises 2,832 persons (approximately 20% of the 
unclassified persons, 1.3% of the Queensland population that received POA drugs, and 
0.09% of the Queensland population aged 18-80 years). This group has higher levels 
of POA drug activity and consumption across all variables, particularly in mean 
volume of prescriptions dispensed and POA drugs consumed per quarter, which 
equated to a high level POA drug consumption of greater than 200 milligrams OME 
per day. This group was named the ‘Aberrant’ group for further descriptive purposes 
and discussion. 
 
For all of the variables of the study there were significant differences between 
the Aberrant and Non-aberrant clusters. However, there appeared small differences 
between both groups on variables of prescribers and dispensers, with less than a single 
prescriber or dispenser difference between either group on average. However, there is 
a far higher maximum range for dispensers and prescribers in the Aberrant group, 
suggesting there might be statistical outliers in this cluster. There were more distinct 
differences between both groups in the numbers of prescriptions dispensed and 
milligrams OME consumed per quarter. The Aberrant group appeared to obtain almost 
twice as many prescriptions and consume more than nine times the volume of POA 
drugs than those persons in the Non-aberrant cluster. 
 
Overall, the Aberrant group, although only 20% of potential unclassified doctor 
shoppers, accounted for over one-third of all prescriptions dispensed and almost three-
quarters of the POA drugs by milligrams OME consumed (see Table 4.28). 
 
Table 4.28 
POA drug prescriptions by volume and OME (mg) dispensed for Unclassified population by two-step 
Cluster solutions (n=14,378) 
  
Non-aberrant 
(n=11,536)   
Aberrant 
(n=2,842)   Total 
Total prescriptions 201,386.00 63.5% 115,780.00 36.5% 317,166.00 
Total OME (mg) 83,461,962.61 27.7% 218,163,915.75 72.3% 301,625,878.36 
 
 
 166 Prescription opioid analgesic drug misuse: What can we learn from doctor-shopping behaviour 
Further examination of the approximate classification of the average daily 
dosage of POA drugs across all quarters dispensed in 2013 for both clusters is shown 
in Figure 4-12 below. This demonstrates that all persons in the Non-aberrant cluster 
were categorised as persons consuming less than 100 milligrams OME per day. For 
the Aberrant cluster almost all persons were classed as either medium (100-
200mg/day) or high (>200mg/day) dosage consumers of POA drugs. 
 
 
Figure 4-12. Percentage of persons for each cluster identified in the Cluster Solution classified by 
their approximate daily dose levels of POA drugs for Unclassified population (n=14,378)  
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Table 4.29 
Total quarters doctor shopped x all quarters dispensed for all persons in Cluster 2 (Aberrant users) 
for Unclassified population by Two-step Cluster solutions (n=2,842) 
    Quarters dispensed       
  
1 2 3 4 Total 
Quarters 1 203 170 146 1137 1656 
doctor  
 
7.1% 6.0% 5.1% 40.0% 
 
shopped 2 - 79 75 578 732   
- 2.8% 2.6% 20.3% 
 
 
3 - - 42 258 300   
- - 1.5% 9.1% 
 
 
4 - - - 154 154   
- - - 5.4% 
 
  Total 203 249 263 2127 2842 
 
 
Table 4.30 
Total prescriptions dispensed for all persons in Cluster 2 (Aberrant users) for Unclassified population 
by Two-step Cluster Solutions for all quarters doctor shopped x all quarters dispensed (n=2,842) 
    Quarters dispensed       
  
1 2 3 4 Total 
Quarters 1 2376 3354 3899 46124 55753 
doctor  
 
2.1% 2.9% 3.4% 39.8% 
 
shopped 2 - 2000 2332 28949 33281   
- 1.7% 2.0% 25.0% 
 
 
3 - - 1832 14614 16446 
  
- - 1.6% 12.6% 
 
 
4 - - - 10300 10300 
  
- - - 8.9% 
 
  Total 2376 5354 8063 99987 115780 
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Table 4.31 
Total volume of OME (mg) dispensed for all prescriptions in Cluster 2 (Aberrant users) for Unclassified population by Two-step Cluster Solutions  
for all quarters doctor shopped x all quarters dispensed (n=2,842) 
    Quarters dispensed     
    1 2 3 4 Total 
Quarters 1 4117088.07 7607803.10 8273722.66 96858852.31 116857466 
doctor  
 
1.9% 3.5% 3.8% 44.4% 
 
shopped 2 - 3388768.80 4609677.94 52102898.57 60101345.31   
- 1.6% 2.1% 23.9% 
 
 
3 - - 2514445.32 24112615.94 26627061   
- - 1.2% 11.1% 
 
 
4 - - - 14578043.04 14578043   
- - - 6.7% 
 
  Total 4117088 10996572 15397846 187652410 218163916 
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4.4.10 Total year figures 
 
The comparisons of the Aberrant and Non-aberrant groups from the Cluster 
Analysis compared the two groups on details of the prescriptions, prescribers and 
dispensers averaged over each of the quarters in which they obtained prescriptions. 
What is not captured is the total numbers of unique prescribers, unique dispensers and 
total prescriptions for each person over the entire year. 
 
Potentially, a person’s average number of unique prescribers consulted per 
quarter might not reflect the full extent of their consulting of different prescribers or 
dispensers. For example, a person could be consulting on average five unique 
prescribers over two quarters. This might represent, at minimum, the same five unique 
prescribers in both quarters or, at most, 10 different prescribers over the two quarters. 
This could represent another factor to discriminate Aberrant from Non-aberrant POA 
drug-obtaining behaviour. This question was further investigated in the dataset of the 
identified potential doctor shoppers used in the Cluster Analysis. 
The PPIDs of Aberrant and Non-aberrant groups were used to extract data from 
the MODDS database of the total number of unique prescribers and unique dispensers 
over the entire 2013 calendar year. The total number of prescriptions was already 
available, based on the sum of prescriptions dispensed in each quarter for each case. 
Table 4.30 above sets out the details for each group below. 
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Table 4.32 
Total unique prescribers, unique dispensers and prescriptions for three-month periods for Aberrant 
and Non-aberrant potential doctor shoppers in 2013 (n=14,378). 
 
  
Non-aberrant  
  Aberrant use     Test statistic use  
  (n=11,536)     (n=2,842)         
  
     
F(1,4376) 
Total unique prescribers  
       
    Mean & SD 4.52 ± 1.76 5.57 ± 3.94 452.318 ** 
    Range 3 - 20 3 - 107  
 
Total unique dispensers  
       
    Mean & SD 3 ± 1.75 3.74 ± 3.76 441.29 ** 
    Range 1 - 17 1 - 86   
Total prescriptions 
     
    Mean & SD 17.50 ± 12.61 41.76 ± 30.99 598.689 ** 
    Range 4 - 106 4 - 496     
 
 
Table 4.32 above shows that for each variable of interest, the Aberrant group 
consulted more unique prescribers, unique dispensers and obtained more prescriptions 
than the Non-aberrant group across the entire year. The difference between the groups 
in the number of unique prescribers was just over one prescriber, and in numbers of 
unique dispensers less than one dispenser. In both cases the range was much greater 
for the Aberrant groups in both variables. 
 
The most pronounced differences were in the total numbers of prescriptions 
obtained over the year. The Aberrant group obtained almost 2.5 times the number of 
prescriptions of the Non-aberrant group. Similarly, with the other variables, the range 
was much greater in the Aberrant group when compared to the Non-aberrant group. 
 
This result is consistent with the results of the previous study where the two 
groups were compared on the averages of these variables within each quarter that a 
person was dispensed a prescription. There were significant but small differences 
between the Aberrant and Non-Aberrant groups for the numbers of prescribers and 
dispensers. Further, there was similarity in the significant difference between both 
groups and the numbers of prescriptions obtained. 
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4.5 DISCUSSION 
 
This study examined persons in the Queensland population who were prescribed 
POA drugs in 2013 and met the minimal criteria of doctor shopping in any quarter of 
that year. Of those persons only those unclassified persons – those without any known 
history of drug dependence – were further examined to see if their doctor-shopping 
behaviour – as described in the variables of doctors consulted, prescriptions obtained, 
dispensers seen and dosages consumed – could allow discrimination of certain sub-
populations of use. Of the total persons prescribed opioids in Queensland in 2013, 
15,545 persons (71%) met these doctor-shopping criteria in any one quarter. 
 
In terms of prescriptions, these persons were predominantly prescribed 
oxycodone preparations (65%), morphine preparations (10.3%), fentanyl patches 
(9.1%) and buprenorphine patches (7.6%). In terms of actual volumes of drugs 
consumed by OME milligrams, the drug consumption by volume was oxycodone 
products (60%), morphine products (16.5%), hydromorphone (6%), and methadone 
(4.6%) with all other POA accounting for the remaining consumption. This matched 
general population consumption and the overwhelming use of oxycodone products in 
all groups suggested the type of drug being consumed would not allow for any 
discrimination amongst users.  It is not clear necessarily whether the pre-dominance 
of the use of oxycodone, morphine and controlled preparations, and their particular 
characteristics in and off themselves, compare to other POA drugs, have contributed 
to increasing misuse of POA drugs.  There is some evidence of assertive promotion of 
these preparations, there access under the PBS subsidy being associated with increased 
use and then increased links to harms  (Pilgrim, 2015; Rintoul, Dobbin, & Ozanne-
Smith). However, other issues such as disruptions to illicit heroin supplies and there 
and increased accessibility and availability of controlled release POA drugs over other 
POA drugs, also appear to be related. Further studies examining patterns of misuse 
and preference for certain preparation by licit and illicit users using these preparations 
might be helpful understanding further whether particular qualities of certain POA 
drugs are more associated with harms., as this does not appear to be assessed at a 
population level by only examining dispensing data. 
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The study also examined the frequency of persons prescribing and frequency of 
doctor shopping over the year to investigate consistency and chronicity of POA drug-
use behaviour. In this population, over half the persons received drugs in all quarters 
of the year, and almost two-thirds were prescribed POA drugs in three or more 
quarters. In contrast, almost three-quarters of persons demonstrated doctor shopping 
in only one quarter of the year, with just over 2% of persons’ doctor shopping in all 
four quarters. 
 
When the data was combined to examine the quarters in which persons obtained 
POA drugs and quarters in which they also doctor shopped it was found that almost 
60% of persons had doctor shopped in any two quarters of the year, but were prescribed 
POA drugs in three or more quarters. This group accounted for over 70% of the 
prescriptions obtained and over three-quarters of the drugs prescribed by volume of 
milligrams (OME). A small proportion of persons (2.1%) doctor shopped for all four 
quarters of the year, accounting for over 5% of prescriptions and almost 6% of volume 
of OME milligrams dispensed. 
 
Of the total potential doctor-shopping population, 14,378 persons had no 
recorded history of dependence on the MODDS database either as an OTP patient or 
under a drug treatment approval with POA drugs. This sub-population was further 
analysed with the known drug-dependent persons excluded. 
 
A two-step cluster analysis was performed to see what grouping might form out 
of this sub-population, and the independent variables used were mean numbers of 
unique prescribers consulted, numbers of prescriptions obtained, numbers of unique 
dispensers involved in dispensing, and mean volume of milligrams (OME) consumed 
per quarter dispensed.  The results provided two distinct clusters: one cluster of 11,536 
persons (80% of the sample) obtained on average approximately 6 prescriptions, saw 
2.5 different prescribers, 1.7 different dispensers and consumed a total of almost 2400 
mg OME for each quarter. This level of consumption could be approximated to an 
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average daily dose of less than 100mg OME, which is considered low by clinical 
standards. This group was named the Non-aberrant group for further reference. 
 
The second cluster of 2,842 persons (20% of the sample) obtained on average 
approximately 12 prescriptions, saw over 2.5 unique prescribers, were dispensed at 2 
unique dispensers, and consumed over 20,000 mg OME for each quarter. This level of 
consumption suggests an approximate daily dose of over 200mg OME, which is 
considered high by clinical standards. This group was named the Aberrant group for 
further reference. 
 
The differences between both groups on all variables were statistically 
significantly. However, the real differences of note appear to be in prescriptions 
obtained (in the order of almost 2:1 between the Aberrant and Non-aberrant group) 
and in volume of drugs in milligrams OME (in the order of 9:1 between the Aberrant 
and Non-aberrant group). While there were significant differences between persons in 
the Aberrant and Non-aberrant groups in regard to the numbers of prescribers and 
dispensers, these were less than whole number differences, making their utility in a 
PDMP-monitoring context less useful. Furthermore, in both groups, persons appeared 
to doctor shop at similar frequencies of approximately 1.5 quarters each year, but the 
Aberrant group appeared be have greater overall long-term prescribing frequency at 
closer to four quarters in the year, as opposed to the Non-aberrant group of closer to 
three quarters per year. 
 
When total prescription records are examined, the variable of numbers of 
different doctors seen in a certain time period does not discriminate different 
populations of Aberrant and Non-aberrant POA drug recipients. Furthermore, the 
numbers of different dispensers involved in a person’s drug supply does not 
discriminate Aberrant from Non-aberrant consumers of POA drugs. The results 
suggest that high-volume prescription and milligrams OME are the most powerful 
factors in determining Aberrant use. Based on the previous descriptive analysis this 
suggests that while there are large numbers of potential doctor shoppers for POA drugs 
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at any time this behaviour is infrequent and often in the context of other unremarkable 
long-term POA drug obtainings characterised by non-doctor shopping behaviour. 
 
The descriptive results suggest that there is a small percentage, less than one per 
cent of person that might either on very high doses, obtaining high volumes of 
prescriptions, or consulting large numbers of different prescribers and dispensers. 
However, this sub-population was not identified as a distinct group in the cluster 
analysis. It appears that the outliers are either persons obtaining very high doses or 
consulting large number of doctors, or dispensers, or obtaining large number of 
prescriptions. These outliers are outliers on each of the variable of interest and not 
necessarily extreme cases of persons undertaking high volume doctor shopping. 
Further examination of these cases would be warranted in future investigations.  
 
These results suggest that in the wider population of persons receiving any POA 
drugs in a year there are potential doctor shoppers in a small percentage (less than 
10%). Of these possible doctor shoppers, approximately 7.5% are recognised as drug 
dependent via current regulatory processes undertaken by the Department of Health. 
However, over 90% of the possible doctor shoppers are not recognised as drug 
dependent. However, it cannot necessarily be assumed these ‘unclassified’ persons are 
suffering a SUD related to their POA drug use. Of these unclassified persons, most are 
consuming POA drugs at low dosages of less than 100mg OME per day and these 
persons could be considered at low risk of harm and potentially unlikely to be suffering 
a SUD related to their POA drug use. Almost one-fifth of the unclassified persons, the 
aberrant group, are consuming POA drugs at high-dose levels, greater than 200mg 
OME and are potentially at more at risk of harm or a classification of a substance use 
disorder. 
 
Of the consumers of POA drugs, subsequent investigation of these persons does 
not suggest they are a homogenous population with high-frequency potential doctor-
shopping or drug-seeking behaviour. Approximately three-quarters of this group will 
only meet the doctor-shopping criteria in any one quarter of the year and most will be 
routine consumers of POA drugs throughout the rest of the year in manner that would 
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not meet any criteria for doctor shopping. A small percentage of persons (just over 
5%) of this Aberrant group demonstrates some form of potential doctor shopping 
across all quarters of the year. However, this number represents less than 1% of the 
total Queensland population receiving POA drugs, and less than 0.5% of the age-
matched Queensland population. 
 
The study has certain strengths and weaknesses needing elaboration, and that 
might support or limit implications drawn from the results. The major strength of this 
study is that it is a complete population capture of the persons of interest across the 
entire Queensland community. The information contains details of prescription drug 
types and volumes and known notifications for persons reported as drug dependent. 
 
The limits to the data set are that it only includes dispensed prescriptions, so 
unsuccessful attempts to obtain prescriptions are not recorded. There are also no 
records of persons treatment with POA drugs within hospitals, or outside of 
Queensland, or in other circumstances such as imprisonment. There is also no 
mechanism to capture diversion of drugs by persons, however, there appears to be 
widespread collateral evidence of this (Cicero et al., 2011; Dobbin, 2010b; Hall & 
Degenhardt, 2007; Hall & Farrell, 2011; Miller & Degenhardt, 2009; National Drug 
and Alcohol Research Centre, 2012) . The data does not include any clinical or medical 
diagnoses, so there is no means to confirming person’s medical conditions. Also the 
data does not include other lower scheduled drug use such, as benzodiazepines, or a 
person’s use of over-the-counter drugs, which do appear to be related to greater risk of 
harms (Dormuth, Miller, Huang, Mamdani, & Juurlink, 2012; Pradel et al., 2010). 
 
The results do not necessarily support the hypothesised subpopulations 
groupings of long term high volume doctor shopping persons, suggesting drug 
dependence, nor a short term high volume doctor shopping group suggesting persons 
who might be abusing POA drugs. The results are perhaps surprising given the 
assumed existence of a population of doctor shopping persons, and evidence of 
increased dependence on and diversion of POA drugs. However, the aberrant group 
identified as high prescription obtaining and high dose consuming persons, seem to 
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resemble the prescription and consumption patterns of known drug dependent persons 
within the POA drug using population. 
 
It is possible that those persons who are drug dependent on POA drugs can meet 
their drug requirements within an established therapeutic relationship with a 
prescriber, without have to seek alternative sources of drugs. As such this population 
might be indistinguishable from, or overlap with persistent pain patients on chronic 
POA drug treatment. A possible interpretation is that these persons are in stable 
treatment and could be maintained on POA drugs in maintenance regimes not 
dissimilar to persons maintained in opioid substitution treatments. 
 
It appears that the using doctor shopping behaviour as a proxy for drug seeking 
behaviour that could be a potential association with a SUD on POA drugs is not 
supported by this analysis.  Perhaps given the complexity of the nature of SUDs and 
the previous lack of consensus by the experts this is a not unexpected outcome of this 
study. Furthermore, as PDMPs will most likely only contain dispensing and 
prescribing event as part of administration of regulatory matters, it is perhaps unlikely 
they will genuine health information or clinical management tools. The concept of 
aberrant POA drugs use discussed previously in the Chapter Two (Section 2.6) is 
perhaps a more relevant consideration for the use of PDMP data. Certainly, potential 
for individual harms from high dosages and the other potential that within this 
population is the source of diverted POA drugs is worth considering bringing to the 
attention of treatment providers and potential enforcement agencies. From a health 
perspective PDMP data would appear to be best to supplement clinical decision 
making and could also assist in better assessing risk of harm in individual cases. 
 
Furthermore, it appears that the small proportion of this population on high dose 
POA drugs over long time periods also account for significant volumes of total drugs 
being prescribed. There is good evidence of persons reporting illicit use of POA drugs 
that were not obtained by prescription. Given, the economic incentives to on-sell or 
divert medications, it is possible there is significant opportunity for diversion of drugs 
in this population. 
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4.6 CONCLUSIONS 
 
The results for this study suggest that the analysis of the entire potential doctor-
shopping sub-population of Queensland POA drug consumers does not seem to show 
sub-categories of persons that are high-level doctor shoppers suffering substance use 
disorders. What the results do suggest is that there is a population of persons who 
routinely obtain prescriptions from multiple dispensers infrequently and those high 
POA drug consuming persons are involved in long-term therapeutic relationships with 
individual prescribers at least across the year of study. That is some persons who 
appear most of risk of harm are those that obtain more prescriptions and by virtue of 
that obtaining are consuming higher doses of POA drugs. Most of these persons obtain 
POA drugs across the year and for most of that time they are in relationships with 
individual prescribers and not apparently drug seeking. When these persons doctor 
shop it is for short periods of time and usually for not more than a three-month period.  
 
Within this population there is a low-volume consuming group and high-volume 
consuming group. The high-volume consuming group is not distinct from the low-
volume consuming group in terms of doctor-shopping activity. They are distinct in 
obtaining greater numbers of prescriptions and consuming larger volumes of POA 
drugs. The persons consuming drug at these higher volumes, while not apparently 
doctor shopping more than the low drug consuming persons, do appear to have 
consumption patterns resembling known drug dependent persons. The overall context 
suggests both populations are in long-term receipt of POA drugs within 2013. Further 
investigations on the study of historical prescribing records are undertaken in Study 3 
to further describe and examine this phenomenon. 
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Chapter 5: Study 3 – Prescribing history of 
doctor shoppers 
5.1 INTRODUCTION 
The results of Study 2 suggest that aberrant POA drug use is most associated 
with higher-average daily dosages greater than 100mg per day. Within this sub-
population of drug seekers, it is not clear that drug seeking – as defined by seeing 
multiple doctors and obtaining multiple prescriptions over certain time periods – 
establishes that a doctor shopping sub-population exists or that drug-seeking 
behaviour, such as doctor shopping, is a particular feature of this population of aberrant 
POA drug use. 
 
In Study 2, an initial population of 14,378 possible doctor shoppers had no prior 
drug dependence records in the MODDS database. Of these, only 2,842 (18.3%) were 
categorised as aberrant POA drug consumers due to their higher consumption of POA 
drugs. Furthermore, the results of Study 2 show that long-term prescribing over 
multiple quarters is more typical for aberrant POA drug users than meeting even a 
conservative or higher threshold for doctor shopping in more than one quarter of the 
study year. 
 
The results of Study 2 suggest that aberrant POA drug use is described by high-
volume prescription obtaining over longer periods of time. Study 3 seeks to investigate 
POA drug dispensing in the 10 years prior to 2013 of the 14,378 persons from Study 
2 with no notified drug dependence that were identified as potential doctor shoppers 
(consulted three or more doctors and obtained four or more prescriptions in any three 
month period of 2013) (see Section 4.2.2 – Page 178). This is to determine what 
aspects of prior exposure to opioids provide further evidence to discriminate other 
patterns of POA drug use. 
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Study 2 examined one year of prescribing records, and it is not apparent if the 
persons in that study year had long histories of exposure to POA drugs and what, if 
any, histories they had of potential doctor-shopping behaviour. Further examination of 
the historical antecedents of these persons’ POA drug prescribing might provide 
further illustrative information. 
 
The long-term POA drug use in persistent pain management is a contentious 
treatment option. There is limited benefit over certain dose thresholds and limited 
evidence of effectiveness of long-term treatment (Chou, et al., 2015; Martell, et al., 
2007). There is also evidence suggesting there is a greater potential for development 
of dependence with high doses over the long term (Campbell, et al., 2015; Keller et 
al., 2012; Martell, et al., 2007). The results of Study 2 demonstrate it is not clear 
whether persons in 2013 are long-term users of POA drugs or have only recently 
commenced use. It is also of interest to understand this whether longer use in terms of 
how persons in Study 2 were classified as aberrant or non-aberrant POA drug users. 
 
It could be hypothesised from current evidence that persons with long-term high-
dosage usage of POA drugs over time are likely to have had ongoing use of these drugs 
at high levels; that is, aberrant group persons are more likely than non-aberrant group 
persons to have lengthy histories of high-dosage POA drug use. Furthermore, it might 
be expected that non-aberrant group persons should have shorter histories of POA drug 
use at lower volumes of consumption. 
 
What is less clear is if doctor shopping is a behaviour might be related to longer 
term POA drug use for the aberrant and non-aberrant group persons. Potentially 
persons with long-term histories of high volume POA drugs use might show different 
patterns of doctor shopping than persons with lower volume POA drug use. These 
differences might not have been captured in the one year time frame of Study 2. 
Therefore, it is proposed to examine these relationships and to describe and investigate 
the POA drug obtainings in the 10 years prior to 2013 for the aberrant and non-aberrant 
group persons described in Study 2. 
 
 181 Prescription opioid analgesic drug misuse: What can we learn from doctor-shopping behaviour 
5.2 METHODS 
Data for Study 3 was extracted from the MODDS database as previously 
described in Study 2. All 14,378 unclassified persons identified as potential doctor 
shoppers in Study 2 were used in this study. Summary prescription data for all persons 
were extracted for the proceeding 10 years: 2003 to 2012. This data extract included 
numbers of prescriptions obtained, unique prescribing doctors, and unique dispensing 
pharmacies for each person for each quarter of each of the 10 years to 2013. Noting 
that over this time only POA dispensed for persons within Queensland would be 
captured as a previous prescription. 
 
A second extract of all the particular prescription details for the above summary 
data was then extracted using another Discoverer query. This extract included all the 
details of drug type and total milligrams dispensed for each prescription identified in 
the first extract. This included details of the drug type and volume in milligrams for 
each dispensed prescription. This extract allowed for the calculation of total oral 
morphine equivalent milligrams (OME (mg)) for each drug type based on the 
conversion factors used in Study 2 (Nielsen, et al., 2014). This data was then 
aggregated for each individual case for each person’s record and from this a total OME 
(mg) was calculated for each year where prescriptions were dispensed for those cases. 
 
The above two data files were extracted via Oracle Discoverer queries and then 
imported as ‘comma separated variable’ files that were managed in Microsoft Excel 
for initial data-checking and cleansing. The two Excel files, containing the summary 
data and the prescription detail data, were then imported to SPSS Version 20.0 (IBM 
Corporation, 2011). The two SPSS data files containing the summary prescription data 
and the aggregated OME milligrams data were then merged into a single file and 
details of each person’s cluster assignment from Study 2 was also included.  
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5.3 RESULTS 
5.3.1 Participants  
 
A total of 14,378 persons who were identified as Unclassified persons in Study 
2 were included in this study. This included 11,536 persons classified in Cluster 1 
(Non-aberrant group) and 2,842 persons classified as Cluster 2 (Aberrant group) in the 
cluster analysis performed in Study 2. The demographics of this group are reported in 
Chapter 4. A total of 10,384 persons, just under three-quarters of the total persons, 
received at least a prior year prescription in the years 2003 to 2012 (7,853 persons: 
68.1% of the Non-aberrant group; 2531 persons, 89.1% of the Aberrant group). This 
left 3,994 persons who received no prior year prescriptions in any of the preceding 10 
years. It is noted that for these previous year records that persons in each were selected 
based on them being identified as possible doctor shoppers in Study 2. Therefore, in 
the preceding ten years, 2003-2012, they may not have demonstrated any doctor 
shopping behaviour. 
 
5.3.2 Prescribing by years 
The alternative view of the prescribing history of these persons is described by 
the number of years in which they had been dispensed any POA drugs. A single 
prescribing event in any quarter of any year would class a person as having been 
prescribed in that year. 
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Table 5.1 
Persons in Non-aberrant and Aberrant groups classified by number of previous years in POA drugs 
prescriptions were dispensed (n=14,378) 
  Two-Step Cluster Group 
membership 
    
Year 
dispensed 
Non-aberrant  Aberrant   Total  
0 3683 32% 311 11% 3994 28% 
1 2588 22% 428 15% 3016 21% 
2 1562 14% 322 11% 1884 13% 
3 1043 9% 267 9% 1310 9% 
4 763 7% 252 9% 1015 7% 
5 547 5% 196 7% 743 5% 
6 408 4% 176 6% 584 4% 
7 254 2% 150 5% 404 3% 
8 186 2% 136 5% 322 2% 
9 143 1% 146 5% 289 2% 
10 359 3% 458 16% 817 6% 
Total 11536 100% 2842 100% 14378 100% 
 
 
Table 5.1 shows the proportions of persons of the Aberrant and Non-aberrant 
groups who were dispensed POA drug prescriptions by the number of years in which 
they were dispensed at least one prescription; however, this does not represent 
immediate sequential years, but only indicates the number of years in which a 
dispensing event occurred. For example, a person who has received a prescription in 
one other year (Years prescribed = 1) could have been dispensed a POA drug in any 
of the last 10 years. There were 3,994 persons who were shown as never having 
received a prescription in any of the previous 10 years to 2013 (Non-aberrant, n=3,683; 
Aberrant, n=311).  
 
Of the Non-aberrant group persons, approximately one-quarter (22%) received 
a prescription in one year of the 10 years prior to the study, and over half (57%) in up 
to five other years. With the Aberrant group persons, over one-third (35%) received 
prescriptions in one to three years across 2003 to 2012. However, 16% (n=458) had 
been dispensed prescriptions for all of the 10 years prior to 2013. 
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Figure 5-1 represents this information graphically. Trends based on the number 
of other years where persons had been dispensed prescriptions from 2003 to 2012 show 
different distributions for the Non-aberrant and Aberrant groups. The Non-aberrant 
group appears to showing a diminishing trend of prescribing from greatest proportion 
of persons obtaining prescriptions in few other years. For the Aberrant group the 
distribution appears almost bi-modal with similar proportions of persons obtaining 
prescriptions in either one or ten other years. 
 
 
 
Figure 5-1. Proportion of persons in Non-aberrant and Aberrant groups by number of prior year in 
which they were dispensed POA drug prescriptions for years 2003-2012.  (n=14.378)  
 
Table 5.2 shows the gender for each category of years dispensed for each cluster. 
For the Non-aberrant group persons there appears similar proportions of males and 
females over number of prior years prescribed reflecting the increasing trend from 10 
years to nil years of prior prescribing.  
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Table 5.2 
Persons in Non-aberrant and Aberrant groups classified by number of previous years of POA drug 
prescribing and gender, with proportion of each gender shown for each group (n=13,794) 
  Group membership   
Years Non-aberrant   Aberrant   
prescribed Female (%) Male (%) Female (%) Male (%) 
0 1728 (28.1%) 1575 (32.4%) 122 (9.5%) 152 (10.2%) 
1 1371 (22.3%) 1114 (23.0%) 201 (15.6%) 213 (14.2%) 
2 849 (13.8%) 679 (14.0%) 132 (10.2%) 185 (12.4%) 
3 608 (9.9%) 431 (8.9%) 131 (10.2%) 133 (8.9%) 
4 464 (7.5%) 297 (6.1%) 93 (7.2%) 159 (10.6%) 
5 318 (5.2%) 229 (4.7%) 87 (6.8%) 109 (7.3%) 
6 252 (4.1%) 154 (3.2%) 89 (6.9%) 87 (5.8%) 
7 160 (2.6%) 94 (1.9%) 78 (6.1%) 72 (4.8%) 
8 117 (1.9%) 69 (1.4%) 71 (5.5%) 65 (4.3%) 
9 85 (1.4%) 58 (1.2%) 76 (5.9%) 70 (4.7%) 
10 205 (3.3%) 154 (3.2%) 208 (16.1%) 250 (16.7%) 
Total 6157   4854   1288   1495   
Note: 584 cases missing gender details 
 
  
 186 Prescription opioid analgesic drug misuse: What can we learn from doctor-shopping behaviour 
Table 5.3 
Age of persons in Non-aberrant and Aberrant groups classified by number of previous years of POA 
drug prescribing (n=13,197) 
  Two-step Cluster - Group membership   
Years Non-aberrant   Aberrant   
prescribed Age  
(years) 
(SD) n Age 
(years) 
(SD) n 
0 54.3 (16.0) 3059 51.6 (15.1) 285 
1 55.7 (15.5) 2296 52.3 (14.6) 396 
2 56.3 (15.6) 1452 49.8 (14.9) 310 
3 57.3 (15.3) 997 49.3 (14.2) 262 
4 57.3 (14.3) 742 49.9 (12.4) 250 
5 58.1 (14.0) 540 50.5 (13.3) 194 
6 59.4 (13.6) 408 52.4 (12.7) 176 
7 59.3 (12.5) 254 52.8 (13.6) 150 
8 58.0 (12.8) 185 53.6 (13.2) 136 
9 57.6 (13.0) 143 54.8 (11.4) 146 
10 59.0 (11.4) 359 56.1 (10.6) 457 
Total 57.0 (14.8) 10435 52.2 (13.3) 2762 
Note: 1,181 cases missing age details 
    
 
 
5.3.3 Prescribing trends from 2003 to 2012 
 
Table 5.4 and Figure 5-2 below shows the proportion of persons in each cluster 
that had any or no POA drug prescription dispensed in any of the quarters of the ten 
years preceding 2013: 2003 to 2012. Note that the percentage totals represent the 
proportion of persons in that class who were dispensed prescriptions in that calendar 
year. The totals do not add to 100% as a person can be counted in multiple years if 
they received prescriptions in different years. 
 
Table 5.4 shows that almost 90% of the Aberrant group (86%) and over half of 
the Non-aberrant group (59%) received at least one prescription in 2012, the year 
immediately prior to the study period. In 2003, almost a quarter (22%) of the Aberrant 
group had been prescribed at least one POA drug prescription but only 6% of the Non-
aberrant group had received a prescription.  
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Table 5.4 
Number of persons in Non-aberrant and Aberrant groups classified by year in which they were 
dispensed any POA drug (2003-2012), (n=14,378) 
  Group membership     
Year 
dispensed 
Non-aberrant 
(n=11,536) 
Aberrant          
(n=2,842) 
Total 
(n=14,378) 
  
Nil years 3683 32% 311 11% 3994 27.8% 
2003 734 6% 630 22% 1364 9.5% 
2004 856 7% 709 25% 1565 10.9% 
2005 980 8% 797 28% 1777 12.4% 
2006 1278 11% 946 33% 2224 15.5% 
2007 1689 15% 1072 38% 2761 19.2% 
2008 2159 19% 1234 43% 3393 23.6% 
2009 2738 24% 1447 51% 4185 29.1% 
2010 3465 30% 1679 59% 5144 35.8% 
2011 4565 40% 1991 70% 6556 45.6% 
2012 6758 59% 2444 86% 9202 64.0% 
 
Figure 5-2 shows the increasing proportion of persons in both 2103 prescribing 
groups receiving prescriptions in the previous 10 years. This figure excludes the 3,994 
persons who had no record of previous POA prescriptions. For each year there was a 
greater proportion of Aberrant persons being prescribed POA drugs than Non-aberrant 
persons. This proportional difference was greatest in 2003, with almost four-fold 
proportional difference (Non-aberrant 6%: Aberrant 22%), and decreased over each 
year until 2012. 
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Figure 5-2. Percentage of persons in Non-aberrant and Aberrant groups who were dispensed POA 
drug prescriptions in 2003-2012 (n=10,384).  
 
Figure 5-2 shows the proportion of persons prescribed in any quarter of the ten 
years (2003 to 2012) and includes the proportion of persons in each cluster who met 
the criteria for doctor shopping (consulting three or more doctors and obtaining four 
or more prescriptions in any three month period) in any of these quarters. With the 
Aberrant group just over one quarter of persons (27%) met the criteria for doctor 
shopping in the last quarter of 2012, whereas in the Non-aberrant group 11% of 
persons met the criteria in the same quarter. In first quarter of 2003, the proportion of 
persons in ether groups had decreased (Aberrant 3%; Non-aberrant < 1%). 
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Figure 5-3. Percentage of persons in Non-aberrant and Aberrant groups who were dispensed POA 
drug prescriptions and persons who met the doctor-shopping criteria in any quarter in years 2003 to 
2012 (n=10,384). 
 
These descriptive results show increasing trends in prescriptions dispensed and 
potential doctor shopping over time, with greater proportions of Aberrant group 
persons obtaining prescriptions and doctor shopping over the last 10 years. To further 
compare the Aberrant and Non-Aberrant groups a number of variables used in Study 
2 were used to compare prescribing in each of the preceding 10 years to 2013. The 
variables of mean prescriptions per quarter, mean prescribers per quarter, mean 
dispensers per quarter and mean Oral Morphine Equivalent milligrams (OME-mg) 
were calculated for any persons who had POA drugs dispensed in any calendar year 
from 2003 to 2012.  
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The full list of means and descriptive data for each of these variables for each 
group in each year are reported in the Appendix I. Furthermore, one-way ANOVA 
were performed for each variable set to compare means within each year and these are 
also reported in Appendix I. 
 
Figure 5-4 shows the mean prescriptions dispensed per quarter for persons in 
either group who were prescribed POA drugs in a respective year. One-way ANOVAs 
found significant differences between Aberrant and Non-aberrant persons (p<.0001). 
For the Non-Aberrant persons there appears little change over the last 10 years in 
prescriptions dispensed per quarter, with a mean of 4.27±4.48 in 2003 and rising to a 
mean of 4.80±3.57. However, the Aberrant group showed a steady increase from a 
mean of 7.06±7.84 prescriptions per quarter dispensed in 2003 to 9.68±7.72 
prescriptions dispensed per quarter in 2012. 
 
 
 
Figure 5-4. Mean prescriptions prescribed per quarter for persons in each group who were dispensed 
POA drug prescriptions in years 2003-2012 – including 95% Confidence Interval error bars 
(n=10,384)  
  
□- Aberrant 
○- Non-aberrant 
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Figure 5-5 shows the mean unique precribers involved in prescribing POA drugs 
per person each year. On average there appears small changes or gradual increases 
over time for persons in both groups in the mean numbers of unique prescribers seen. 
However, in 2012 mean numbers of prescribers exceeded two prescibers for the 
Aberrant group (Mean=2.18±1.42 prescribers). One-way ANOVA did find significant 
differences between mean prescribers for Aberrant and Non-aberrant persons, at 
p<.0001.  
 
 
Figure 5-5. Mean unique prescribers who prescribed each quarter for persons in each group who were 
dispensed POA drug prescriptions in years 2003-2012 – including 95% Confidence Interval error bars 
(n=10,384) 
 
Figure 5-6 compares the mean unique dispensers per quarter over each year 
between the Aberrant and Non-aberrant groups. This trends over 10 years show less 
evidence of increasing over time, and neither group in any one year showed a mean of 
greater than 2 unique dispensers seen. However, one-way ANOVAs did find that in 
each year the mean unique dispensers of Aberrant persons was greater than Non-
aberrant persons. 
  
□- Aberrant 
○- Non-aberrant 
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Figure 5-6. Mean unique dispensers who prescribed each quarter for persons in each group who were 
dispensed POA drug prescriptions in years 2003-2012 – including 95% Confidence Interval error bars 
(n=10,384)  
 
Figure 5-7 shows the mean OME-mg dispensed per quarter for Aberrant and 
Non-aberrant persons in each year where persons were dispensed POA drugs. As with 
the previous variables, one-way ANOVAs revealed significant differences between 
both groups in each year, at p<.0001. The mean OME-mg per quarter in each year 
dispensed for Non-aberrant persons reduces for these persons over time: starting at 
3376.29±6630.53 milligrams in 2003 and reducing to 1998.74±3175.51 milligrams in 
2012. In contrast, the Aberrant persons OME-mg dispensed increased steadily over 
time from over 9000 milligrams in 2003 to over 16,000 milligrams in 2012. 
  
□- Aberrant 
○- Non-aberrant 
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Figure 5-7. Mean Oral Morphine Equivalent milligrams (OME-mg) dispensed each quarter for 
persons in each cluster who were dispensed POA drug prescriptions in years 2003-2012 – including 
95% Confidence Interval error bars (n=10,384). 
 
The mean OME in milligrams per quarter for each year was obtained as per the 
procedure outlined in Study 2. From this the approximate daily dosage level for all 
persons’ POA drug use could be obtained using the same method from Study 2 to 
classify a person’s estimated drug consumption as either low (less than 100 milligrams 
per day); medium (between 100 – 200 milligrams per day); or high (greater than 200 
milligrams per day). 
 
 
□- Aberrant 
○- Non-aberrant 
Years 
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Figure 5-8. Non-aberrant group: Proportion of persons in each dose level of all persons in the Non-
aberrant group who were dispensed POA drug prescriptions in years 2003-2012 (n=10,384). 
 
For the Non-aberrant persons shown in Figure 5-8 over 90% of all persons were 
classified in the low dose category. In 2012, this was at the highest proportion of all 
years at 97%. 
 
For the Aberrant persons shown in Figure 5-9 the proportion of persons 
receiving low doses over the preceding 10 years dropped from 65.8% in 2003 to 37.8% 
in 2012. The proportions of medium-dose persons and high-dose persons both 
increased over time and in the same direction such that the proportion of medium-dose 
persons increased over the same period from 16.5 to 29.8% and proportion of high-
dose persons from 17.6 to 32.4%. This means that at 2003 almost two-thirds of 
Aberrant persons were low-dose consumers of POA drugs, and by 2012 almost two-
thirds were medium or high-dose consumers. 
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Figure 5-9. Aberrant group: Proportion of persons in each dose level of all persons in the Aberrant 
group who were dispensed POA drug prescriptions in years 2003-2012 (n=10,384) 
 
5.4 DISCUSSION 
This study sought to examine the historical POA drugs-prescribing patterns of 
the Aberrant and Non-aberrant persons identified in Study 2, which included all 
potential doctor-shopping persons with no histories of drug dependence. Historical 
records were extracted for these persons’ records for the previous ten years to 2013: 
2003 to 2012.  
 
 The strength of this study is the access to 10 years of data from the MODDS 
database to allow extraction of a history of POA drug prescribing for the Unclassified 
potential doctor shoppers from Study 2. However, further to the limitations from Study 
2, another potential limitation is that the records will also not capture out of jurisdiction 
treatment, hospital inpatient or imprisoned persons and some persons’ POA drug 
information might be incomplete. Also, by only using the sample of persons from 
Study 2, there is no other context of doctor shopping or POA drug trends for the full 
POA drug using population in these preceding years. The data extracted for each year 
was only for those Study 2 identified persons who were dispensed POA drugs any of 
the 10 previous years. As such analysis of trends and differences between and within 
Aberrant and Non-Aberrant persons over each year was not attempted as each year’s 
sample potentially represented different subsets of the 2013 study population. 
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 A potential limitation of this study is that there is no comparison within each 
previous year of prescribing of persons with similar POA drug use obtainings with the 
identified cohort of 2013 doctor shoppers, or actual doctor shoppers in those years. 
That is cases selected are already known later doctor shoppers, classed as aberrant or 
non -aberrant based on previous analyses. Therefore, it is not apparent what the 
historical course of other POA drug using persons might have taken and how similar 
or different they might be to the 2013 cohort of this study.  
 
Furthermore, the previous Study 2 identified small numbers of outliers on 
variables of interest that were not doctor shoppers (see Section 4.4.8, Page153).  The 
potential influence of outliers is unlikely given these results however it has not been 
able to tested for given the methods of data extraction. 
 
In examining the numbers of previous years dispensings of POA drugs, it should 
be noted that almost one-third of all persons had no prior prescribings, and most of 
these persons were from the Non-aberrant group.  For those persons with one and two 
years of previous prescribings, greater portions of the Non-aberrant persons than 
Aberrant persons were represented in these years. However, for three or more years of 
previous prescribings, at each year there were more Aberrant persons and there was a 
larger proportion of Aberrant persons (16%) prescribed for 10 years compared to only 
3% of Non-aberrant persons. This suggests that for most of the Non-aberrant persons 
they only had a prior prescription history of up to three years, whereas the Aberrant 
persons had a far more varied and extensive history spread over the prior 10 years. 
 
Examining the actual calendar years in which prescribing occurred showed that 
proportionally over a quarter of persons received prescriptions in the years 2009 to 
2012, with fewer persons obtaining prescriptions in the earlier years of the prior 
decade. In contrast, the Aberrant persons showed great proportions of persons 
receiving prescriptions in all years, with almost a quarter of all persons having been 
prescribed in 2003, 10 years prior to the study period. 
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An assessment of potential doctor shopping also found there was limited evidence of 
historical doctor shopping for the Non-aberrant persons. However, for the Aberrant 
persons there was increasing evidence of doctor shopping. These results suggest a 
longer history of POA drug use for the Aberrant persons that extends over 10 years for 
a significant proportion of those persons. The Non-aberrant persons in comparison 
seem to have most persons experiencing limited prior year prescribing of POA drugs 
and most of that has occurred in the past three years. 
 
The Aberrant and Non-aberrant persons were compared on the variables of unique 
doctors consulted, prescriptions obtained, unique dispensers seen, and volume of drugs 
consumed by milligrams OME on average per quarter prescribed within each calendar 
year. For each year there is limited separation in dispensers and prescriptions between 
the two groups. However, in terms of prescriptions obtained there were clearer 
differences. The Non-aberrant persons saw similar numbers of prescribers to the 
Aberrant persons, with no differences shown over the previous ten years, 2003 to 2012. 
In contrast, the Aberrant persons obtained increasing prescriptions over time in 
comparison to the non-Aberrant persons. 
 
A similar pattern was evident with milligrams OME consumed in each quarter 
of the year prescribed from 2003 to 2012. The consumption of the Non-aberrant 
persons who received any POA drugs in the preceding 10 years on average remained 
at very low levels and appears to decrease leading up to 2103. In comparison, the 
Aberrant group persons’ consumption increased steadily in the years approaching 
2013. Furthermore, across the 10 years most of Aberrant group persons who received 
POA drugs were in the low category (less than 100mg per day OME). However, there 
appeared to be increasing proportions of Aberrant group persons in medium (100-
200mg per day OME) and high dose (greater than 200 mg per day OME) over the 10 
years until 2013. 
 
These results suggest further confirmation of the results of Study 2: that the 
variable of prescribers and dispensers that indicate doctor shopping do not appear to 
discriminate between Aberrant and Non-aberrant use over time. However, also in 
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support of the Study 2 results, prescriptions obtained and volume of drugs consumed 
appear to be strong discriminatory factors between the two groups. In terms of non-
aberrant there is a suggestion here that some persons can be maintained on low doses 
over long periods of time without evidence of developing problematic use. 
Alternatively, some persons appear to escalate dosage consistently over time however, 
they may or may not demonstrate doctor shopping behaviour, but will continue to 
obtain POA drugs at high dose and be subject to greater risk of harm.   
 
This further suggests that, as was found in the study of persons in 2013, that 
doctor-shopping behaviour, in terms of ongoing consulting of multiple different 
doctors, is not a strong indicator of aberrant POA drug use even when historical 
prescribing trends are considered. Furthermore, as found in Study 2, high volume of 
prescriptions and high volumes of drug consumed are strong factors indicating 
aberrant use of POA drugs over time. This has particular implications for regulators 
and clinicians in moderating prescribing behaviour and managing persons who are in 
receipt of long-term opioid therapies and these are discussed in the following chapter.  
 
 
 
 
Prescription opioid drugs misuse 
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Chapter 6: Discussion 
6.1 INTRODUCTION 
It is generally accepted that misuse of POA drugs is a significant public health 
concern in Australia, as well as the USA and Canada. The increasing prescribing of 
these drugs has led to increased access for many Australians. Increased use of these 
POA drugs is predominantly for genuine therapeutic pain management needs. 
However, there remain concerns in regards to over-prescribing, efficacy of long-term 
treatment for chronic pain, and misuse and diversion of these drugs, as well as the 
increasing evidence of harms from POA drugs use such as death, overdose, and the 
development of substance use disorders (SUDs). A particular focus of concern is the 
issue of ‘doctor shopping’, where persons obtain multiple prescriptions from multiple 
prescribers, unbeknownst to each prescriber, for doses in excess of therapeutic needs.  
POA drugs obtained via doctor shopping are believed to be promoting dependence and 
abuse in consumers and being diverted into illicit markets for non-therapeutic use. 
 
The aim of this thesis was to identify and investigate doctor-shopping behaviour 
and examine its potential relationship to the misuse of and development of SUDs, in 
relation to POA drugs. The objectives of this thesis (see Section 2.9) were seek to 
develop a definition of doctor shopping through expert consensus, test that definition 
in a population of persons who had been prescribed POA drugs, investigate if doctor-
shopping behaviour could discriminate between aberrant and non-aberrant POA drug 
use, and examine if there were any means to determine a relationship between doctor 
shopping and SUDs with POA drugs. 
 
These objectives were articulated in three studies and the outcomes of these are 
set out in the following three sections. The implications for public health, monitoring 
and regulation, and individual person’s health care are discussed in the final section. 
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6.2 STUDY 1: DEFINING DOCTOR SHOPPING 
 
Study 1 examined a number of aspects of POA drug misuse and the relationship 
to SUDs and attempted to establish if some criteria for doctor-shopping behaviour could 
be agreed on that suggests a person could be suffering from a SUD due to their use of 
POA drugs. This was done using a Delphi Technique study with a number of experts 
across the domains of pain management and drug dependence. Experts were given a 
number of open-ended questions and over two rounds asked to moderate their responses 
based on the feedback of the collective responses of all expert participants. The intent 
of this was to use these criteria to test what patterns of POA drug prescribing this 
describes and whether it discriminates aberrant from non-aberrant POA drug use.  
 
Doctor shopping is a term that is poorly defined in the literature and open to broad 
range of interpretations and as such has limited utility as a clinical assessment measure. 
It is not clear what the relationship is between doctor shopping and aberrant POA drug 
use or a person suffering a SUD. What is also problematic in teasing apart these issues 
is that many persons receiving POA drugs are doing so for treatment of genuine pain 
conditions. Leaving aside the question about the efficacy of long-term treatment, it 
might not always be clear to prescribers when a person on long-term POA drug 
treatment might have developed or is suffering a SUD. It can reasonably be assumed 
any persons on long-term treatment POA drug therapy will develop tolerance and suffer 
withdrawal on cessation or reduction of treatment given the known effects of POA 
drugs. As such the recognition of SUDs with POA drugs remains a complex matter for 
treatment providers in primary care settings. 
 
The results of this study suggested there was limited support among experts for 
highly rating the DSM-IV criteria of tolerance and withdrawal in determining if 
someone has a SUD on POA drugs. However, much of the importance of the other 
criteria is problematic when used to determine SUDs on POA drugs as most relate to 
the use of illicit drugs. This is also an awkward definition, as POA drug use might be 
approved by a treating doctor in an ongoing manner and there might also be underlying 
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illness or disease that could equally explain a person’s behaviour. Doctor-shopping 
behaviour might most closely relate to the DSM-IV criteria of ‘time spent in obtaining 
drugs’. However, this was not highly ranked as a criterion for determining POA drugs 
SUDs by the experts. Furthermore, the amount of drug taken, which could arguably 
relate to drug seeking, was ranked the lowest of all DSM-IV criteria for determining a 
SUD.  This might also be explained by the low ranking for criteria of tolerance and 
withdrawal, give than chronic pain patients could be maintained on high doses without 
meeting a definition of suffering a SUD. 
 
The experts were then asked to set definitional criteria to outline what levels of 
doctor shopping, in terms of prescriptions, prescribers, dispensers and dose might 
indicate problematic POA drug use. The first round of responses was mixed, with many 
experts qualifying their responses by stating any level of use or doctor shopping could 
be potentially problematic for a particular individual. The second round was modified 
to ask experts to give green (unproblematic), amber (suspicions of misuse) and red 
(problematic use) traffic light assessments of the doctor-shopping criteria. The 
outcomes demonstrated differences between each of the traffic light categories in the 
expected directions: each variable of doctor-shopping increased from green to amber to 
red. Also, despite the dosage level of drug being ranked as the lowest of DSM-IV 
criteria, there were clear differences from the experts in what dosage level is relevant 
to determine problematic doctor shopping. 
 
A particular conceptual issue in Study 1 was that questions were being asked to 
clinical experts to reduce their concerns to a set number of particular criteria for use in 
a database study. A clinical expert might use information about doctor shopping as part 
of building an assessment of a person’s possible SUD. However, it would be unlikely 
they would rely on that information alone, and an assessment or review would most 
likely involve considerably more corroborative information before determining a 
diagnosis of a SUD. 
 
Given the reservations expressed by many of the experts that any amount of 
doctor shopping would be indicative of problematic behaviour it was decided to use a 
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definition of doctor shopping that was the most conservative or minimal that might 
potentially capture potential misuse for investigation in Study 2. Therefore, a definition 
was established for all potential doctor shoppers (more than three prescriptions and 
three or more different prescribers within a three-month period) that could potentially 
detect any level of POA drug use that might constitute doctor shopping. This criterion 
was established to capture the range of experts’ views that suggested any level of doctor 
shopping could be indicative of POA drug misuse. By setting this conservative level 
the Study 2 could capture the full population of potentially problematic POA drug use 
to examine the full extent of possible doctor-shopping definitions. 
 
6.3 STUDY 2: THE DOCTOR SHOPPING POPULATION 
Study 2 aimed to apply a doctor-shopping definition to a population of POA drug 
prescribed persons to identify potential aberrant use that might relate to a person with 
a SUD. However, Study 1 did not deliver a definitive doctor-shopping definition so the 
conservative and broad definition of doctor shopping was used to extract any persons 
who might have met that criteria within any quarter of the study year, 2013. This was 
to capture any person who at any time in 2013 might have been classified as a doctor 
shopper. 
 
15,545 persons met these criteria in any one quarter of 2013 and were extracted 
from MODDS for all possible doctor shoppers in that year. This included all POA drug 
prescriptions dispensed at any community pharmacy across Queensland. Descriptive 
analyses of the patterns of POA drug use found that doctor shopping was an infrequent 
activity, occurring most frequently for only in one quarter of the year for most persons, 
and this was in the context of long-term prescribing across three or four quarters of the 
year. 
 
A cluster analysis found there were two distinct sub-groups  of persons within 
this population. There was a group defined as ‘Non-aberrant’ who were mostly typified 
by low-volume consumption of POA drugs of less than 100mg (OME) for any quarter. 
The second or “Aberrant” group was typified by persons consuming POA drugs at 
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medium levels (100-200mg (OME) per day) or high levels (>200mg (OME) per day) 
for any quarter. 
 
Between the aberrant and non-aberrant groups there were significant differences 
in the variables of numbers of prescriptions, unique prescriber and dispenser seen and 
the approximate dosage of POA drugs obtained. The numbers of prescriptions and 
volume of POA drugs by OME (mg) seemed to best separate the two clusters 
statistically and descriptively. 
  
The results of Study 2 suggest that doctor shopping as described in terms of 
consulting multiple prescribers for multiple prescriptions is evident but is not a defining 
feature of the aberrant POA drug-using sub-population, aberrant use is better 
discriminated from non-aberrant use by volumes of POA drugs consumed. However, 
the aberrant population does appear to be consuming POA drugs at similar levels to 
known drug dependent persons who are possible doctor shoppers 
 
6.4 STUDY 3: PRESCIBING HISTORY OF DOCTOR SHOPPERS 
Study 3 involved the sub-population of 15,545 unclassified persons that were 
categorised into the aberrant and non-aberrant clusters to describe their previous POA 
drug prescribing over the 10 years prior to 2013. 
 
The results of Study 3 showed that Aberrant persons obtained POA drugs for 
longer periods of time and at greater volumes than Non-aberrant persons. Non-aberrant 
persons, regardless of the length of time over which they might have received POA 
drugs prior to 2013, rarely consumed these drugs at a high level of greater than 
approximately 200 milligrams (OME) per day over any quarter of a year in which they 
were prescribed. In contrast, Aberrant persons who obtained POA drugs were more 
likely to consume POA drugs at medium (100-200 mg (OME)/day) or high levels in 
any quarter of a year in which they were prescribed. This proportion of high and 
medium levels of consumption was also higher in the years closer to 2013. 
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Across all the years, Aberrant persons received more prescriptions on average per 
quarter than Non-aberrant persons. This suggests a considerable positive correlation 
with levels of consumption as might be expected. There appeared statistically 
significant differences between Aberrant and Non-aberrant persons in each of the 10 
years, 2003 to 2012, in terms of numbers of prescribers and dispensers. However, these 
differences were only in the order of less than one prescriber or dispenser and, 
considering standard deviations, all showed considerable overlap. Therefore, to use 
these in PDMPs as variables to potentially discriminate or predict problematic drug-
seeking might not have particular utility. 
 
These results suggest the aberrant POA drug use over time is most related to high 
volume of prescribing and high levels of consumption but not necessarily related to 
drug-seeking behaviour by seeing multiple different prescribers or dispensers. There 
were greater levels of doctor shopping over time in Aberrant persons compared to Non-
aberrant persons. However, it does not appear that this behaviour is consistent or 
continued over time for Aberrant persons, and does not appear to allow further 
discrimination with this group. This suggests that this Aberrant population is 
characterised by longer-term high-volume POA drug use over time. This population is 
more likely to show evidence of doctor shopping, but doctor shopping per se was not a 
particular defining characteristic of this group. 
 
6.5 STRENGTHS AND LIMITATIONS 
The thesis and its constituent studies have some strengths and weakness to 
consider in terms of drawing implications from the results presented. These strengths 
and weaknesses are discussed as follows. 
 
This thesis is the first study to attempt to develop an expert consensus decision of 
doctor shopping behaviour for POA drugs and to operationalise a definition of doctor 
shopping or drug seeking behaviour in a prescription drug monitoring program. Real-
time reporting PDMPs are being promoted as front-line regulatory mechanism to seek 
to moderate prescribing practices of health practitioners. It is important for that the 
information provided to practitioners is structured in a manner to promote sound 
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treatment decisions based on population level trends, to ensure POA drug are prescribed 
or not-prescribed to ensure the best treatment outcomes for patients. This study seeks 
to begin to help synthesis that information, so that real-time PDMP can add value and 
not complicate POA drug prescribing decisions. 
 
A major strength of this study is that it is a complete population capture of the 
persons who are using POA drugs in the Queensland community. The information 
captured in the MODDS data contains details of prescription drug types and volumes 
and known notifications for persons reported as drug dependent. Furthermore that 
information has been recorded in a consistent and reliable manner over the last two 
decades to allow for maintenance of reliable historical and contemporary records. This 
data set is used for regulatory purposes so it is subject to quality assurance measures to 
improve the accuracy of the information, so there is high standard in terms of error 
checking and matching persons processes to ensure correct information is maintained. 
The MODDS dataset is also actively in use to provide prescriber information and 
support regulatory compliance activities of the Department of Health. As such this 
represents accurately the actual information prescribers are using to make treatment 
decisions. 
 
Some limitations of these studies need to be considered. In terms of the population 
of persons of interest, these studies only capture prescriptions of POA drugs that are 
dispensed in Queensland community pharmacies. There is considerable evidence from 
multiple studies that persons suffering SUDs will also seek out and use other lesser-
controlled opioid drugs, such as over-the-counter codeine and other drug types such as 
benzodiazepines. Information about a person’s obtainings of these other drugs might 
aid in identifying doctor shoppers who suffer abuse or dependence. Furthermore, a 
person who is not resident in Queensland, who is incarcerated or has had periods of in-
patient hospital care might have obtained treatment with POA drugs not apparent to this 
study over the course of 2013 in the case of Study 2 (Chapter 4) or over the course of 
the previous ten year in relation to Study 3 (Chapter 5). However, there is no prima 
facie reason to suggest that this would be systematically different between the Aberrant 
and Non-aberrant groups. 
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 While there seems limited evidence of a population of high level doctor 
shoppers or outliers, this might still warrant further investigation. Other techniques of 
analysis might also be of assistance here.  A facet of aberrant use that this might uncover 
is the possible differentiation between impaired person seeking POA drugs from 
multiple doctors from criminal enterprise or persons seek to consciously evade scrutiny 
by drug seeking in a manner to maximise obtainings without arousing suspicions of 
treatment providers or regulators. Furthermore, this study can not identify areas of 
diversion, where POA drugs might be being onsold to other parties. Potentially, this is 
just as possible in a non-doctor shopping or non-aberrant population, if a person was 
receiving a greater than therapeutic dose and was sufficiently motivated to divert their 
dispensed POA drugs. 
 
Another issue is that a person might seek POA drugs from multiple prescribers 
and might be refused or denied a prescription. It should be noted that dispensed 
prescriptions only serve as an approximation of drug-seeking behaviour and might 
underestimate such behaviour as attempts to obtain drugs are not fully captured or are 
thwarted by diligent prescribers or regulatory mechanisms. For example, in Queensland 
a prescriber can call a 24-hour enquiry service and obtain a POA drug prescription 
history. Furthermore, the Department of Health routinely contacts prescribers when its 
surveillance techniques identify persons who are potential doctor shoppers. 
 
The study population excluded those persons already diagnosed with drug 
dependence by not including opioid treatment patients and those notified to the 
Department of Health as drug dependent and thus under regulatory approval. The 
reason for this was to examine the unclassified population where there had been no 
controls or influences attempted on a person’s drug-seeking behaviour. However, the 
known drug dependent OTP and approval patients do doctor shop for POA drugs. 
Further examination of how those persons sought drugs before their diagnoses could be 
of value.  
 
Furthermore, there is no linkage with death data or treatment outcome data. 
Therefore, it is not clear for what reasons a patient might cease treatment. It could be 
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the resolution of a pain condition, hospital admission, a move out of the jurisdiction, 
death, or other reasons.  Lastly, the studies also did not obtain any information about 
the patient or consumer experience in regard to the reasons they might be consulting 
multiple prescribers.  This is a potential limitation in understanding the reasons why a 
person might seek alternative or supplementary POA drug treatment. The views and 
beliefs of patients might also provide further insights into this phenomenon. 
 
6.6 SUMMARY AND RECOMMENDATIONS 
The overall conclusion is that it appears that there is not a particular homogenous 
population of POA drug users characterised by a high level or frequency of doctor 
shopping behaviour. However, there is a POA drug using population of potentially at 
risk persons who are receiving high doses of POA drugs and large volumes of 
prescriptions over long periods of time, and persons in this population might be 
suffering SUDs. A particular profile or population of doctor shopping persons does not 
appear to be emergent feature of the POA drug using population in terms of persons 
consulting multiple doctors or dispensers. These persons have not been considered drug 
dependent, or reported to authorities as such, by their treating medical practitioner under 
current regulatory requirements nor have they had prior histories of known treatments 
for illicit drug use. While doctor shopping exists within this sub-population, it is not a 
behaviour that appears to be consistent or necessarily associated with aberrant POA 
drug use. 
 
This overall finding seems at odds with some of the research and clinical literature 
and popular media that have given particular emphasis to the issue of doctor shopping. 
As mentioned previously the research literature is still not settled on the extent and 
implications of doctor shopping and drug seeking behaviour in large populations. The 
clinical literature is perhaps more focussed on known cases of harm such as POA drug-
related deaths and SUDs related to POA drug use in drug treatment settings. Even the 
association is primarily about exposure to POA drugs, and linking doctor shopping to 
harms or SUDs is still limited with many findings still reporting substantial associations 
with diverted POA drugs in drug treatment settings and findings of coronial matters. 
Furthermore, popular and non-scientific accounts of rampant POA drug use and doctor 
 208 Prescription opioid analgesic drug misuse: What can we learn from doctor-shopping behaviour 
shopping, perhaps create an impression of a phenomenon that is more complex and 
nuanced than is portrayed. 
 
There could be a variety of explanations for this finding. Potentially, aberrant 
drug-using persons appear to be being prescribed adequate levels of POA drugs to either 
manage their pain management needs or their dependence or a combination of both. 
Occasional or infrequent drug seeking across multiple prescribers occurs from time-to-
time in the context of longer-term high volume POA drug consumption.  Alternatively, 
these persons are being managed explicitly or implicitly for their drug dependence by 
being maintained of long-term dosages, well after their other medical requirements for 
POA drugs has been resolved. Effectively, managing persons on a regime similar to an 
opioid substitution program. 
 
There could be a small proportion, of as yet undefined persons, who seek high 
volumes of drugs over short or extended periods of times. However, these persons 
would appear to be a small heterogeneous grouping, as their drug seeking or doctor 
shopping would seem sporadic and infrequent. Potentially, short-term POA drug 
seeking, in the context of a short POA drug-using history might represent behaviour to 
supplement an illicit opioid drug dependence disorder. However, the studies taken had 
no means to confirm or refute this. Conceivably persons with no established 
relationship with a prescriber, with possible symptoms of withdrawal, or intoxication, 
or other objective evidence of illicit drugs would be more heavily scrutinised by a first 
time prescriber and less likely to be prescribed POA drugs. 
 
Limited episodes of doctor shopping in the context of a history of long-term POA 
drug prescribing could represent some change in treatment, treatment provider, pain 
condition or other factors that might lead to the initiation of doctor shopping to meet a 
pain management or dependence need until that person is re-established with a medical 
practitioner that manages their POA drug requirements effectively. 
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The overall picture of aberrant POA drug use suggests that long-term high dosage 
of POA drugs is the greater issue of concern in terms of being a public health risk. The 
results of this study suggest that a significant proportion of this aberrant population is 
consuming these drugs at either medium or high levels. Further evidence from this study 
suggests that as length of exposure increases there is a corresponding rise in the 
proportion of persons consuming POA drugs at high levels.  This appears to be an issue 
for consideration of treatment provider particularly given the increasing evidence that 
there is a lack of support for the effectiveness of long-term use of POA drugs for chronic 
pain conditions (Chou, et al., 2015; Martell, et al., 2007). 
 
This study’s results suggest that higher-level long-term POA drug consumption 
appears to be a greater immediate concern than doctor-shopping behaviour. There is a 
small sub-population of persons on long-term opioid use over many years and at various 
times in their POA drug-using histories they might seek prescriptions from other 
prescribers. However, this behaviour is not regularly occurring over time and appears 
to be over short timeframes and these persons POA drug supply then returns to single 
prescriber suppliers over the longer term. These persons might also be unrecognised as 
suffering SUDs by their treatment providers. This population would also appear to 
represent the most likely source of diverted POA drugs that are being found in illicit 
markets and reported as being used for non-medical purposes. 
 
It is of note that this study did not particularly identify any distinct sub-
populations of persons who were either infrequent and high-level doctor shoppers, or 
any frequent and high-level doctor shoppers, that might be consistent with persons 
suffering SUDs of abuse or dependence. Similarly, no category of persons that might 
be potentially obtaining POA drugs for on-selling or diversion could be identified, 
noting that the studies did not seek to identify such a group of persons. It is of interest 
that a discrete no doctor-shopping population is found using the largely descriptive 
techniques of these studies, despite there being widespread acknowledgement of this 
phenomenon related to POA drug misuse. Potentially, however, other analyses 
including other variables of interest might detect such a population; however, this study 
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is using those variables that are those actually actively used  in a PDMP for monitoring 
POA drug use by health-based regulators across a population. 
 
Two major recommendations are suggested by the outcomes of this thesis’s 
studies. The first is that a major focus on doctor shopping as a behaviour of concern is 
potentially unwarranted – certainly if that is to the exclusion of other concerns. The 
second, and related recommendation is that there appears to be a need for particular 
focus on persons maintained on long-term high dose POA drug therapies. The 
implications of the findings and recommendations are discussed below. 
 
6.7 IMPLICATIONS 
A particular implication of this study is an emphasis on managing POA drug 
misuse and diversion by focussing on doctor shopping alone is not supported as optimal 
approach. The greatest volume of POA drugs is being consumed by persons on long-
term high dose treatment. There is a risk of those persons developing SUDs on POA 
drugs, and a risk these persons are the source of diverted POA drugs finding their way 
into illicit markets. 
 
The results of the three studies of this thesis has implications in relation to 
management of the use and possible misuse of POA drugs in the Australian community. 
There are particular implications for the development and implementation of real-time 
PDMPs, the capacity and capability of health system to meet treatment needs, the 
overall strategic approaches to managing POA drug concerns, and the role of regulators 
of health professionals and POA drugs, and the impact on patients. These matters are 
discussed in more detail following. 
 
A major implication of this study is that an emphasis on managing POA drug 
misuse and diversion by focussing on doctor shopping alone, or to the exclusion of 
other approaches, is not supported by this study’s results as the optimal approach to 
managing POA drug misuse. The greatest volume of POA drugs is being consumed by 
persons on long-term high dose treatment. There is a significant risk of these persons 
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developing SUDs on POA drugs, and a reasonable assumption that these persons are 
the source of diverted POA drugs finding their way into illicit markets. 
 
Real-time prescription drug-monitoring appears to have good face value utility in 
allowing treatment providers to improve monitoring of their patients POA drug use and 
there would appear to be considerable value in implementing these systems.  However, 
this study’s findings support that there is a lack of agreement on what constitutes drug 
dependence in context of doctor shopping for POA drugs and there are many patients 
maintained on long-term high dose POA drug treatment. Given these issues there is 
some concern that the provision of information without appropriate structure and 
supporting interpretative information could potentially create more confusion or 
uncertainty for treatment providers. 
 
An unintended consequence to responding to aberrant POA drug use with ceasing 
of prescribing might cause more imminent harm to a patient on long-term treatment 
who most likely would exhibit significant withdrawal. Rapid cessation could also cause 
problematic drug-seeking use and this would have potentially greater costs to the 
medical and regulatory systems, as that person sought to re-establish their treatment 
regime. Some USA state jurisdictions have discussed a ‘chilling’ effect on POA 
prescriptions; that is, a significant reduction when PDMPs were introduced (Reisman, 
et al., 2009). 
 
Some pain specialists have argued there should be compelling and justified 
reasons for attempting to change a person’s POA drug regime, especially if they have 
been established on a certain dose for considerable time (Chou et al., 2009; Hallinan, et 
al., 2011). Alternatively, drug-dependent persons maintained on oral POA drug might 
be at less risk of harm than persons engaging in illicit injecting drug use. These options 
are perhaps sub-optimal care arrangements and persons with SUDs and persistent pain 
conditions should be offered best practice treatment options. However, management of 
POA drug misuse must be considered in the broader context of a harm minimisation 
framework and in the broader capacity of the healthcare system consider the limits of 
that system and how to provide the best outcomes for their patients. 
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It is recommended any such implementation of real-time PDMPs with access to 
treatment providers should consider providing treatment providers with support and 
training to be able to recognise problematic drug seeking behaviour, and also substance 
use disorders and inappropriate pain management treatment in long term POA drug 
using and apparently stable patients. Furthermore, development of information systems 
can represent significant investments, and often result in loss of expenditure in other 
areas such as treatment or prevention.  Possibly appropriate health economic or return 
on investment analyses should consider the merits of particular approaches to determine 
the best allocation of limited health expenditure. 
 
Persons who are on long-term POA drug treatment in primary care settings might 
require particular interventions to better manage their needs. PDMP real-time 
monitoring might also increase detection of persons that are not suitable for treatment 
in primary care or general practice settings or require more specialist review or 
treatment. Appropriate capacity within the health system to meet possibly increased 
pain management and drug treatment needs would also have to be considered. This 
could be managed by improving capacity of primary care providers or improving the 
capacity and access to specialist pain management or drug treatment services, or some 
combination of both. It is recommended that any approach to intervene in population 
wide POA drug use should consider and anticipate the potential flow on treatment needs 
this might create. 
 
For treatment providers there are potentially a significant considerations in 
regards to managing persons with POA drugs. The first is that it is particularly complex 
in assessing SUDs in this area, and perhaps understanding aberrant behaviour as a signal 
for concerns is important. Secondly, that use of high doses or doses over 100 
millligrams OME daily appears to be risky and more likely to lead to increasing dosages 
over time. The new CDC Guidelines (Dowell, et al., 2016) and other emerging  
guidelines suggesting maximum dosages of no more than 100 milligrams (OME) daily 
are particularly relevant. 
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In regard to the application and utility of PDMPs the implications are more 
complex. The first is cautionary in that doctor shopping per se might not be indicative 
of aberrant POA drug use. Treatment providers and regulators will need to be mindful 
of cases of false positives and ensure legitimate patients with non-problematic use are 
not denied access to treatment. Secondly, and also cautionary, is that no evidence of 
doctor shopping might not be the same as no evidence of problematic POA drug use. 
Treatment providers should be potentially alert to issue of dose escalation and PDMPs 
might be one of the appropriate tools to review and manage patients POA drug use over 
time. The third issue is that aberrant use appears more linked to prescriptions and high 
dosages over time, and less so to patients moving between prescribers who might be 
unaware of their actual use.  Therefore, with new guidelines suggesting upper limits on 
prescribing, PDMPs can become professional practice improvement tools at best, or 
regulatory mechanisms to control errant prescribers at worst.  In a worst case scenario 
prescribing limits could be imposed on prescribers by regulatory or enforcement 
agencies and this could erode the independent decision making of treatment providers. 
 
Regulatory agencies and professional bodies might need to provide further 
guidance to practitioners about their obligations and requirements, and also to patients 
as to their rights to treatment and obligations in regard to the use of POA drugs. 
Prescribers will perhaps require increased training in pain management and SUD issues 
around POA drug use to improve patient care. Regulators and professional standards 
bodies will have to ensure health practitioners are appropriately informed about their 
obligations and professional requirements before they could legitimately enforce 
compliance with health practitioners’ treatment and prescribing practices. 
 
Patients will also need some information and support to understand any changes 
in their treatment regimes and their rights to treatment and requirements to use POA 
drugs lawfully. There is a risk that treatment providers using doctor shopping as reason 
to choose to refuse continue treatment, might cause their patients considerable harms 
and actual create apparent doctor shopping behaviour as they seek to find alternative 
treatment providers. The engagement of consumers is perhaps an issue with many 
implications. If patients are having long term treatment approaches modified without 
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their support or consent, there are now options for complaints and review of health 
practitioner practice across most Australia jurisdictions. If patients have been 
inappropriately managed over lengthy periods and they have developed SUDs as a 
result of this treatment, this is the potential of litigation or complaint action by that 
person against their treating health practitioner. 
 
In Australia the national strategic approach established in the Pharmaceutical 
Drug Misuse – Framework for Action (Ministerial Council on Drug Strategy, 2011) is 
a comprehensive approach that appears to address the interventions required in a 
balance manner. As such consistent uniform adoption of the strategy across Australian 
jurisdictions would appear the best informed approach. Real-time prescription drug-
monitoring with the capability of direct access by prescribers and dispensers, at present 
is a key strategic focus across Australian jurisdiction at present, derived from the above 
framework. As such it is recommended that the strategy framework recommendations 
should implemented would be most effective if implemented in comprehensive fashion 
rather than in part. 
 
These results also suggest that the overall subsidisation of POA drugs under the 
PBS in Australia might need further examination. If there are large numbers of patients 
on long-term high dose POA drug treatment and in most cases these ongoing 
prescriptions meet requirements for PBS subsidies for prolonged treatment. The PBS 
seeks to ensure accessible and cost effective medicines for the community. If treatment 
with POA for a proportion of this population is not appropriate or effective, and given 
there are concerns about drug diversion, then continuing low cost access to POA drugs, 
potentially acts as a perverse incentive for practitioners and patients to maintain these 
treatment regimes. However, any changes to subsidised treatment and medicines would 
need careful consideration to ensure there is no disadvantage to patients with legitimate 
needs. 
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6.8 FUTURE STUDY SUGGESTIONS 
The results also suggest further areas for investigation based on the available 
MODDS dataset and other matters requiring information from other sources. Areas of 
potential future study could focus on further aspects of patients, healthcare providers, 
role of regulators and the real-time PDMPs. These are discussed in the following 
section. 
 
In current MODDs dataset, drug dependent patients, and non-doctor shopping 
patients were excluded from part or all of the study. For the known drug dependent 
persons, it might be worthwhile to investigate aspects of their reported SUDs and the 
relationship to their POA drugs use. For the non-doctor shopping patients, it would be 
assumed a significant proportion of these are also on long term high dose POA 
treatments. Further investigation of overall POA drug trends over time could also 
include the entire population receiving POA drugs and potentially identify time points 
when persons POA drug treatment changed. 
 
Further qualitative information from patients as health care consumers is a largely 
untapped area of research and could shed further light on the reasons for some persons’ 
drug seeking behaviour. Further quantitative or clinical information about patients’ 
diagnosis and assessment of their conditions, could also add value and perhaps help 
discriminate or identify SUDs better. Information on patients who have experienced 
episodes of overdose on POA drug, or died and the causes of death would also be 
relevant in assessing POA drug related harms. 
 
These studies in this thesis did not focus on aspects of the quality of prescribers. 
Potentially, poor prescribing practices or treatment outside of accepted professional 
standards by health practitioner could contribute to some of poor POA drug treatment 
outcomes.  Further investigation into the role of prescribers and means of identifying 
poor practice could also have value and suggest targets for interventions. 
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Finally, if real-time PDMPs are to be implemented and this is done so with 
appropriate support and structure, then there is a unique opportunity to change in POA 
drug use due to a naturally occurring experiment. Ideally, any PDMP implementation 
would be undertaken with an evaluation component. There is the potential to examine 
the effect of such an intervention by contrasting the pre and post stages of the 
implementation of a real-time PDMP to assess its effect on prescribing practices and 
POA drug consumption. 
 
6.9 CONCLUSION 
This thesis set out to investigate the phenomenon of doctor shopping in order to 
ascertain the purported relationship to POA drug misuse. The aim of the studies was to 
provide doctor shopping definitions that could be operationalised in PDMPs to inform 
prescribers, identify aberrant POA drug use, and improve prescribing decisions and 
treatment outcomes.  While it is not disputed that doctor shopping behaviour exists, the 
results of these studies did not identify a discrete doctor shopping population nor find 
an association with aberrant POA drug use. However, the studies did show concerning 
evidence of a sub-population of persons on high dose long term POA drugs, that could 
be at risk of, or suffering SUDs.  The outcomes suggest that alarmist depictions of 
doctor shopping are not supported. It is recommended that Australian jurisdictions 
seeking to make considerable health investments in real-time reporting PDMPs might 
consider how such systems can also address long term high dose POA drug use to 
improve patient treatment outcomes and reduce drug diversion. 
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Appendix A: DSM-IV-TR & ICD-Diagnostic Criteria 
 
Diagnostic and Statistical Manual of Mental Disorders- Fourth Edition -Text 
Revision (DSM-IV-TR): Criteria for Substance Dependence and Substance 
Abuse 
DSM-IV_TR Criteria for Substance Dependence 
   
A maladaptive pattern of substance use, leading to clinically significant impairment 
or distress, as manifested by three (or more) of the following, occurring at 
any time in the same 12-month period: 
(1) tolerance, as defined by either of the following: 
(a) a need for markedly increased amounts of the substance to achieve intoxication 
or desired effect 
(b) markedly diminished effect with continued use of the same amount of 
the substance 
(2) withdrawal, as manifested by either of the following: 
(a) the characteristic withdrawal syndrome for the substance (refer to Criteria 
A and B of the criteria sets for Withdrawal from the specific substances) 
(b) the same (or a closely related) substance is taken to relieve or avoid withdrawal 
symptoms 
(3) the substance is often taken in larger amounts or over a longer period than 
was intended 
(4) there is a persistent desire or unsuccessful efforts to cut down or control substance 
use 
(5) a great deal of time is spent in activities necessary to obtain the substance 
(e.g., visiting multiple doctors or driving long distances), use the substance 
(e.g., chain-smoking), or recover from its effects 
(6) important social, occupational, or recreational activities are given up or reduced 
because of substance use 
(7) the substance use is continued despite knowledge of having a persistent or 
recurrent physical or psychological problem that is likely to have been caused 
or exacerbated by the substance (e.g., current cocaine use despite recognition 
of cocaine-induced depression, or continued drinking despite recognition 
that an ulcer was made worse by alcohol consumption) 
   
Specify if: 
With Physiological Dependence: evidence of tolerance or withdrawal 
(i .e .• either Item 1 or 2 is present) 
Without Physiological Dependence: no evidence of tolerance or withdrawal 
(i.e., neither Item 1 nor 2 is present) 
Course specifiers (see text f or definitions): 
Early Full Remission 
Early Partial Remission 
Sustained Full Remission 
Sustained Partial Remission 
On Agonist Therapy 
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In a Controlled Environment 
(pp197-198. (American Psychiatric Association, 2000))    
    
    
DSM-IV-TR - Criteria for Substance Abuse    
A maladaptive pattern of substance use leading to clinically significant impairment 
or distress, as manifested by one (or more) of the following, occurring within a 12- 
month period: 
(1) recurrent substance use resulting in a failure to fulfil major role obligations at 
work, school, or home (e.g., repeated absences or poor work performance related to substance  
use; substance-related absences. suspensions, or expulsions 
from school; neglect of children or household) 
(2) recurrent substance use in situations in which it is physically hazardous (e.g. .driving an 
automobile or operating a machine when impaired by substance use) 
(3) recurrent substance-related legal problems (e.g., arrests for substance-related 
disorderly conduct) 
(4) continued substance use despite having persistent or recurrent social or interpersonal 
problems caused or exacerbated by the effects of the substance (e.g., 
arguments with spouse about consequences of intoxication, physical fights) 
B. The symptoms have never met the criteria for Substance Dependence for this class of 
substance. 
   
(pp199. (American Psychiatric Association, 2000)    
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Diagnostic and Statistical Manual of Mental Disorders 5th Edition (DSM-5)  
 
Opioid Use Disorder Criteria: 
A minimum of 2-3 criteria is required for a mild substance use disorder diagnosis, while 
4-5 is moderate, and 6-7 is severe. Opioid Use Disorder is specified instead of Substance 
Use Disorder, if opioids are the drug of abuse.  
1. Taking the opioid in larger amounts and for longer than intended 
2. Wanting to cut down or quit but not being able to do it 
3. Spending a lot of time obtaining the opioid 
4. Craving or a strong desire to use opioids 
5. Repeatedly unable to carry out major obligations at work, school, or home due to 
opioid use 
6. Continued use despite persistent or recurring social or interpersonal problems 
caused or made worse by opioid use 
7. Stopping or reducing important social, occupational, or recreational activities 
due to opioid use 
8. Recurrent use of opioids in physically hazardous situations 
9. Consistent use of opioids despite acknowledgment of persistent or recurrent 
physical or psychological difficulties from using opioids 
10. *Tolerance as defined by either a need for markedly increased amounts to 
achieve intoxication or desired effect or markedly diminished effect with 
continued use of the same amount. (Does not apply for diminished effect when 
used appropriately under medical supervision) 
11. *Withdrawal manifesting as either characteristic syndrome or the substance is 
used to avoid withdrawal (Does not apply when used appropriately under 
medical supervision) 
 
   
(American Psychiatric Association, 2014)    
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International Classification of Disease Ninth Edition, Clinical Modification 
(ICD-9-CM) classifications of drug dependence and drug abuse related to opioids 
Drug dependence 304 
• Drug dependence - replaced the term "drug addiction" and is defined as a 
state, psychic and sometimes also physical, resulting from the interaction 
between a living organism and a drug, characterized by behavioural and other 
responses that always include a compulsion to take the drug on a continuous or 
periodic basis in order to experience its psychic effects, and sometimes to 
avoid the discomfort of its absence. Tolerance may or may not be present. A 
person may be dependent on more than one drug. 
• Physical and emotional dependence on a chemical substance. Compare drug 
dependency. 
• Psychological craving for or habituation to the use of a chemical substance 
which may or may not be accompanied by physical dependency. Used for 
animal or human populations. Compare drug addiction. 
• State of heavy dependence on any drug, including alcohol; sometimes defined 
as physical dependence but usually also including emotional dependence, i.e., 
compulsive or pathological drug use. 
 
•  304 Drug dependence 
•  304.0 Opioid type dependence 
•  304.00 Opioid type dependence, unspecified convert 304.00 to ICD-
10-CM 
•  304.01 Opioid type dependence, continuous convert 304.01 to ICD-
10-CM 
•  304.02 Opioid type dependence, episodic convert 304.02 to ICD-10-
CM 
•  304.03 Opioid type dependence, in remission convert 304.03 to ICD-
10-CM 
See: http://www.icd9data.com/2013/Volume1/290-319/300-316/304/ 
 
 
(Medicode (Firm), 1996)  
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Nondependent abuse of drugs 305 
• Drug abuse is a serious public health problem that affects almost every 
community and family in some way. Each year drug abuse results in around 
40 million serious illnesses or injuries among people in the United States. 
Abused drugs include 
o amphetamines 
o anabolic steroids 
o club drugs 
o cocaine 
o heroin 
o inhalants 
o marijuana 
o prescription drugs 
drug abuse also plays a role in many major social problems, such as drugged 
driving, violence, stress and child abuse. Drug abuse can lead to homelessness, 
crime and missed work or problems with keeping a job. It harms unborn 
babies and destroys families. There are different types of treatment for drug 
abuse. But the best is to prevent drug abuse in the first place. nih: national 
institute on drug abuse 
• Excessive use of distilled liquors 
• Excessive use of drugs or chemicals with associated psychological symptoms 
and impairment in social or occupational functioning. 
• Excessive use of habit forming medications 
• Excessive use of habit forming medications. 
• The use of a drug for a reason other than which it was intended or in a manner 
or in quantities other than directed. 
• The use of alcoholic beverages to excess, either on individual occasions 
("binge drinking") or as a regular practice. 
• The use of illegal drugs or the use of prescription or over-the-counter drugs for 
purposes other than those for which they are meant to be used, or in large 
amounts. Drug abuse may lead to social, physical, emotional, and job-related 
problems. 
•  305.5 Nondependent opioid abuse 
•  305.50 Opioid abuse, unspecified convert 305.50 to ICD-10-CM 
•  305.51 Opioid abuse, continuous convert 305.51 to ICD-10-CM 
•  305.52 Opioid abuse, episodic convert 305.52 to ICD-10-CM 
•  305.53 Opioid abuse, in remission convert 305.53 to ICD-10-CM 
 
 
See: http://www.icd9data.com/2013/Volume1/290-319/300-316/305/default.htm 
(Medicode (Firm), 1996) 
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Appendix B: 
Summary of regulatory requirements for controlled (Schedule 8) drugs under 
the Health (Drugs & Poisons) Regulation, 1996 in Queensland, Australia. 
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Appendix C: Research Approvals 
 
C-1 – Queensland University of Technology Ethical Approval 
 
 
 256 Prescription opioid analgesic drug misuse: What can we learn from doctor-shopping behaviour 
C-2 Queensland Health Ethical Approval 
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C-3 Approval under the Health Act, 1937 to use public health information. 
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Appendix D: Expert bodies 
 
Table C-1  
Pain management and drug dependence organisations, that were approached for participants in the Delphi Technique for Study One – classified by country in which based, 
pain or addiction focus and associated journals (n=34) 
Organisation name Internet webpage Country Pain Addiction Journal 
Addiction Treatment Forum http://www.atforum.com/ USA 
 
X 
 
Alcohol and Drug Council of Australia www.adca.org.au Aust 
 
X 
 
American Academy of Pain Management http://www.aapainmanage.org/ USA X 
  
American Academy of Pain Medicine http://www.painmed.org/ USA X 
 
Pain Medicine 
American Association for the Treatment of 
Opioid Dependence 
http://www.aatod.org/sitemap.html USA 
 
X 
 
American Association of Addiction Medicine www.asam.org USA 
 
X 
 
American Board of Pain Medicine http://www.abpm.org/ USA X 
  
American Chronic Pain Association http://www.theacpa.org/ USA X 
  
American Chronic Pain Association http://www.theacpa.org/default.aspx USA X 
  
American Pain Society http://www.ampainsoc.org/ USA X 
 
Journal of Pain 
American Society for Pain Management Nursing http://www.aspmn.org/ USA X 
  
Australian Pain Management Association http://www.painmanagement.org.au/ Aust X 
  
Australian Pain Society http://www.apsoc.org.au/ Aust X 
  
Australian Professional Society on Alcohol and 
Drugs 
http://www.apsad.org.au/ Aust 
 
X Drug and Alcohol 
Review 
Canadian Academy of Pain Management http://www.canadianapm.com/ Can X 
  
Canadian Centre on Substance Abuse http://www.ccsa.ca/Eng/ Can 
 
X 
 
Canadian Drug Policy Coalition http://drugpolicy.ca/ Can 
 
X 
 
 259 Prescription opioid analgesic drug misuse: What can we learn from doctor-shopping behaviour 
Canadian Pain Society http://www.canadianpainsociety.ca/en/ Can X 
  
Canadian Society of Addiction Medicine www.csam.org Can 
 
X Canadian Journal of 
Addiction Medicine 
Centre for Addiction and Mental Health http://www.camh.net/ Can 
 
X 
 
Centre for Applied Research in Mental Health & 
Addiction 
http://www.carmha.ca/ Can 
 
X 
 
Chapter of Addiction Medicine (Royal Australian 
College of Physicians) 
http://www.racp.edu.au/page/australasian-
chapter-of-addiction-medicine/ 
Aust 
 
X 
 
Chronic Pain Australia http://www.chronicpainaustralia.org.au/ Aust X 
  
College of Physicians and Surgeons of Ontario http://www.cpso.on.ca/ Can X X 
 
College on Problems of Drug Dependence http://www.cpdd.vcu.edu/ USA 
 
X Drug and Alcohol 
Dependence 
Drug and Alcohol Nurses - Australia http://www.danaonline.org/ Aust 
 
X 
 
Faculty of Pain Medicine of the Australian and 
New Zealand College of Anaesthetists 
http://www.anzca.edu.au/fpm Aust X 
 
Pain Medicine 
International Association for Pain & Chemical 
Dependency 
http://www.iapcd.org/ Int X X 
 
International Association for Study of Pain http://www.iasp-pain.org/ Int X 
 
Pain 
Network of Alcohol and Drug Agencies www.nada.org.au Aust 
 
X 
 
New Zealand Pain Society http://www.nzps.org.nz/ NZ X 
 
Pain Research & 
Treatment 
Pain Medicine Research Institute http://sydney.edu.au/medicine/pmri/ Aust X 
  
Queensland Self-Management Alliance http://www.qsma.org.au/ Aust X 
  
The American Society for Interventional Pain 
Physicians 
http://www.asipp.org/index.html USA X   Pain Physician 
Note: Aust – Australia, Can – Canada, NZ – New Zealand, USA – United States of America, Int – International (membership available to all 
nationalities).
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Appendix E: Study 1 Questionnaires 
 
Appendix E-1: Study 1 – Round One Questionnaire 
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Appendix E-2: Study 1 – Round Two Questionnaire 
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Appendix F: Prescription details 
 
A sample de-identified controlled (Schedule 8) drug prescription with data 
elements highlighted 
 
 
scriber name & 
ress
escriber number
Quantity Dispenser 
name & 
address
Dosing 
instructions
Date of birth
Drug name 
Formulation
Strength 
Patient name &
address
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Appendix G: Controlled (Schedule 8) drugs 
 
List of all controlled (Schedule 8) drugs capture by the MODDS database as at 2013. 
 
 
Drug 
Id 
Drug 
Group 
Id 
Drug Group Generic Name Strength Unit Type Trade Names Drug Type 
422 NULL NULL J .000 AMPOULES NULL NULL 
421 69 OXYCODONE HCL 
CONTROLLED 
RELEASE ORAL 
OXYCONTIN NEW-
FORMULATION CR-T 
80.000 TABLETS OXYCONTIN OXYCODONE 
420 69 OXYCODONE HCL 
CONTROLLED 
RELEASE ORAL 
OXYCONTIN NEW 
FORMULATION CR-T 
40.000 TABLETS OXYCONTIN OXYCODONE 
419 69 OXYCODONE HCL 
CONTROLLED 
RELEASE ORAL 
OXYCONTIN NEW 
FORMULATION CR-T 
30.000 TABLETS OXYCONTIN OXYCODONE 
418 69 OXYCODONE HCL 
CONTROLLED 
RELEASE ORAL 
OXYCONTIN NEW-
FORMULATION CR-T 
20.000 TABLETS OXYCONTIN OXYCODONE 
417 69 OXYCODONE HCL 
CONTROLLED 
RELEASE ORAL 
OXYCONTIN NEW-
FORMULATION CR-T 
15.000 TABLETS OXYCONTIN OXYCODONE 
416 69 OXYCODONE HCL 
CONTROLLED 
RELEASE ORAL 
OXYCONTIN NEW-
FORMULATION CR-T 
10.000 TABLETS OXYCONTIN OXYCODONE 
415 95 ALPRAZOLAM ALPRAZOLAM 
500MCG 
.500 TABLETS XANAX / KALMA BENZODIAZEPINE 
414 95 ALPRAZOLAM ALPRAZOLAM 
250MCG 
.250 TABLETS XANAX / KALMA BENZODIAZEPINE 
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413 95 ALPRAZOLAM ALPRAZOLAM 2MG 2.000 TABLETS XANAX / KALMA BENZODIAZEPINE 
412 95 ALPRAZOLAM ALPRAZOLAM 1MG 1.000 TABLETS XANAX / KALMA BENZODIAZEPINE 
411 93 LISDEXAMFETAMINE 
DISMESILATE 
LISDEXAMFETAMINE 
DISMESILATE 70MG 
70.000 CAPSULES VYVANSE AMPHETAMINE 
410 93 LISDEXAMFETAMINE 
DISMESILATE 
LISDEXAMFETAMINE 
DISMESILATE 50MG 
50.000 CAPSULES VYVANSE AMPHETAMINE 
409 93 LISDEXAMFETAMINE 
DISMESILATE 
LISDEXAMFETAMINE 
DISMESILATE 30MG 
30.000 CAPSULES VYVANSE AMPHETAMINE 
408 94 TAPENTADOL TAPENTADOL (SR) 
250MG 
250.000 TABLETS PALEXIA OTHER 
407 94 TAPENTADOL TAPENTADOL (SR) 
200MG 
200.000 TABLETS PALEXIA OTHER 
406 94 TAPENTADOL TAPENTADOL (SR) 
150MG 
150.000 TABLETS PALEXIA OTHER 
405 94 TAPENTADOL TAPENTADOL (SR) 
100MG 
100.000 TABLETS PALEXIA OTHER 
404 94 TAPENTADOL TAPENTADOL (SR) 
50MG 
50.000 TABLETS PALEXIA OTHER 
403 86 BUPRENORPHINE + 
NALOXONE SUB-
LINGUAL 
SUBOXONE SUB-
LINGUAL FILM 1MG 
(PROGRAM) 
1.000 MILLIGRAMS SUBOXONE FILM BUPRENORPHINE 
402 73 FENTANYL 
PATCHES 
FENTANYL  
PATCHES 100 
MCG/HR 16.5MG 
7.200 PATCHES DUROGESIC FENTANYL 
401 73 FENTANYL 
PATCHES 
FENTANYL 
PATCHES 75 
MCG/HR 12.375MG 
5.400 PATCHES DUROGESIC FENTANYL 
400 73 FENTANYL 
PATCHES 
FENTANYL 
PATCHES 50 
MCG/HR 8.25MG 
3.600 PATCHES DUROGESIC FENTANYL 
399 73 FENTANYL 
PATCHES 
FENTANYL 
PATCHES 25 
MCG/HR 4.125MG 
1.800 PATCHES DUROGESIC FENTANYL 
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398 73 FENTANYL 
PATCHES 
FENTANYL 
PATCHES 12 
MCG/HR 2.063MG 
.864 PATCHES DUROGESIC FENTANYL 
397 73 FENTANYL 
PATCHES 
FENTANYL 
PATCHES 
12MCG/HR 1.28MG 
.864 PATCHES DENPAX FENTANYL 
396 73 FENTANYL 
PATCHES 
FENTANYL 
PATCHES 
25MCG/HR 2.55MG 
1.800 PATCHES DENPAX FENTANYL 
395 73 FENTANYL 
PATCHES 
FENTANYL 
PATCHES 
50MCG/HR 5.1MG 
3.600 PATCHES DENPAX FENTANYL 
394 73 FENTANYL 
PATCHES 
FENTANYL 
PATCHES 
75MCG/HR 7.65MG 
5.400 PATCHES DENPAX FENTANYL 
393 73 FENTANYL 
PATCHES 
FENTANYL 
PATCHES 
100MCG/HR 10.2MG 
7.200 PATCHES DENPAX FENTANYL 
392 91 OXYCODONE HCL; 
NALOXONE HCL 
DIHYDRATE 
OXYCODONE HCI 
40MG, NALOXONE 
HCI (DIHYDRATE) 
20MG 
40.000 TABLETS TARGIN OXYCODONE 
391 91 OXYCODONE HCL; 
NALOXONE HCL 
DIHYDRATE 
OXYCODONE HCI 
20MG, NALOXONE 
HCI (DIHYDRATE) 
10MG 
20.000 TABLETS TARGIN OXYCODONE 
390 91 OXYCODONE HCL; 
NALOXONE HCL 
DIHYDRATE 
OXYCODONE HCI 
10MG, NALOXONE 
HCI (DIHYDRATE) 
5MG 
10.000 TABLETS TARGIN OXYCODONE 
389 91 OXYCODONE HCL; 
NALOXONE HCL 
DIHYDRATE 
 OXYCODONE HCI 
5MG, NALOXONE 
HCI (DIHYDRATE) 
2.5MG 
5.000 TABLETS TARGIN OXYCODONE 
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388 76 METHYLPHENIDATE 
LONG ACTING 
METHYLPHENIDATE 
(SR) 10MG 
10.000 CAPSULES RITALIN LA (LONG ACTING) AMPHETAMINE 
387 90 KETAMINE SUB-
LINGUAL 
KETAMINE 
LOZENGE 50MG 
50.000 LOZENGE KETAMINE LOZENGE TUGUN 
COMPOUNDING 
KETAMINE 
386 83 HYDROMORPHONE 
EXTENDED 
RELEASE ORAL 
HYDROMORPHONE 
(SR) 4MG 
4.000 TABLETS JURNISTA MR-TAB 4MG HYDROMORPHONE 
385 83 HYDROMORPHONE 
EXTENDED 
RELEASE ORAL 
HYDROMORPHONE 
(SR) 64MG 
64.000 TABLETS JURNISTA MR-TAB 64MG HYDROMORPHONE 
384 83 HYDROMORPHONE 
EXTENDED 
RELEASE ORAL 
HYDROMORPHONE 
(SR) 32MG 
32.000 TABLETS JURNISTA MR-TAB 32MG HYDROMORPHONE 
383 83 HYDROMORPHONE 
EXTENDED 
RELEASE ORAL 
HYDROMORPHONE 
(SR) 16MG 
16.000 TABLETS JURNISTA MR-TAB 16MG HYDROMORPHONE 
382 83 HYDROMORPHONE 
EXTENDED 
RELEASE ORAL 
HYDROMORPHONE 
(SR) 8MG 
8.000 TABLETS JURNISTA MR-TAB 8MG HYDROMORPHONE 
381 69 OXYCODONE HCL 
CONTROLLED 
RELEASE ORAL 
OXYCODONE HCL 
(SR) 15MG 
15.000 TABLETS OXYCONTIN OXYCODONE 
380 69 OXYCODONE HCL 
CONTROLLED 
RELEASE ORAL 
OXYCODONE HCL 
(SR) 30MG 
30.000 TABLETS OXYCONTIN OXYCODONE 
378 85 DEXAMPHETAMINE 
LONG ACTING ORAL 
DEXAMPHETAMINE 
(SR) 7.5MG 
7.500 CAPSULES DEXAMPHETAMINE 7.5MG SR CAPSULES 
CUSTOM COMPOUNDING 
AMPHETAMINE 
377 88 KETAMINE 
SOLUTION/GEL 
KETAMINE HCL 10% 
GEL 
.100 GRAMS KETAMINE 
10%/KETOPROFEN10%/AMITIPTYLENE5% 
KETAMINE 
376 86 BUPRENORPHINE + 
NALOXONE SUB-
LINGUAL 
BUPRENORPHINE 
8MG + NALOXONE 
2MG SUB-LINGUAL 
8.000 TABLETS SUBOXONE BUPRENORPHINE 
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375 86 BUPRENORPHINE + 
NALOXONE SUB-
LINGUAL 
BUPRENORPHINE 
2MG + NALOXONE 
0.5MG SUB-LINGUAL 
2.000 TABLETS SUBOXONE BUPRENORPHINE 
374 86 BUPRENORPHINE + 
NALOXONE SUB-
LINGUAL 
SUBOXONE SUB-
LINGUALTABS 1MG 
(PROGRAM) 
1.000 MILLIGRAMS SUBOXONE BUPRENORPHINE 
371 62 COCAINE 
SOLUTION/GEL 
COCAINE HCL 
SOLUTION/GEL 15% 
.150 MILLILITRES COCAINE HCL SOLUTION/GEL 15% COCAINE 
370 76 METHYLPHENIDATE 
LONG ACTING 
METHYLPHENIDATE 
(SR) 27MG 
27.000 TABLETS CONCERTA AMPHETAMINE 
369 13 OXYCODONE 
INJECTIONS 
OXYCODONE HCL 
20MG/2ML 
20.000 AMPOULES OXYNORM OXYCODONE 
368 89 SUFENTANIL 
INJECTIONS 
SUFENTANIL 
250MCG/5ML 
.250 AMPOULES SUFENTA FORTE, SUFENTIL SUFENTANIL 
366 73 FENTANYL 
PATCHES 
FENTANYL 
PATCHES 12 
MCG/HR 2.1MG 
.864 PATCHES DUROGESIC FENTANYL 
365 84 BUPRENORPHINE 
PATCHES 
BUPRENORPHINE 
PATCHES 
20MCG/HR 20MG 
3.360 PATCHES NORSPAN BUPRENORPHINE 
364 84 BUPRENORPHINE 
PATCHES 
BUPRENORPHINE 
PATCHES 
10MCG/HR 10MG 
1.680 PATCHES NORSPAN BUPRENORPHINE 
363 84 BUPRENORPHINE 
PATCHES 
BUPRENORPHINE 
PATCHES 5MCG/HR 
5MG 
.840 PATCHES NORSPAN BUPRENORPHINE 
359 83 HYDROMORPHONE 
EXTENDED 
RELEASE ORAL 
HYDROMORPHONE 
EXTENDED 
RELEASE 32MG 
32.000 CAPSULES PALLADONE HYDROMORPHONE 
357 82 KETAMINE 
INJECTIONS 
KETAMINE HCL 
200MG/2ML 
200.000 AMPOULES KETALAR KETAMINE 
356 30 FENTANYL 
INJECTIONS 
FENTANYL CITRATE 
1000MCG/20ML 
1.000 VIALS SUBLIMAZE FENTANYL 
355 77 FENTANYL SUB-
LINGUAL 
FENTANYL 
LOZENGE 1600MCG 
1.600 LOZENGE ACTIQ FENTANYL 
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354 77 FENTANYL SUB-
LINGUAL 
FENTANYL 
LOZENGE 1200MCG 
1.200 LOZENGE ACTIQ FENTANYL 
353 77 FENTANYL SUB-
LINGUAL 
FENTANYL 
LOZENGE 800MCG 
.800 LOZENGE ACTIQ FENTANYL 
352 77 FENTANYL SUB-
LINGUAL 
FENTANYL 
LOZENGE 600MCG 
.600 LOZENGE ACTIQ FENTANYL 
350 76 METHYLPHENIDATE 
LONG ACTING 
METHYLPHENIDATE 
(SR) 54MG 
54.000 TABLETS CONCERTA AMPHETAMINE 
349 77 FENTANYL SUB-
LINGUAL 
FENTANYL 
LOZENGE 200MCG 
.200 LOZENGE ACTIQ FENTANYL 
348 8 METHADONE ORAL METHADONE LIQUID 
5MG/ML (200ML) 
(NON-PROGRAM) 
1000.000 BOTTLE BIODONE FORTE SYR 5MG/ML (ML) METHADONE 
347 12 OXYCODONE 
SUPPOSITORIES 
OXYCODONE 15MG 15.000 SUPPOSITORIES PINDARA OWN BRAND OXYCODONE 
346 77 FENTANYL SUB-
LINGUAL 
FENTANYL 
LOZENGE 400MCG 
.400 LOZENGE ACTIQ FENTANYL 
345 6 MORPHINE 
INJECTIONS 
MORPHINE 
TARTRATE 
400MG/5ML 
400.000 AMPOULES NULL MORPHINE 
344 5 MORPHINE ORAL MORPHINE 
SULPHATE 10MG 
10.000 TABLETS SEVREDOL MORPHINE 
343 5 MORPHINE ORAL MORPHINE 
SULPHATE 20MG 
20.000 TABLETS SEVREDOL MORPHINE 
342 11 OXYCODONE ORAL OXYCODONE HCL 
10MG/ML (120ML) 
1200.000 BOTTLE OXYNORM CONCENTRATE (120ML) OXYCODONE 
341 69 OXYCODONE HCL 
CONTROLLED 
RELEASE ORAL 
OXYCODONE HCL 
(SR) 5MG 
5.000 TABLETS OXYCONTIN OXYCODONE 
340 11 OXYCODONE ORAL OXYCODONE HCL 
LIQUID 5MG/5ML 
(250ML) 
250.000 BOTTLE OXYNORM LIQ OXYCODONE 
337 76 METHYLPHENIDATE 
LONG ACTING 
METHYLPHENIDATE 
(SR) 36MG 
36.000 TABLETS CONCERTA AMPHETAMINE 
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336 62 COCAINE 
SOLUTION/GEL 
COCAINE HCL 
SOLUTION/GEL 25% 
.250 MILLILITRES COCAINE HCL SOLUTION/GEL 25% COCAINE 
335 64 COCAINE POWDER COCAINE HCL 
POWDER 100MG 
100.000 MILLIGRAMS COCAINE HCL POWDER 100MG COCAINE 
334 30 FENTANYL 
INJECTIONS 
FENTANYL CITRATE 
100MCG/2ML 
.100 AMPOULES NULL FENTANYL 
333 76 METHYLPHENIDATE 
LONG ACTING 
METHYLPHENIDATE 
(SR) 40MG 
40.000 CAPSULES RITALIN LA (LONG ACTING) AMPHETAMINE 
332 76 METHYLPHENIDATE 
LONG ACTING 
METHYLPHENIDATE 
(SR) 30MG 
30.000 CAPSULES RITALIN LA (LONG ACTING) AMPHETAMINE 
331 76 METHYLPHENIDATE 
LONG ACTING 
METHYLPHENIDATE 
(SR) 18MG 
18.000 TABLETS CONCERTA AMPHETAMINE 
330 76 METHYLPHENIDATE 
LONG ACTING 
METHYLPHENIDATE 
(SR) 20MG 
20.000 CAPSULES METADATE, RITALIN LA (LONG ACTING) AMPHETAMINE 
329 21 CODEINE ORAL CODEINE 
PHOSPHATE 
LINCTUS  5MG/ML 
(100ML) 
500.000 BOTTLE ACTACODE CODEINE 
327 81 REMIFENTANIL 
INJECTIONS 
REMIFENTANIL HCL 
2MG/5ML 
2.000 AMPOULES ULTIVA REMIFENTANIL 
326 81 REMIFENTANIL 
INJECTIONS 
REMIFENTANIL HCL 
1MG/3ML 
1.000 AMPOULES ULTIVA REMIFENTANIL 
325 33 HYDROMORPHONE 
ORAL 
HYDROMORPHONE 
HCL 1MG/1ML 
(473ML) 
473.000 BOTTLE DILAUDID O-LIQ HYDROMORPHONE 
324 5 MORPHINE ORAL MORPHINE HCL 
MIXTURE 1MG/ML 
(200ML) 
200.000 BOTTLE ORDINE MORPHINE 
323 80 OPIUM ORAL OPIUM TINCTURE 
(100ML) 
.500 BOTTLE FOXLEE LINCTUS OPIUM 
322 5 MORPHINE ORAL MORPHINE HCL 
MIXTURE 5MG/ML 
(200ML) 
1000.000 BOTTLE ORDINE MORPHINE 
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321 74 ALFENTANIL 
INJECTIONS 
ALFENTANIL 
5MG/10ML 
5.000 AMPOULES RAPIFEN ALFENTANIL 
320 74 ALFENTANIL 
INJECTIONS 
ALFENTANIL 
1MG/2ML 
1.000 AMPOULES RAPIFEN ALFENTANIL 
319 11 OXYCODONE ORAL OXYCODONE HCL 
20MG 
20.000 CAPSULES OXYNORM OXYCODONE 
318 11 OXYCODONE ORAL OXYCODONE HCL 
10MG 
10.000 CAPSULES OXYNORM OXYCODONE 
317 38 BUPRENORPHINE 
SUB-LINGUAL 
BUPRENORPHINE 
SUB-LINGUAL 1MG 
(PROGRAM) 
1.000 MILLIGRAMS SUBUTEX BUPRENORPHINE 
316 11 OXYCODONE ORAL OXYCODONE HCL 
5MG 
5.000 CAPSULES OXYNORM OXYCODONE 
315 4 MORPHINE SLOW 
RELEASE ORAL 
MORPHINE 
SULPHATE (SR) 
120MG 
120.000 CAPSULES MS MONO MORPHINE 
314 4 MORPHINE SLOW 
RELEASE ORAL 
MORPHINE 
SULPHATE (SR) 
90MG 
90.000 CAPSULES MS MONO MORPHINE 
313 4 MORPHINE SLOW 
RELEASE ORAL 
MORPHINE 
SULPHATE (SR) 
60MG 
60.000 CAPSULES MS MONO MORPHINE 
312 4 MORPHINE SLOW 
RELEASE ORAL 
MORPHINE 
SULPHATE (SR) 
30MG 
30.000 CAPSULES MS MONO MORPHINE 
311 38 BUPRENORPHINE 
SUB-LINGUAL 
BUPRENORPHINE 
SUB-LINGUAL 8MG 
8.000 TABLETS SUBUTEX BUPRENORPHINE 
310 38 BUPRENORPHINE 
SUB-LINGUAL 
BUPRENORPHINE 
SUB-LINGUAL 2MG 
2.000 TABLETS SUBUTEX BUPRENORPHINE 
309 38 BUPRENORPHINE 
SUB-LINGUAL 
BUPRENORPHINE 
SUB-LINGUAL 0.4MG 
.400 TABLETS SUBUTEX BUPRENORPHINE 
308 4 MORPHINE SLOW 
RELEASE ORAL 
MORPHINE 
SULPHATE (SR) 
15MG 
15.000 TABLETS MS CONTIN MORPHINE 
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307 34 HYDROMORPHONE 
INJECTIONS 
HYDROMORPHONE 
HCL 500MG/50ML 
500.000 VIALS DILAUDID HYDROMORPHONE 
306 34 HYDROMORPHONE 
INJECTIONS 
HYDROMORPHONE 
HCL 50MG/5ML 
50.000 AMPOULES DILAUDID HYDROMORPHONE 
305 34 HYDROMORPHONE 
INJECTIONS 
HYDROMORPHONE 
HCL 10MG/ML 
10.000 AMPOULES DILAUDID HYDROMORPHONE 
304 33 HYDROMORPHONE 
ORAL 
HYDROMORPHONE 
HCL 8MG 
8.000 TABLETS DILAUDID HYDROMORPHONE 
303 33 HYDROMORPHONE 
ORAL 
HYDROMORPHONE 
HCL 4MG 
4.000 TABLETS DILAUDID HYDROMORPHONE 
302 33 HYDROMORPHONE 
ORAL 
HYDROMORPHONE 
HCL 2MG 
2.000 TABLETS DILAUDID HYDROMORPHONE 
301 31 FLUNITRAZEPAM 
ORAL 
FLUNITRAZEPAM 
1MG 
1.000 TABLETS ROHYPNOL, HYPNODORM BENZODIAZEPINE 
300 73 FENTANYL 
PATCHES 
FENTANYL 
PATCHES 100 
MCG/HR 16.8MG 
7.200 PATCHES DUROGESIC FENTANYL 
299 73 FENTANYL 
PATCHES 
FENTANYL 
PATCHES 75 
MCG/HR 12.6MG 
5.400 PATCHES DUROGESIC FENTANYL 
298 73 FENTANYL 
PATCHES 
FENTANYL 
PATCHES 50 
MCG/HR 8.4MG 
3.600 PATCHES DUROGESIC FENTANYL 
297 73 FENTANYL 
PATCHES 
FENTANYL 
PATCHES 25 
MCG/HR 4.2MG 
1.800 PATCHES DUROGESIC FENTANYL 
295 4 MORPHINE SLOW 
RELEASE ORAL 
MORPHINE 
SULPHATE (SR) 
200MG 
200.000 SACHETS MS CONTIN MORPHINE 
294 4 MORPHINE SLOW 
RELEASE ORAL 
MORPHINE 
SULPHATE (SR) 
100MG 
100.000 SACHETS MS CONTIN MORPHINE 
293 4 MORPHINE SLOW 
RELEASE ORAL 
MORPHINE 
SULPHATE (SR) 
60MG 
60.000 SACHETS MS CONTIN MORPHINE 
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290 69 OXYCODONE HCL 
CONTROLLED 
RELEASE ORAL 
OXYCODONE HCL 
(SR) 80MG 
80.000 TABLETS OXYCONTIN OXYCODONE 
289 69 OXYCODONE HCL 
CONTROLLED 
RELEASE ORAL 
OXYCODONE HCL 
(SR) 40MG 
40.000 TABLETS OXYCONTIN OXYCODONE 
288 69 OXYCODONE HCL 
CONTROLLED 
RELEASE ORAL 
OXYCODONE HCL 
(SR) 20MG 
20.000 TABLETS OXYCONTIN OXYCODONE 
287 69 OXYCODONE HCL 
CONTROLLED 
RELEASE ORAL 
OXYCODONE HCL 
(SR) 10MG 
10.000 TABLETS OXYCONTIN OXYCODONE 
286 4 MORPHINE SLOW 
RELEASE ORAL 
MORPH SULPHATE 
(SR) 10MG 
10.000 CAPSULES KAPANOL MORPHINE 
279 61 QUINALBARBITONE 
ORAL 
QUINALBARBITONE 
50MG 
50.000 CAPSULES SECONAL SODIUM BARBITURATE 
274 16 PETHIDINE 
INJECTIONS 
PETHIDINE HCL 
2500MG/50ML 
2500.000 VIALS NULL PETHIDINE 
272 16 PETHIDINE 
INJECTIONS 
PETHIDINE HCL 
75MG/1.5ML 
75.000 AMPOULES NULL PETHIDINE 
270 16 PETHIDINE 
INJECTIONS 
PETHIDINE HCL 
50MG/ML 
50.000 AMPOULES NULL PETHIDINE 
268 16 PETHIDINE 
INJECTIONS 
PETHIDINE HCL 
50MG/10ML 
50.000 AMPOULES NULL PETHIDINE 
267 16 PETHIDINE 
INJECTIONS 
PETHIDINE HCL 
50MG ATR SULPH 
0.6MG 1ML 
50.000 AMPOULES NULL PETHIDINE 
266 15 PETHIDINE ORAL PETHIDINE HCL 
50MG 
50.000 TABLETS NULL PETHIDINE 
265 16 PETHIDINE 
INJECTIONS 
PETHIDINE HCL 
25MG/1ML 
25.000 AMPOULES NULL PETHIDINE 
262 16 PETHIDINE 
INJECTIONS 
PETHIDINE HCL 
100MG/2ML 
100.000 AMPOULES NULL PETHIDINE 
260 16 PETHIDINE 
INJECTIONS 
PETH HCL 50MG 
PROMETH HCL 
50.000 AMPOULES NULL PETHIDINE 
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50MG HYOSC HBR 
.43MG 2ML 
259 16 PETHIDINE 
INJECTIONS 
PETH HCL 100MG 
PROMETH HCL 
50MG HYOSC HBR 
.43MG 2M 
100.000 AMPOULES NULL PETHIDINE 
258 16 PETHIDINE 
INJECTIONS 
PETH HCL 100MG 
PROMETH HCL 
25MG ATR SULPH 
.6MG 1ML 
100.000 AMPOULES NULL PETHIDINE 
257 NULL NULL PENTOBARBITONE 
SODIUM 50MG 
50.000 CAPSULES NEMBUTAL BARBITURATE 
256 NULL NULL PENTOBARB 
SODIUM 100MG 
100.000 CAPSULES CARBRITAL, NEMBUTAL, PENTONE BARBITURATE 
254 NULL NULL PENTOBARBITONE 
50MG 
50.000 TABLETS NULL BARBITURATE 
252 NULL NULL PENTOBARBITONE 
100MG 
100.000 TABLETS NULL BARBITURATE 
248 NULL NULL PENTAZOCINE BASE 
60MG/2ML 
60.000 AMPOULES FORTRAL PENTAZOCINE 
247 NULL NULL PENTAZOCINE BASE 
50MG 
50.000 TABLETS FORTRAL PENTAZOCINE 
245 NULL NULL PENTAZOCINE BASE 
30MG/ML 
30.000 AMPOULES FORTRAL PENTAZOCINE 
244 NULL NULL PENTAZOCINE BASE 
25MG 
25.000 TABLETS FORTRAL PENTAZOCINE 
243 NULL NULL PAPAVERETUM 
5MG/ML 
5.000 AMPOULES NULL PAPAVERETUM 
241 NULL NULL PAPAVERETUM 
20MG/ML 
20.000 AMPOULES NULL PAPAVERETUM 
240 42 PAPAVERETUM 
ORAL 
PAPAVERETUM 
20MG/ML 
20.000 MILLILITRES NULL PAPAVERETUM 
239 NULL NULL PAPAVERETUM 
20MG HYOSCINE 
20.000 AMPOULES NULL PAPAVERETUM 
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HYDROBROMIDE 
0.4MG 1ML 
238 NULL NULL PAPAVERETUM 
15MG/ML 
15.000 AMPOULES NULL PAPAVERETUM 
237 NULL NULL PAPAVERETUM 
10MG/ML 
10.000 AMPOULES NULL PAPAVERETUM 
235 42 PAPAVERETUM 
ORAL 
PAPAVERETUM 
10MG ORAL 
10.000 TABLETS OMNOPON PAPAVERETUM 
234 11 OXYCODONE ORAL OXYCODONE HCL 
5MG 
5.000 TABLETS ENDONE OXYCODONE 
233 11 OXYCODONE ORAL OXYCODONE HCL 
4.4MG TEREPHTH 
.38MG 
4.400 TABLETS PERCODAN OXYCODONE 
231 12 OXYCODONE 
SUPPOSITORIES 
OXYCODONE BASE 
30MG 
30.000 SUPPOSITORIES PROLADONE OXYCODONE 
230 13 OXYCODONE 
INJECTIONS 
OXYCODONE HCL 
10MG/ML 
10.000 AMPOULES OXYNORM OXYCODONE 
228 80 OPIUM ORAL OPIUM TINCTURE 1.000 MILLILITRES NULL OPIUM 
225 75 NORMETHADONE 
ORAL 
NORMETHADONE 
HCL 1% (TICARDA 
DROPS) 
.010 MILLILITRES NULL NORMETHADONE 
223 NULL NULL PENTOBARBITONE 
SODIUM 30MG 
30.000 TABLETS NEMBUDEINE, PENTALGIN BARBITURATE 
222 6 MORPHINE 
INJECTIONS 
MORPHINE 
TARTRATE 
120MG/1.5ML 
120.000 AMPOULES NULL MORPHINE 
220 5 MORPHINE ORAL MORPHINE 
SULPHATE 
SOLUTION 10MG/ML 
10.000 MILLILITRES NULL MORPHINE 
218 6 MORPHINE 
INJECTIONS 
MORPHINE 
SULPHATE 5MG/ML 
5.000 AMPOULES NULL MORPHINE 
217 6 MORPHINE 
INJECTIONS 
MORPHINE 
SULPHATE 30MG/ML 
30.000 AMPOULES NULL MORPHINE 
216 5 MORPHINE ORAL MORPHINE 
SULPHATE 30MG 
30.000 TABLETS ANAMORPH MORPHINE 
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215 6 MORPHINE 
INJECTIONS 
MORPHINE 
SULPHATE 15MG/ML 
15.000 AMPOULES NULL MORPHINE 
214 6 MORPHINE 
INJECTIONS 
MORPHINE 
SULPHATE 15MG 
ATROPINE 
SULPHATE 0.6MG 
1ML 
15.000 AMPOULES NULL MORPHINE 
213 6 MORPHINE 
INJECTIONS 
MORPHINE 
SULPHATE 10MG/ML 
10.000 AMPOULES NULL MORPHINE 
212 4 MORPHINE SLOW 
RELEASE ORAL 
MORPHINE 
SULPHATE (SR) 
60MG 
60.000 TABLETS MS CONTIN, MOMEX MORPHINE 
211 4 MORPHINE SLOW 
RELEASE ORAL 
MORPHINE 
SULPHATE (SR) 
30MG 
30.000 TABLETS MS CONTIN, MOMEX MORPHINE 
210 4 MORPHINE SLOW 
RELEASE ORAL 
MORPHINE 
SULPHATE (SR) 5MG 
5.000 TABLETS MS CONTIN MORPHINE 
209 4 MORPHINE SLOW 
RELEASE ORAL 
MORPHINE 
SULPHATE (SR) 
10MG 
10.000 TABLETS MS CONTIN, MOMEX MORPHINE 
208 4 MORPHINE SLOW 
RELEASE ORAL 
MORPHINE 
SULPHATE (SR) 
100MG 
100.000 TABLETS MS CONTIN, MOMEX MORPHINE 
207 6 MORPHINE 
INJECTIONS 
MORPHINE 
SULPHATE 10MG & 
ATROPINE 
SULPHATE 0.6MG 
10.000 AMPOULES NULL MORPHINE 
206 4 MORPHINE SLOW 
RELEASE ORAL 
MORPHINE 
SULPHATE (SR) 
50MG 
50.000 CAPSULES KAPANOL MORPHINE 
205 4 MORPHINE SLOW 
RELEASE ORAL 
MORPHINE 
SULPHATE (SR) 
20MG 
20.000 CAPSULES KAPANOL MORPHINE 
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204 4 MORPHINE SLOW 
RELEASE ORAL 
MORPHINE 
SULPHATE (SR) 
100MG 
100.000 CAPSULES KAPANOL MORPHINE 
203 4 MORPHINE SLOW 
RELEASE ORAL 
MORPHINE 
SULPHATE (SR) 
20MG 
20.000 SACHETS MS CONTIN MORPHINE 
202 4 MORPHINE SLOW 
RELEASE ORAL 
MORPHINE 
SULPHATE (SR) 
30MG 
30.000 SACHETS MS CONTIN MORPHINE 
201 4 MORPHINE SLOW 
RELEASE ORAL 
MORPHINE 
SULPHATE (SR) 
200MG 
200.000 TABLETS MS CONTIN MORPHINE 
200 5 MORPHINE ORAL MORPHINE LINCTUS .000 BOTTLE MORPHINE LINCTUS MORPHINE 
198 5 MORPHINE ORAL MORPHINE HCL 
MIXTURE 4MG/ML 
4.000 MILLILITRES NULL MORPHINE 
197 5 MORPHINE ORAL MORPHINE HCL 
MIXTURE 2MG/ML 
(200ML) 
400.000 BOTTLE ORDINE MORPHINE 
196 5 MORPHINE ORAL MORPHINE HCL 
MIXTURE 10MG/ML  
(200ML) 
2000.000 BOTTLE ORDINE MORPHINE 
195 5 MORPHINE ORAL MORPHINE HCL 5MG 
ASPIRIN 250MG 
(SOLUBLE) 
5.000 TABLETS NULL MORPHINE 
192 5 MORPHINE ORAL MORPHINE 30MG 
TACRINE 15MG 
30.000 TABLETS MORTHA MORPHINE 
189 5 MORPHINE ORAL MORPHINE 15MG 
TACRINE 30MG 
1.5ML 
30.000 AMPOULES MORTHA NO 3 MORPHINE 
186 25 METHYLPHENIDATE 
INJECTIONS 
METHYLPHENIDATE 
HCL 20MG 
20.000 AMPOULES RITALIN AMPHETAMINE 
185 24 METHYLPHENIDATE 
ORAL 
METHYLPHENIDATE 
HCL 10MG 
10.000 TABLETS RITALIN, ATTENTA, LORENTIN AMPHETAMINE 
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183 1 METHADONE LIQUID METHADONE HCL 
SYRUP 5MG/ML 
(PROGRAM) 
5.000 MILLILITRES NULL METHADONE 
182 8 METHADONE ORAL METHADONE HCL 
5MG 
5.000 TABLETS PHYSEPTONE METHADONE 
181 8 METHADONE ORAL METHADONE HCL 
2MG/5ML (500ML) 
200.000 BOTTLE PHYSEPTONE LINCTUS METHADONE 
180 9 METHADONE 
INJECTIONS 
METHADONE HCL 
10MG/ML 
10.000 AMPOULES PHYSEPTONE METHADONE 
179 8 METHADONE ORAL METHADONE HCL 
10MG 
10.000 TABLETS PHYSEPTONE METHADONE 
177 80 OPIUM ORAL KAOLIN & OPIUM 
MIXTURE (200ML) 
.000 BOTTLE NULL OPIUM 
176 34 HYDROMORPHONE 
INJECTIONS 
HYDROMORPHONE 
HCL 2MG/ML 
2.000 AMPOULES DILAUDID HYDROMORPHONE 
175 33 HYDROMORPHONE 
ORAL 
HYDROMORPHONE 
HCL 2.5MG 
2.500 TABLETS DILAUDID HYDROMORPHONE 
169 31 FLUNITRAZEPAM 
ORAL 
FLUNITRAZEPAM 
2MG 
2.000 TABLETS ROHYPNOL, HYPNODORM BENZODIAZEPINE 
168 30 FENTANYL 
INJECTIONS 
FENTANYL CITRATE 
100MCG/20ML 
.100 VIALS SUBLIMAZE FENTANYL 
166 30 FENTANYL 
INJECTIONS 
FENTANYL CITRATE 
500MCG/10ML 
.500 AMPOULES SUBLIMAZE 500MCG/10ML OR 
0.5MG/10ML 
FENTANYL 
164 30 FENTANYL 
INJECTIONS 
FENTANYL CITRATE 
.157MG/2ML 
DROPERIDOL 
5MG/2ML 2ML 
.157 AMPOULES NULL FENTANYL 
163 30 FENTANYL 
INJECTIONS 
FENTANYL CITRATE 
100MCG/2ML 
.100 AMPOULES SUBLIMAZE 100MCG/2ML OR 0.1MG/2ML FENTANYL 
151 NULL NULL DIAMORPHINE HCL 
10MG/ML 
10.000 AMPOULES HEROIN OTHER 
149 28 DEXTROMORAMIDE 
INJECTIONS 
DEXTROMORAMIDE 
BASE 5MG/ML 
5.000 AMPOULES PALFIUM DEXTROMORAMIDE 
148 26 DEXTROMORAMIDE 
ORAL 
DEXTROMORAMIDE 
BASE 5MG 
5.000 TABLETS PALFIUM DEXTROMORAMIDE 
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147 27 DEXTROMORAMIDE 
SUPPOSITORIES 
DEXTROMORAMIDE 
BASE 10MG 
10.000 SUPPOSITORIES PALFIUM DEXTROMORAMIDE 
145 18 DEXAMPHETAMINE 
ORAL 
DEXAMPHETAMINE 
SULPHATE 5MG 
5.000 TABLETS NULL AMPHETAMINE 
144 18 DEXAMPHETAMINE 
ORAL 
DEXAMPHETAMINE 
SULPHATE 15MG 
15.000 CAPSULES NULL AMPHETAMINE 
142 18 DEXAMPHETAMINE 
ORAL 
DEXAMPHETAMINE 
SULPHATE 10MG 
10.000 CAPSULES CUSTOM COMPOUNDING AMPHETAMINE 
140 22 CODEINE 
INJECTIONS 
CODEINE 
PHOSPHATE 
50MG/1ML 
50.000 AMPOULES NULL CODEINE 
139 21 CODEINE ORAL CODEINE 
PHOSPHATE 30MG 
30.000 TABLETS NULL CODEINE 
138 23 CODEINE POWDER CODEINE 
PHOSPHATE 
1000.000 GRAMS NULL CODEINE 
137 NULL NULL COCAINE NASAL 
GEL 5% 
.050 GRAMS COCAINE NASAL GEL 5% COCAINE 
136 62 COCAINE 
SOLUTION/GEL 
COCAINE HCL 
SOLUTION/GEL 10% 
.100 MILLILITRES COCAINE HCL SOLUTION/GEL 10% COCAINE 
135 62 COCAINE 
SOLUTION/GEL 
COCAINE HCL 
SOLUTION/GEL 0.5% 
.005 MILLILITRES COCAINE HCL SOLUTION/GEL 0.5% COCAINE 
134 62 COCAINE 
SOLUTION/GEL 
COCAINE HCL 
SOLUTION/GEL 3% & 
ADRENALINE 
.030 MILLILITRES COCAINE HCL SOLUTION/GEL 3% & 
ADRENALINE 
COCAINE 
133 62 COCAINE 
SOLUTION/GEL 
COCAINE HCL 
SOLUTION/GEL 5% 
.050 MILLILITRES COCAINE HCL SOLUTION/GEL 5% COCAINE 
132 62 COCAINE 
SOLUTION/GEL 
COCAINE HCL 
SOLUTION/GEL 4% 
.040 MILLILITRES COCAINE HCL SOLUTION/GEL 4% COCAINE 
131 62 COCAINE 
SOLUTION/GEL 
COCAINE HCL 
SOLUTION/GEL 2% 
.020 MILLILITRES COCAINE HCL SOLUTION/GEL 2% COCAINE 
130 62 COCAINE 
SOLUTION/GEL 
COCAINE HCL 
SOLUTION/GEL 1% 
.010 MILLILITRES COCAINE HCL SOLUTION/GEL 1% COCAINE 
128 65 COCAINE 
INJECTIONS 
COCAINE HCL 
5MG/0.3ML 
5.000 AMPOULES COCAINE HCL 5MG/0.3ML COCAINE 
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126 65 COCAINE 
INJECTIONS 
COCAINE HCL 4% 
1ML 
4.000 AMPOULES COCAINE HCL 4% 1ML COCAINE 
122 62 COCAINE 
SOLUTION/GEL 
COCAINE HCL 15MG 
& MORPHINE HCL 
15MG/10ML 
15.000 MILLILITRES COCAINE HCL 15MG & MORPHINE HCL 
15MG/10ML 
COCAINE 
119 64 COCAINE POWDER COCAINE HCL 
POWDER 1000MG 
1000.000 GRAMS COCAINE HCL POWDER 1000MG COCAINE 
116 57 BUTOBARBITONE 
ORAL 
BUTOBARBITONE 
100MG 
100.000 TABLETS SONABARB BARBITURATE 
115 NULL NULL BUTOBARBITONE 
1000G 
1000.000 GRAMS NULL BARBITURATE 
114 38 BUPRENORPHINE 
SUB-LINGUAL 
BUPRENORPHINE 
SUB-LINGUAL 0.2MG 
.200 TABLETS TEMGESIC BUPRENORPHINE 
113 39 BUPRENORPHINE 
INJECTIONS 
BUPRENORPHINE 
HCL 0.6MG/2ML 
.600 AMPOULES TEMGESIC BUPRENORPHINE 
112 39 BUPRENORPHINE 
INJECTIONS 
BUPRENORPHINE 
HCL 0.3MG/ML 1ML 
.300 AMPOULES TEMGESIC BUPRENORPHINE 
111 NULL NULL BROMPTONS 
MIXTURE 
.000 MILLILITRES BROMPTONS MIXTURE OTHER 
110 54 AMYLOBARBITONE 
ORAL 
AMYLOBARBITONE 
50MG 
50.000 CAPSULES NEUR-AMYL/AMYTAL SODIUM 50MG BARBITURATE 
108 54 AMYLOBARBITONE 
ORAL 
AMYLOBARBITONE 
50MG 
50.000 TABLETS AMYTAL, NEUR-AMYL BARBITURATE 
107 54 AMYLOBARBITONE 
ORAL 
AMYLOBARBITONE 
30MG 
30.000 TABLETS AMYTAL, NEUR-AMYL BARBITURATE 
105 54 AMYLOBARBITONE 
ORAL 
AMYLOBARBITONE 
100MG 
100.000 TABLETS AMYTAL BARBITURATE 
101 20 DEXAMPHETAMINE 
POWDER 
AMPHETAMINE 
SULPHATE 
1000.000 GRAMS AMPHETAMINE SULPHATE AMPHETAMINE 
100 54 AMYLOBARBITONE 
ORAL 
AMESEC 25MG 25.000 CAPSULES NULL BARBITURATE 
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Appendix H: Two-Step Cluster Analysis results 
 
SPSS for Windows results output from Two-Step Cluster Analysis 
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Page 1
Misuse of Pharmaceutical Opioid Drugs: Doctor Shopping Behaviour
The electronic monitoring of, and 'real­time reporting' of prescriptions of pharmaceutical opioid drugs is widely 
recognised as one means of reducing misuse and increasing appropriate use of this class of drugs. This information 
can be used to inform health practitioners to guide their decisions where possible aberrant drugs use is detected. 
 
Substance use disorders (abuse & dependence) in relation to pharmaceutical opioids are poorly understood. There is 
diversity of opinion about what use constitutes problematic use and what is appropriate treatment in chronic opioid 
therapy. 
 
Clinical diagnoses of substance use disorders are undertaken by health practitioners in their face to face assessment 
of patients, based on a range of criteria. 
 
The use of prescription information, in the absence of clinical information, might not on its own be sufficient to allow 
clinicians to arrive at conclusions about a person's potential drug misuse.  
 
However, database information derived from patterns of prescription events across populations, could be used to 
assist health practitioners in making better informed decisions on an individual's potentially problematic medication 
use. 
 
This study seeks to obtain information from clinical experts,such as yourself, in regards to their experience with 
treatment of persons with pharmaceutical opioids where problematic use has occurred. The purpose is to derive 
methods to potentially assess, detect and predict, aberrant prescription opioid drug use behaviour that might be 
indicative of substance use disorders using a prescription monitoring program.  
 
Participation will involve completing three rounds of a questionnaire based on the Delphi Technique. That is, the 
survey will be conducted in three iterations, where the results of the previous rounds will be reported back to you for 
further feedback. This is to obtain a convergence of opinion in defining this behaviour of concern. The questions will 
involve matters relating to opinions about dependence on and management with opioid analgesic drugs. 
 
It is anticipated that the first survey should take at the maximum 30 minutes to complete, and further iterations will 
take less time. Second and third round questionnaires will be circulated within 3 weeks of the completion of each 
questionnaire. 
 
This first study involves four separate but related surveys, on the following topics: 
 
1. Utility of DSM­IV criteria in assessing substance use disorders involving pharmaceutical opioids; 
2. Ratings of the harmfulness of pharmaceutical opioid drugs; 
3. Assessment of risk factors for persons with substance use disorders related to prescription opioids; and, 
4. Questions on prescription or doctor shopping definitions. 
1. This study has obtained Ethics Approval of Queensland Health & Queensland 
University of Technology, 
 
Do you wish to read the full copy of Participant Information of this Research Project? 
Misuse of Pharmaceutical Opioid Analgesic Drugs: Doctor shopping behaviour. 
Queensland Health Ethics Approval Number HREC/11/QHC/1 
QUT Ethics Approval Number 1100000526 
 
1. Introduction
 
2. Participant Information for QUT Research Project
Yes, I wish to read the Participant Information
 
nmlkj
No, I am happy to proceed with the survey
 
nmlkj
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RESEARCH TEAM  
Principal Researcher: Bill Loveday, Doctor of Health Science student, QUT 
 
Associate Researcher: Dr Kirsten McKenzie, Deputy Director & Senior Research Fellow 
National Health Information Research & Training 
Queensland University of Technology. 
DESCRIPTION 
This project is being undertaken as part of a research project as part of a Doctor of Health Science degree for the Principal Researcher with the 
Queensland University of Technology.  
 
This study is being done to learn more about dependence on, and misuse of, pharmaceutical opioid analgesic drugs and the phenomenon of 
drug seeking known as ‘doctor shopping’. There is a diversity of opinion across various stakeholders as to what constitutes misuse or 
inappropriate management with this class of drugs. The purpose of this project is to obtain a range of specialist opinions in regards to the 
determining definitions of drug dependence or abuse on pharmaceutical opioid analgesic drugs via measures of an individual’s drug seeking 
and other behaviour.  
 
The research team requests your assistance because of your interest in the field of drug dependence or chronic pain management. 
PARTICIPATION 
Your participation in this project is entirely voluntary. If you do agree to participate, you can withdraw from the project at any time without 
comment or penalty. Any identifiable information already obtained from you will be destroyed. Your decision to participate, or not participate, 
will in no way impact upon your current or future relationship with QUT or with Queensland Health. 
 
Participation will involve completing multiple rounds of a questionnaire based on the Delphi Technique. That is, the survey will be conducted 
in three iterations, where the results of the previous rounds will be reported back to you for further feedback. This is to obtain a convergence of 
opinion in defining this behaviour of concern. The questions will involve matters relating to opinions about dependence on and management 
with opioid analgesic drugs. 
 
It is anticipated that the first survey should take at the maximum 30 minutes to complete, and further iterations will take less time. Second and 
third round questionnaires will be circulated within 3 weeks of the completion of each questionnaire. 
 
If you agree to participate you do not have to complete any questions that you are uncomfortable answering. 
EXPECTED BENEFITS 
It is not expected that this project will directly benefit you. However, it will assist improving knowledge in the field of this growing public health 
concern in Australia. 
 
You will not be recompensed for your participation however the results will be made available to you on completion of the project. 
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RISKS 
There are no risks beyond normal day­to­day living associated with your participation in this project. 
 
PRIVACY AND CONFIDENTIALITY 
All comments and responses will be treated confidentially and will be made anonymous for analysis and feedback. The names of individual 
persons are not required in any of the responses.Please note that non­identifiable data collected in this project may be used as comparative 
data in future projects. 
 
CONSENT TO PARTICIPATE 
Submitting the completed online questionnaire is accepted as an indication of your consent to participate in this project. 
 
QUESTIONS / FURTHER INFORMATION ABOUT THE PROJECT 
If have any questions or require any further information please contact one of the research team members below. 
 
Bill Loveday ­ DHS Student 
School of Public Health 
Phone : 61+ 7 0419 782 846 
Email : bill.loveday@student.qut.edu.au  
 
Dr Kirsten McKenzie ­ Principal Supervisor 
Faculty of Health ­ QUT Deputy Director & Senior Research Fellow 
National Health Information Research & Training 
School of Public Health ­ QUT 
Phone : 61+ 7 3138 9753 
Email : k.mckenzie@qut.edu.au  
 
 
*Please note that Mr Loveday is also a Queensland Health employee and works for the Drugs of Dependence Unit. This Unit has legislative 
responsibilities in monitoring activity and compliance with legislation in regards to the use of opioid analgesic drugs in the state of 
Queensland. 
 
CONCERNS / COMPLAINTS REGARDING THE CONDUCT OF THE PROJECT 
Both Queensland Health and QUT are committed to research integrity and the ethical conduct of research projects. If you do have any 
concerns or complaints about the ethical conduct of the project you may contact either Queensland Health Research & Ethics Governance 
Unit on +61 7 3234 0654 or email regu@health.qld.gov.au quoting approval number: HREC/11/QHC/1. However, you may also contact you 
may contact the QUT Research Ethics Unit on +61 7 3138 5123 or email ethicscontact@qut.edu.au quoting approval 1100000526. 
 
Both the Queensland Health Research & Ethics Governance Unit and the QUT Research Ethics Unit are not connected with the research 
project and can facilitate a resolution to your concern in an impartial manner. 
1. Thank you for helping with this research project. A copy of this Participant 
Information can be sent you if required. Please indicate below if you wish a copy sent to 
your email address. 
The DSM­IV (TR) defines substance dependence as a maladaptive pattern of substance use leading to clinically 
significant impairment or distress, as manifested by three or more, of seven, criteria occurring any time in the same 
12­month period. 
 
Substance abuse is defined as a maladaptive pattern of substance use leading to clinically significant impairment or 
distress as manifested by one (or more), of four, criteria occurring within a 12­month period. 
 
 
3. Diagnostic Criteria for Pharmaceutical Opioid Substance Use Disorders
Yes, please send me a copy of the Participant Information.
 
nmlkj
No thank you, I do not require a copy.
 
nmlkj
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There are concerns that the DSM­IV(TR) definitions of substance use disorders using these criteria, might be less 
applicable in diagnosing cases of dependence on, or abuse of, pharmaceutical opioids. 
 
In general there appears to be a lack of consistency in the clinical assessment of problematic use of pharmaceutical 
opioids, due to the long­term therapeutic application of opioids in the treatment of chronic pain conditions.  
 
Each of the following criteria are based on DSM­IV criteria for substance dependence and abuse. The following 
questions seek your views, as an expert, on the importance of each criteria in defining pharmaceutical opioid 
dependence and abuse. 
 
Please indicate for each of the following criteria how importance you believe it is in determining that an individual 
suffers from a substance use disorder due to their use of pharmaceutical opioid drugs.  
 
It would be appreciated if you could also give your reasons as to why you rated each criteria as you did. 
1. How important is evidence of tolerance in assessing a person for substance use 
disorders on pharmaceutical opioid drugs? 
2. How important is evidence of withdrawal symptoms in assessing a person for 
substance use disorders on pharmaceutical opioid drugs? 
*
*
Very important
 
nmlkj
Important
 
nmlkj
Moderately important
 
nmlkj
Of little importance
 
nmlkj
Unimportant
 
nmlkj
Can you please explain your reasons for the above response. 
5
6
Very important
 
nmlkj
Important
 
nmlkj
Moderately important
 
nmlkj
Of little importance
 
nmlkj
Unimportant
 
nmlkj
Can you please explain your reasons for the above response. 
5
6
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3. How important is the amount of drug being taken, in assessing a person for 
substance use disorders on pharmaceutical opioid drugs? 
4. How important are attempts to reduce or control drug use, in assessing a person 
for substance use disorders on pharmaceutical opioid drugs? 
5. How important is time spent in obtaining drugs, in assessing a person for 
substance use disorders on pharmaceutical opioid drugs? 
*
*
*
Very important
 
nmlkj
Important
 
nmlkj
Moderately important
 
nmlkj
Of little importance
 
nmlkj
Unimportant
 
nmlkj
Can you please explain your reasons for the above response. 
5
6
Very important
 
nmlkj
Important
 
nmlkj
Moderately important
 
nmlkj
Of little importance
 
nmlkj
Unimportant
 
nmlkj
Can you please explain your reasons for the above response. 
5
6
Very important
 
nmlkj
Important
 
nmlkj
Moderately important
 
nmlkj
Of little importance
 
nmlkj
Unimportant
 
nmlkj
Can you please explain your reasons for the above response. 
5
6
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6. How important are the effects of drugs use on social, occupational, or recreational 
activities, in assessing a person for substance use disorders on pharmaceutical opioid 
drugs? 
7. How important is continued drug use despite health or psychological effects, in 
assessing a person for substance use disorders on pharmaceutical opioid drugs? 
*
*
Very important
 
nmlkj
Important
 
nmlkj
Moderately important
 
nmlkj
Of little importance
 
nmlkj
Unimportant
 
nmlkj
Can you please explain your reasons for the above response. 
5
6
Very important
 
nmlkj
Important
 
nmlkj
Moderately important
 
nmlkj
Of little importance
 
nmlkj
Unimportant
 
nmlkj
Can you please explain your reasons for the above response. 
5
6
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8. How important are the drug use effects on work, school or home obligations, in 
assessing a person for substance use disorders on pharmaceutical opioid drugs? 
9. How important is drug use use in hazardous situations, in assessing a person for 
substance use disorders on pharmaceutical opioid drugs? 
10. How important are drug­related legal problems, in assessing a person for 
substance use disorders on pharmaceutical opioid drugs? 
*
*
*
Very important
 
nmlkj
Important
 
nmlkj
Moderately important
 
nmlkj
Of little importance
 
nmlkj
Unimportant
 
nmlkj
Can you please explain your reasons for the above response. 
5
6
Very important
 
nmlkj
Important
 
nmlkj
Moderately important
 
nmlkj
Of little importance
 
nmlkj
Unimportant
 
nmlkj
Can you please explain your reasons for the above response. 
5
6
Very important
 
nmlkj
Important
 
nmlkj
Moderately important
 
nmlkj
Of little importance
 
nmlkj
Unimportant
 
nmlkj
Can you please explain your reasons for the above response. 
5
6
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11. How important are social or interpersonal problems, in assessing a person for 
substance use disorders on pharmaceutical opioid drugs? 
12. Are there any other criteria or behaviour you believe might also be important in 
determining inappropriate use of pharmaceutical opioid drugs? 
 
The assessment of the harms of certain drugs, can take into account the physical harms caused by continued use, 
the potential for a drug to cause dependence, and the social harms caused by use. 
 
Physical harms refer to the propensity of drugs to cause damage to organs or systems or have negative effects on 
physiological functions, eg, respiratory or cardiac. 
 
Dependence potential of a drug is related to the interaction between its pleasurable effects and propensity to produce 
dependent behaviour or be abused. 
 
Social harms related to drugs relate to various effects of intoxication, through damaging family and social life and 
associated costs with health care, social care and legal responses. 
 
Pharmaceutical opioid drugs are produced in different forms, preparations and are designed for various particular 
routes of administration.  
 
Please consider which pharmaceutical opioid drugs you believe are more harmful than others, and what reasons you 
think this might be so. 
1. What pharmaceutical opioid drugs do you believe are the most prone to cause 
physical harm?  
 
*
5
6
 
4. Harmfulness of pharmaceutical opioid drugs
*
5
6
Very important
 
nmlkj
Important
 
nmlkj
Moderately important
 
nmlkj
Of little importance
 
nmlkj
Unimportant
 
nmlkj
Can you please explain your reasons for the above response. 
5
6
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2. What pharmaceutical opioid drugs do you believe are the most prone to cause 
dependence?  
 
3. What pharmaceutical opioid drugs do you believe are the most prone to be 
abused?  
 
4. What pharmaceutical opioid drugs do you believe are the most prone to cause 
social harms?  
 
5. What do you believe are some of the features of pharmaceutical opioid drugs that 
might contribute to their potential for harm? 
 
6. What do you believe are some of the features of pharmaceutical opioid drugs that 
might reduce their potential for harm? 
 
7. What other reasons do you believe some pharmaceutical opioid drugs might be more 
harmful than others? 
 
The biopsychosocial model suggests that complex interactions between various biological, psychological and social 
factors contribute to the development of substance use disorders. 
 
Biological factors can refer to genetic vulnerability to risk factors for drug use, vulnerability to pharmacological effects 
*
5
6
*
5
6
*
5
6
*
5
6
5
6
5
6
 
5. Individual Risk Factors
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of drugs, and the actual pharmacological effects of drugs. 
 
Psychological factors often relate to learning and conditioning, self­concept, cultural and spiritual beliefs,  
stress and coping style, and mental health. 
 
Social factors refer to social, cultural, economic and environmental, risk and protective factors (including normative 
influences, social networks and social identity). 
 
Within these categories, what factors do you believe are most relevant in the development of a substance use 
disorder related to pharmaceutical opioid drugs? 
'Doctor shopping' or 'prescription shopping' is broadly defined as a person who is attending multiple doctors and 
obtaining multiple prescriptions over a certain time for certain drugs. 
1. What biological factors do you believe are most relevant in the 
development of a substance use disorder related to pharmaceutical 
opioid drugs? 
 
*
5
6
2. What psychological factors do you believe are most relevant in 
the development of a substance use disorder related to 
pharmaceutical opioid drugs? 
 
*
5
6
3. What social or cultural factors do you believe are most relevant in 
the development of a substance use disorder related to 
pharmaceutical opioid drugs? 
 
*
5
6
4. What other factors do you believe are most relevant in the 
development of a substance use disorder related to pharmaceutical 
opioid drugs? 
 
*
5
6
 
6. Drug seeking behaviour
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1. What do you understand by the term 'doctor shopping' or 'prescription shopping' in 
the context of potential misuse of pharmaceutical medications? 
 
2. What extent (frequency of consultations, prescriptions obtained, volume of drug 
obtained, over what time period) of doctor/prescription shopping do you believe would 
suggest a person is suffering from a substance use disorder? 
 
3. Are there any other features of doctor/prescription shopping that you believe that 
are relevant in considering whether a person suffering from a substance use disorder? 
 
1. Please provide the following information about your professional practice. 
5
6
*
5
6
*
5
6
 
7. Demographic & Background Information
Yes No
Do you primarily work in 
field of drug dependence?
nmlkj nmlkj
Do you primarily work in 
the field of pain 
management?
nmlkj nmlkj
Are you a registered 
medical practitioner?
nmlkj nmlkj
Are you a registered nurse 
or allied health 
practitioner?
nmlkj nmlkj
Do you work in a hosptial? nmlkj nmlkj
Do you work in private 
practice?
nmlkj nmlkj
Do you work in a university 
or research facilitiy?
nmlkj nmlkj
Do you undertake research 
in this field?
nmlkj nmlkj
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2. Can you please provide details of your professional qualifications and affiliations. 
3. Are you male or female? 
4. Which category below includes your age? 
5. Please provide the following information for the purposes of our response 
tracking. 
Thank you for participation in the first round of this survey. All participants responses will be collated and merged and 
returned to you for further feedback. 
*
Degrees
Professional 
associations
Current 
position
Years in 
practice
Location 
(urban, 
rural, 
remote)
*
Name:
Institution/Agency
City/Town:
State/Province:
ZIP/Postal Code:
Country:
Email Address:
Phone Number:
 
8. The next round
Male
 
nmlkj
Female
 
nmlkj
17 or younger
 
nmlkj
18­20
 
nmlkj
21­29
 
nmlkj
30­39
 
nmlkj
40­49
 
nmlkj
50­59
 
nmlkj
60 or older
 
nmlkj
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1. Do you agree to participate in the second round of this study? 
YES
 
nmlkj NO
 
nmlkj
Page 1
ROUND 2 - Misuse of Pharmaceutical Opioid Drugs: Doctor Shopping
You previously participated in Round 1 of this survey regarding issues of misuse of pharmaceutical opioids. 
 
In completing Round 1 you also agreed to further participate in the following 2 rounds of the survey. 
 
This study is using the Delphi Technique to collate and consider a range of expert opinions in this area. This 
technique involves feedback you participants of the total group results from the first survey and your own results to 
determine to ascertain if you would reconsider your answer on this based on the group's average response. 
 
Once you have responded I will then feedback the results for a final time to see if you wish to reconsider any of your 
response for the second time based on the groups amended second round responses.  
 
 
1. Introduction
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Misuse of Pharmaceutical Opioid Analgesic Drugs: Doctor shopping behaviour. 
Queensland Health Ethics Approval Number HREC/11/QHC/1 
QUT Ethics Approval Number 1100000526 
RESEARCH TEAM  
Principal Researcher: Bill Loveday, Doctor of Health Science student, QUT 
 
Associate Researcher: Dr Kirsten McKenzie, Deputy Director & Senior Research Fellow 
National Health Information Research & Training 
Queensland University of Technology. 
DESCRIPTION 
This project is being undertaken as part of a research project as part of a Doctor of Health Science degree for the Principal Researcher with the 
Queensland University of Technology.  
 
This study is being done to learn more about dependence on, and misuse of, pharmaceutical opioid analgesic drugs and the phenomenon of 
drug seeking known as ‘doctor shopping’. There is a diversity of opinion across various stakeholders as to what constitutes misuse or 
inappropriate management with this class of drugs. The purpose of this project is to obtain a range of specialist opinions in regards to the 
determining definitions of drug dependence or abuse on pharmaceutical opioid analgesic drugs via measures of an individual’s drug seeking 
and other behaviour.  
 
The research team requests your assistance because of your interest in the field of drug dependence or chronic pain management. 
PARTICIPATION 
Your participation in this project is entirely voluntary. If you do agree to participate, you can withdraw from the project at any time without 
comment or penalty. Any identifiable information already obtained from you will be destroyed. Your decision to participate, or not participate, 
will in no way impact upon your current or future relationship with QUT or with Queensland Health. 
 
Participation will involve completing multiple rounds of a questionnaire based on the Delphi Technique. That is, the survey will be conducted 
in three iterations, where the results of the previous rounds will be reported back to you for further feedback. This is to obtain a convergence of 
opinion in defining this behaviour of concern. The questions will involve matters relating to opinions about dependence on and management 
with opioid analgesic drugs. 
 
It is anticipated that the first survey should take at the maximum 30 minutes to complete, and further iterations will take less time. Second and 
third round questionnaires will be circulated within 3 weeks of the completion of each questionnaire. 
 
If you agree to participate you do not have to complete any questions that you are uncomfortable answering. 
EXPECTED BENEFITS 
It is not expected that this project will directly benefit you. However, it will assist improving knowledge in the field of this growing public health 
concern in Australia. 
 
You will not be recompensed for your participation however the results will be made available to you on completion of the project. 
 
2. Participant Information for QUT Research Project
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RISKS 
There are no risks beyond normal day­to­day living associated with your participation in this project. 
 
PRIVACY AND CONFIDENTIALITY 
All comments and responses will be treated confidentially and will be made anonymous for analysis and feedback. The names of individual 
persons are not required in any of the responses.Please note that non­identifiable data collected in this project may be used as comparative 
data in future projects. 
 
CONSENT TO PARTICIPATE 
Submitting the completed online questionnaire is accepted as an indication of your consent to participate in this project. 
 
QUESTIONS / FURTHER INFORMATION ABOUT THE PROJECT 
If have any questions or require any further information please contact one of the research team members below. 
 
Bill Loveday ­ DHS Student 
School of Public Health 
Phone : 61+ 7 0419 782 846 
Email : bill.loveday@student.qut.edu.au  
 
Dr Kirsten McKenzie ­ Principal Supervisor 
Faculty of Health ­ QUT Deputy Director & Senior Research Fellow 
National Health Information Research & Training 
School of Public Health ­ QUT 
Phone : 61+ 7 3138 9753 
Email : k.mckenzie@qut.edu.au  
 
 
*Please note that Mr Loveday is also a Queensland Health employee and works for the Drugs of Dependence Unit. This Unit has legislative 
responsibilities in monitoring activity and compliance with legislation in regards to the use of opioid analgesic drugs in the state of 
Queensland. 
 
CONCERNS / COMPLAINTS REGARDING THE CONDUCT OF THE PROJECT 
Both Queensland Health and QUT are committed to research integrity and the ethical conduct of research projects. If you do have any 
concerns or complaints about the ethical conduct of the project you may contact either Queensland Health Research & Ethics Governance 
Unit on +61 7 3234 0654 or email regu@health.qld.gov.au quoting approval number: HREC/11/QHC/1. However, you may also contact you 
may contact the QUT Research Ethics Unit on +61 7 3138 5123 or email ethicscontact@qut.edu.au quoting approval 1100000526. 
 
Both the Queensland Health Research & Ethics Governance Unit and the QUT Research Ethics Unit are not connected with the research 
project and can facilitate a resolution to your concern in an impartial manner. 
1. Thank you for helping with this research project. A copy of this Participant 
Information can be sent you if required. Please indicate below if you wish a copy sent to 
your email address. 
 
Yes, please send me a copy of the Participant Information.
 
nmlkj
No thank you, I do not require a copy.
 
nmlkj
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In Round 1 of the survey all participants rated the various DSM­IV(TR) criteria on how important they might be in 
assessing substance use disorders related to pharmaceutical opioid use. The results are shown below list from most 
important (1) to least important (11), based on all responses. 
 
You might be aware of some issues with the proposed revisions of DSM­IV in the DSM­V,in regards to the criteria for 
substance use disorders.  
 
In the context of long­term treatment with opioid medications, it is proposed that symptoms of tolerance & withdrawal 
be disregarded in diagnosing a substance use disorder . 
 
Secondly, the criterion relating to 'drug related legal problems' is proposed to be omitted in the DSM­V, for most 
diagnoses of substance use disorder as it was found to add no extra diagnostic value in field trials. 
 
Bearing the above in mind, and the questions ranked below, please consider if you would change the order of the 
rankings as set out here. 
1. Please make any changes in the following ranked order by dragging and dropping 
the items. Alternatively you can mark any items as non­applicable (N/A).
 
3. Diagnostic Criteria for Pharmaceutical Opioid Substance Use Disorders
6 1. Effects on social, occupational, or recreational activities gfedc N/A
6 2. Effects on work, school or home obligations gfedc N/A
6 3. Continued use despite health or psychological effects gfedc N/A
6 4. In hazardous situations gfedc N/A
6 5. Social or interpersonal problems gfedc N/A
6 6. Attempts to reduce or control use gfedc N/A
6 7. Drug­related legal problems gfedc N/A
6 8. Time spent in obtaining drugs gfedc N/A
6 10. Evidence of tolerance gfedc N/A
6 10. Evidence withdrawal symptoms gfedc N/A
6 10. Amount of drug taken gfedc N/A
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2. If you do not wish to change the rankings you can indicate below & move to the 
next question. You are welcome to provide any further comments if you wish. 
*
 
I am satisfied with the ranked order
 
nmlkj
I have made some changes
 
nmlkj
My comments 
5
6
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You previously rated all opioid drugs based on their harmfulness across certain categories of harm,  
1) the physical harms caused by continued use,  
2) the potential for a drug to cause dependence, and  
3) the social harms caused by use. 
 
Overall for each category the same five drugs were nominated across the majority of respondents in different orders 
(oxycodone, morphine, any opioids, fentanyl & hydromorphone). 
 
Considering these drugs how would you rate their overall harmfulness across all types of harm they might cause? 
1. Please make any changes in the following ranked order by dragging and dropping 
the items. Alternatively you can mark any items as non­applicable (N/A).
2. Do you believe there are any other pharmaceutical opioids that should be included 
the above list, or any of the above listed drugs that should be removed? 
 
 
4. Harmfulness of pharmaceutical opioid drugs
6 Oxycodone gfedc N/A
6 Morphine gfedc N/A
6 Fentanyl gfedc N/A
6 Hydromorphone gfedc N/A
6 Any opioid gfedc N/A
5
6
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3. You previously rated all opioid drugs based on certain aspects that might increase 
their harmfulness.  
 
Listed beneath are the five most frequently reported aspects from all respondents 
where (1) most frequent response, (2) the second most frequent response, and so forth. 
 
Please make any changes to the rankings you believe appropriate by dragging and 
dropping the items in the order you best believe rates harmfulness of these factors. 
Alternatively you can mark any items as non­applicable (N/A).
4. Do you believe there are any other aspects of prescription opioids that should be 
included the above list, or any of the above listed aspects that should be removed? If 
so, please add details below.
 
5. You previously rated all opioid drugs based on certain aspects that might reduce 
their harmfulness.  
 
Listed beneath are the five most frequently reported aspects from all respondents 
where (1) most frequent response, (2) the second most frequent response, and so forth. 
 
Please make any changes to the rankings you believe appropriate by dragging and 
dropping the items in the order you best believe rates harmfulness of these factors. 
Alternatively you can mark any items as non­applicable (N/A).
6 Extended/controlled/slow release preparations gfedc N/A
6 High potency/dose formulations gfedc N/A
6 Injectable preparations (ampoules, vials) gfedc N/A
6 Injectability of preparations gfedc N/A
6 Rapid onset/immediate release preparations gfedc N/A
5
6
6 Extended/controlled/slow release preparations gfedc N/A
6 High potency/dose formulations gfedc N/A
6 Injectable preparations/injectability of preparations gfedc N/A
6 Rapid onset/immediate release preparations gfedc N/A
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6. Do you believe there are any other aspects of prescription opioids that should be 
included the above list, or any of the above listed aspects that should be removed? If 
so, please add details below.
 
5
6
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The biopsychosocial model suggests that complex interactions between various biological, psychological and social 
factors contribute to the development of substance use disorders. 
 
Biological factors can refer to genetic vulnerability to risk factors for drug use, vulnerability to pharmacological effects 
of drugs, and the actual pharmacological effects of drugs. 
 
Psychological factors often relate to learning and conditioning, self­concept, cultural and spiritual beliefs,  
stress and coping style, and mental health. 
 
Social factors refer to social, cultural, economic and environmental, risk and protective factors (including normative 
influences, social networks and social identity). 
 
The following ranked list show the most frequent responses for each set of factors. The first item is the most frequent 
response, and the second item, the second most frequent response and so forth. 
 
Please consider the following lists. If you believe any items should be ranked higher or lower make any changes you 
consider appropriate. 
2. Do you believe there are any other biological factors that should be included the 
above list, or any of the above items that should be removed? If so, please add details 
below.
 
 
5. Individual Risk Factors
1. Biological factors ­ Please make any changes in the following 
ranked order by dragging and dropping the items. Alternatively you 
can mark any items as non­applicable (N/A).
6 Genetics gfedc N/A
6 Age gfedc N/A
6 Individual biology (absorption/metabolism) gfedc N/A
6 Chronic pain conditions gfedc N/A
6 Family history gfedc N/A
5
6
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4. Do you believe there are any other psychological factors that should be included the 
above list, or any of the above items that should be removed? If so, please add details 
below.
 
6. Do you believe there are any other social or cultural factors that should be included 
the above list, or any of the above items that should be removed? If so, please add 
details below.
 
3. Psychological factors ­ Please make any changes in the following 
ranked order by dragging and dropping the items. Alternatively you 
can mark any items as non­applicable (N/A).
6 Mental health issues gfedc N/A
6 Low self­efficacy gfedc N/A
6 Expectancies/beliefs gfedc N/A
6 Previous history of dependence gfedc N/A
5
6
5. Social or cultural factors ­ Please make any changes in the 
following ranked order by dragging and dropping the items.
6 Peer use gfedc N/A
6 Lack of social suppport gfedc N/A
6 Low socio­economic status gfedc N/A
6 Availability of prescription drugs gfedc N/A
6 Poor parenting/upbringing gfedc N/A
5
6
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7. Considering the categories of risk factors related to the 
development of a substance use disorder related to pharmaceutical 
opioid drugs, can you rank them them in order of importance from 
most important to least important? Alternatively you can mark any 
items as non­applicable (N/A).
6 Biological gfedc N/A
6 Psychological gfedc N/A
6 Social gfedc N/A
6 Cultural gfedc N/A
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Doctor shopping' or 'prescription shopping' is broadly defined as a person who is attending multiple doctors and 
obtaining multiple prescriptions over a certain time for certain drugs. Most respondents in the first round suggested a 
obtaining multiple prescriptions from multiple doctors could be a cause for concern as to a possible substance use 
disorder. 
 
However, some respondents suggested alternative explanations that might account for drug seeking behaviour. A 
person with poorly managed persistent pain condition could possibly seek alternative sources of opioids. 
Furthermore, a person engaged in primarily criminal enterprise could be seeking to flout the system to obtain opioids 
for illicit markets for financial gain. 
 
Prescription monitoring programs now employed in many USA, Canadian and Australian jurisdictions generally only 
contain information about prescription records. This can include details of numbers of prescriptions obtained, medical 
practitioners consulted, pharmacies involved in dispensing, and details of the type of drugs and dosages over certain 
time periods. 
 
There are now large volumes of pharmaceutical opioids prescribed and the increasing numbers of patients in receipt 
of long­term therapy with these drugs. Therefore identifying or predicting aberrant patterns of drug seeking behaviour 
can be complicated, when examining limited information at population levels.  
 
The potential of monitoring systems is allow for alerting of health practitioners when unusual patterns of prescription 
obtaining occur. However, this could be fraught with problems. 
 
Too sensitive a level of possible aberrant behaviour would capture too many persons of interest. This would set 
unmanageable volumes of work for health regulators and potentially lead to the cause of unwarranted suspicion of 
patients by medical practitioners.  
 
Setting a too specific a level might exclude many persons of interest who are potentially developing substance use 
disorders, or deliberately manipulating the system to obtain opioids for non­medical purposes,  
 
Some PMPs employ assessment system that can classify persons of interest in terms of green, amber or red ‘traffic 
lights’ rating, where:  
 
­ Green signifies, no concerns, 
 
­ Amber, cause of further investigation, and  
 
­ Red, a direction not to prescribe with out particular authority or action. 
 
Please consider, if you were asked to set limits as to what criteria you would rate as meeting the above criteria for 
green, amber or red lights in terms of a person’s obtaining of pharmaceutical opioid prescriptions WITHOUT any other 
direct knowledge of their clinical presentation. 
1. GREEN LIGHT ­ What is the 'HIGHEST LEVEL' of opioid prescription obtainings 
over the last 2 month period would you consider non­problematic? (Please provide 
answers in numbers)
 
6. Drug seeking behaviour & prescription monitoring
*
Prescriptions obtained
Doctors consulted
Pharmacies dispensing
Average daily dose* (mg morphine equivalent)
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2. Are there any other issues in a person's prescription history that you believe would 
be relevant to the assessment of non­problematic opioid use?
 
3. AMBER LIGHT ­ What is the 'LOWEST level' of prescription obtainings over the last 
2 month period that you believe could indicate potential issues of inappropriate pain 
management or a substance use disorder? (Please provide answers in numbers)
4. Are there any other issues in a person's prescription history that you believe would 
be relevant to the assessment of possible problematic opioid use?
 
5. RED LIGHT ­ What is the 'LOWEST level' of prescription obtainings over the last 2 
month period that you believe could indicate definite substance use disorder or drug 
diversion? (Please provide answers in numbers)
6. Are there any other issues in a person's prescription history that you believe would 
be relevant to the definitive assessment of problematic opioid use?
 
5
6
*
Prescriptions obtained
Doctors consulted
Pharmacies dispensing
Average daily dose* (mg morphine equivalent)
5
6
*
Prescriptions obtained
Doctors consulted
Pharmacies dispensing
Average daily dose* (mg morphine equivalent)
5
6
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Thank you for participation in the first round of this survey. All participants responses will be collated and merged and 
returned to you for further feedback, if required. 
1. Do you agree to participate in the final round of this study?
 
7. The next round
YES
 
nmlkj NO
 
nmlkj
